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ABSTRACT

THE IDENTIFICATION AND CHARACTERIZATION OF ESTROGEN
RECEPTORS IN THE MOUSE AND HUMAN LENS AND THEIR ROLE IN
CATARACT DEVELOPMENT

By
M. Rachel Kirker
December 2009

Dissertation supervised by Vicki L. Davis, Ph.D.
The increased risk of age‐related cataracts in postmenopausal women and
studies in animal models suggest that estrogen may have a protective role in the
lens. However, very little is known regarding the role of estrogen and its
receptors in the lens. To begin unraveling the estrogen signaling mechanism in
the lens, the following aims were investigated: 1) to determine if estrogen
receptors are expressed in the lens, [125I]‐17β‐estradiol binding and mRNA
expression of ERα, ERβ and GPR30 were examined in the mouse and human
lens; 2) to determine if the loss of ERα and/or ERβ receptors will induce
spontaneous development of cataracts and to examine their role in an inducible
iv

cataract model; and 3) to identify estrogen‐regulated genes in the lens that
influence cataract development in the ER∆3‐induced cataract model.

High‐

affinity, saturable binding sites for 17β‐estradiol were identified in the nuclear,
cytosolic, and membrane fractions of the mouse and human lens. Additionally,
detectable binding in the membrane fraction and expression of GPR30 mRNA in
the mouse and human lens are the first evidence of this novel transmembrane
estrogen receptor in the lens of any species. Transcripts for ERα, ERβ, and
GPR30 were expressed in the mouse lens which suggests that one or more of
these estrogen receptor subtypes are responsible for the binding detected. With
the loss of nuclear ER in the lens, spontaneous cataracts did not occur; however,
diminished levels or loss of ERα in ER∆3 female mice increased the severity of
cortical cataracts with age. These results suggest that ERα in the lens may
provide protection against the progression of cataracts in the ER∆3 model.
Together with the cataract induction and gene expression studies, six genes were
identified to be differentially expressed with estrogen versus vehicle treatment in
the lenses of ER∆3 mice. The pax6, tcfap2a, tgfβ2, six3, sox2, and pdgfα genes are
known to have a critical role in lens development, proliferation, differentiation
and maintenance of lens homeostasis. Therefore, future examination of these
genes and their pathways in the lens may contribute to the understanding of the
mechanisms of estrogen‐mediated protection of lens transparency. Knowledge

v

of pathways that function to maintain lens transparency and how estrogen
regulated these pathways will assist in the development of estrogen therapies
that can be clinically used to delay the onset and/or progression of cataracts.

vi
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Introduction

The eye and its components act as a vehicle to allow for communication
between the outside world and the central nervous system. Together, the lens
and cornea function to focus light onto the retina. It is the retina, a neural tissue,
which coverts the light impulses into electrical signals that can be interpreted by
the central nervous system. In order for light to be transmitted onto the retina,
the lens and cornea need to be transparent. Impaired vision results when light
becomes scattered as it passes through the lens. A cataract is a pathological
condition that results in light scattering when transmitted through the lens. By
definition, cataracts are clouding of the normally crystalline lens and/or its
capsule.
Briefly, the lens is an avascular tissue composed of cells of ectodermal
origin. As the lens develops it is mainly comprised of two different cell types ‐
epithelial and fiber cells. The lens epithelial cells (LEC) are classified as simple
cuboidal epithelial cells. The bulk of the lens is composed of long, tightly packed
fiber cells derived from the epithelial cells. The LEC and highly elongated fiber
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cells are enclosed by a true basement membrane, called the lens capsule; the lens
capsule functions in the maintenance of normal morphological and physiological
properties of the lens (Yan et al., 2002). The fiber cells function to keep the lens
transparent and help maintain homeostasis. The relative absence of organelles or
high‐molecular‐weight aggregates in the fiber cells, in addition to other factors,
such as degree of hydration and the ability to sustain a single light ray, are
important in maintaining normal lens transparency (Phillipson, 1973; Griess and
Zigman, 1973). The lens is also an excellent example of how an organ can modify
its structure through terminal differentiation to accomplish its function, which, in
the case of the lens, is transparency.

Cataracts
Cataracts, or clouding of the crystalline lens, result in a loss of
transparency that may occur in one or both eyes. On a global scale, cataracts are
the leading cause of blindness; approximately 48% (17.6 million individuals) of
the world‐wide population suffers from cataract‐related blindness (World Health
Organization, 2004). The World Health Organization (WHO) estimates that in
2020, approximately 75 million individuals will suffer from blindness with a
projected economical cost of $110 billion dollars in the United States (World
Health Organization, 2005). In the United States alone, the National Eye Institute
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estimates that a 10‐year delay in the onset of cataracts would result in a 50
percent reduction in the prevalence of cataracts (Javitt et al., 1996). Therefore,
therapies designed to prevent or delay the onset of cataracts would reduce the
enormous projected costs related to the treatment of lens opacities in the United
States.
To date, the only available treatment for cataracts is surgery to remove the
cataractous lens. On an annual basis, more than 3.7 million office visits in the
U.S. are a result of cataracts (Research to Prevent Blindness, NISE, NSF) with a
startling 1.5 million cataracts surgeries performed (NEI, 2008). Prior to surgery,
practitioners recommend new glasses, stronger bifocals, magnification, and
appropriate lighting to aid in vision improvement. Cataract surgery will be
recommended only after poor vision greatly impacts the individual’s daily life,
for example, impairing driving and other daily activities. Cataract surgery is
considered to be a minimally invasive surgery that has a high success rate in
restoring vision; 9 out of 10 individuals regain their vision with acuity between
20/20 and 20/40.
There are numerous types of cataracts, but the most common type is age‐
related cataracts, which will be the main focus of the studies presented within.
Age‐related cataracts can be classified as immature senile cataracts, described as
a partially opaque lens; mature senile cataracts, described as a completely
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opaque lens; and hypermature senile cataracts, with liquefied cortical matter.
Besides cataracts associated with aging, other notable types of cataracts include
posterior capsular opacifications (PCO) and traumatic, congenital, drug‐induced,
and disease‐induced (i.e., diabetes mellitus) cataracts.

PCO is sometimes

referred to as secondary cataracts or after‐cataracts due to the nature of origin.
PCO is the most common post‐operative complication following cataract
surgery. The residual LEC migrate along the posterior lens capsule, proliferate,
and secrete aberrant proteins. Typically this type of cataract occurs within 3
months to 2 years post‐surgery. Traumatic cataracts result from an eye injury
and typically take a few years to develop. Congenital cataracts are defined as a
cataract that is present at birth due to various reasons, such as hereditary factors,
infection during pregnancy, and metabolic disorders.
Currently there are no known therapies that have been scientifically
proven to prevent or delay the formation of age‐related cataracts; however,
based on what is known about the risk factors, removal or decreasing the
incidence of exposure to these risk factors may account for a preventive measure
against this type of cataracts. Risk factors for developing age‐related cortical
cataracts include female gender, sunlight exposure, and myopia.

Cigarette

smoking has been shown to be a risk factor for age‐related cataracts; its proposed
mechanism is via oxidative damage to the cells of the lens because of the large
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amounts of reactive oxygen species detected in tissues exposed to cigarette
smoke (Shalini et al., 1994). Numerous epidemiological studies show an increase
in the prevalence of cataracts in women when compared to men. It is suspected
that the early reduction in estrogen that occurs after menopause may play a role
in the gender‐induced cataract difference between women and men. The work
presented in this paper will focus on the hormone estrogen, and its correlation
with gender and age‐related cortical cataracts.
Numerous epidemiological studies suggest that estrogen provides
protection in the lens against cataract risk factors.

For example, the Blue

Mountain Eye Study (BMES) assessed the relationship between cataract
incidence and the ages at menarche and menopause, number of children, use of
the oral contraceptive pill, and surgical menopause (Cumming and Mitchell,
1997). For example, women with an earlier onset of menarche and/or a later age
of menopause have an increased duration of exposure to endogenous estrogens
and decreased cataract risk. The BMES found evidence to suggest that hormone
replacement therapy (HRT) offered long‐term users protection against cortical
cataract (Cumming and Mitchell, 1997); however, there were trends of an
increase in the risk of posterior subcapsular cataracts. The BMES reports an
association between an older age of menarche onset and an increased prevalence
of cortical, nuclear, and subcapsular cataracts; suggesting that shorter exposure
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to endogenous estrogens might increase the risk of all three types of cataract
development. Therefore, the BMES study suggests that an increase in the length
of estrogen exposure during a woman’s lifetime may provide protection against
the development of age‐related cataracts.
The Beaver Dam Eye Study (BDES) also suggests that estrogen‐related
exposures might influence the risk of some types of cataract (Klein et al., 1993),
such as hormone exposures related to the age of menarche, current and past HRT
or oral contraceptive use, number of live births, and the incidence of cataracts.
The BDES found a correlation between late age at menarche and an increased
prevalence of nuclear cataracts and an older age at menopause was associated
with a decreased risk of cortical cataracts (Klein et al., 2000), which suggests that
the duration of endogenous estrogen exposure is associated with the
maintenance of lens transparency. In contrast to the BMES, users of HRT had a
lower prevalence of nuclear cataracts and no benefits of HRT on cortical cataracts
(Klein et al., 1994). Younan et al., (2002) also report a decrease in the incidence of
cortical cataracts and cataract surgery in women prescribed HRT. Therefore,
both the data from BMES and BDES support the notion that estrogen provides
protection against age‐related cataracts.

The work presented within will

investigate the potential mechanism since little is known about estrogen actions
in the lens.
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In conjunction with the BMES and BDES, estrogen has been shown to
directly protect the lens against cataract development in animal models.

One

rodent study, using the methylnitrosurea (MNU) model, reported that estrogen
provides protection against cataracts.

In this model, the highly carcinogenic

MNU, induces cortical cataracts 6 to 8 months after a single intravenous injection
(Roy et al., 1989). The mechanisms by which MNU induces cataracts are
unknown; however, MNU is known to produce DNA adducts in tissues within
minutes of its administration to rats (Swann and Magee, 1968). It has been
suggested that alkylating agents, such as MNU, are cataractogenic because of
interference with cell proliferation (von Sallman, 1966) or gene expression
(Calvin et al., 1996). Bigsby and coworkers (1999) have shown that estradiol‐
treated, ovariectomized rats had a significantly lower incidence of MNU‐induced
cataracts when compared to non‐treated ovariectomized rats; however, the
mechanisms involved in the protective effects of estrogen remain unclear.
As mentioned previously, oxidative damage to cells of the lens is the
proposed mechanism for cataract risk associated with cigarette smoking.
Oxidative damage to the lens epithelium, which then spreads to the cortex, may
lead to the formation of cortical cataracts, one of the three types of age‐related
cataracts (Spector, 1995). One method of inducing oxidative damage in the lens
is through the use of hydrogen peroxide (H2O2). In H2O2‐treated human lens
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epithelial cells (LEC), Wang et al., (2003) showed that estrogen can conserve lens
cell viability during oxidative stress by preserving mitochondrial function, cell
viability, and ATP levels.

Wang et al. (2003) suggest that the antioxidant

properties of estrogen may be mediated by non‐classical receptor‐dependent
mechanisms, receptor‐independent, and/or ER‐dependent mechanisms.
Another rodent model of cataract induction protected by estrogen is the
TGFβ2 model of inducible cataracts. In this model, opacities, that are similar to
human anterior subcapsular cataracts, develop in the rat lens cultured with
TGFβ2 (Hales et al., 1995a).

The anterior subcapsular cataracts result from

abberant LEC proliferation and differentiation which forms fibrotic plaques
(Lovicu et al., 2002).

Interestingly, lenses from adult female rats producing

endogenous estrogens are more resistant to TGFβ‐induced cataract formation
than male and ovariectomized female rats (Hales et al., 1997).

Additionally

lenses of ovariectomized rats cultured with TGFβ2 display subtle histological
changes associated with cortical cataracts, such as swelling of cortical fiber cells
with signs of degeneration (Worgul, 1982) in the region anterior to the equator.
However, these changes were not observed in lenses of estrogen‐treated,
ovariectomized rats (Hales et al., 1997). Morphological alterations associated
with cortical cataracts are also observed in the ER∆3 model of inducible cataracts,
which is described below (ERΔ3 Transgenic Mouse Model section) and was used
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for the current studies (see Results). In the ER∆3 mouse model, inhibition of
estrogen action via a dominant negative estrogen receptor causes cortical
cataracts (Davis et al., 2002).
The combination of information obtained from the epidemiologic and
animal studies suggest estrogen provides protection against the development of
age‐related cataracts. In women in the BMES, protection was associated with the
long‐term use of HRT as evidenced by a decrease in the incidence of cortical
cataracts (Cumming and Mitchell, 1997). Several rodent‐based studies have
shown the benefits of estrogen in models of inducible cataracts that mimic
morphological changes associated with age‐related cataracts (Bigsby et al., 1999;
Hales et al., 1997; Davis et al., 2002). Research focusing on the role of estrogen in
the pathogenesis of cataracts is a new area of research and little is known about
the mechanism in which estrogen elicits protection. It is possible that estrogen
may have more than one mechanism of action to maintain a normal functioning
lens that remains transparent.

Additional epidemiologic studies assessing

associations between estrogen and incident cataract, as well as further laboratory‐
based studies that focus on the role of estrogen in the pathogenesis of cataract, are
needed to identify potential mechanism(s) of estrogen action. In order to deduce
potential estrogen mechanisms of action that may be influencing the lens, it is
important to understand the mechanisms of action of estrogen and what is
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already known about estrogen’s role in physiology and disease states. As the
research project designed and addressed within this paper investigates the
protective nature of estrogen in the lens, the following information will be
reviewed below: 1) the types of estrogen receptors and their mechanisms of
action, 2) estrogen receptor mouse models for the investigation of estrogen
action, and 3) the basic structure and physiology of the lens.

Estrogen Receptors
Estrogen receptors (ER) belong to the nuclear hormone receptor
superfamily. They are transcription factors that depend on an estrogen ligand
for activation and primarily, but not exclusively, mediate their effects at the
genomic level. ERα was the first estrogen receptor identified and cloned in 1986
(Green et al., 1986). The second ER, ERβ, was identified in 1996 (Kuiper et al.,
1996). When compared at the amino acid level, ERα and ERβ show a high
degree of similarity (refer to Figure 1), with approximately 97% homology in the
DNA binding domain and approximately 56% in the ligand binding domain.
ERα and ERβ have low homology in the N terminus, with only approximately
24% similarity.
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Figure 1: An Illustration of the Structure of the Estrogen Receptor. The amino terminal end of
the ER includes the A/B domains, the C domain forms the DNA‐binding domain (DBD) while
domain E constitutes the ligand‐binding domain (LBD). The AF‐1 and AF‐2 activation units are
part of the variable NH2‐terminal region and ligand‐binding domains, respectively. The two ER
subtypes, ERα and ERβ, are almost identical in the DNA‐binding domain (~95% homology), but
differ in the ligand‐binding domain (about 60% homology). Akingbemi, 2005.

Recently, there have been reports that show estrogens bind to a
membrane‐associated receptor, either similar to or distinct from the classical
nuclear estrogen receptors (Acconcia et al., 2004; Li et al., 2003; Razandi et al.,
2003; Toran‐Allerand et al., 2002). Govind and Thampan (2003) hypothesize the
membrane‐associated estrogen receptors can mediate traditional genomic
signaling as well as novel non‐genomic signaling.

Non‐genomic signaling

includes pathways traditionally associated with growth factor receptors and G‐
protein‐coupled receptors (GPCR) to rapidly influence cellular physiology via
the activation of a diverse array of intracellular non‐nuclear signaling
mechanisms (Prossnitz et al., 2008).

- 11 -

In the late 1990s, researchers identified a GPCR that displayed little
homology to other GPCRs, referred to as GPR30 (Carmeci et al., 1997; O’Dowd et
al., 1998; Takada et al., 1997). These reports classified this novel GPCR as an
orphan receptor due to the lack of a known ligand for the receptor. In 2000,
estrogens were identified as possible ligands for GPR30. In breast cancer cell
lines expressing GPR30, estrogen agonists and the antiestrogens, ICI 182,780 and
tamoxifen, were able to activate MAP kinases via GPR30 (Filardo et al., 2000).
However, the expression and role of GPR30 in the lens is unknown.
Ongoing research supports the notion that GPCR and their signaling
pathways are active in the lens. A few examples, of GPCR identified in the lens
are β‐adrenergic receptors, muscarinic receptors, and purinergic receptors.
Therefore, GPR30 may be acting in the lens along with the other identified
GPCR.

GPCRs linked with calcium signaling have generated considerable

interest due to the possible implications in lens pathology, more specifically
cataractogenesis (Duncan and Wormstone, 1999; Duncan et al., 1994).
Irreversible damage to key cytoplasmic and membrane proteins can be a result of
prolonged increase of intracellular free Ca2+ which could activate proteases, such
as calpain.

Another theory is that Ca2+‐mediated signaling could alter lens

development and maintenance processes to induce opacities.
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Estrogen Receptor Expression
ERα and/or ERβ are detected in a broad spectrum of tissues. ERα is
predominately expressed in the following tissues: uterus, the stroma of the
prostate, theca cells of the ovary, Leydig cells of the testes, epididymis, bone,
breast, various regions of the brain, heart, skeletal muscle, liver, and white
adipose tissue; while ERβ is predominately expressed in the colon, prostate
epithelium, testis, granulosa cells of the ovary, bone marrow, salivary glands,
vascular endothelium, and certain regions of the brain (Gustafsson, 1999).
Although both nuclear estrogen receptor subtypes are sometimes present in the
same tissue, they are also found in different cell types. Little is known about the
distribution of GPR30; however, GPR30 mRNA has been detected in the
placenta, lung, liver, prostate, and ovary (Carmeci et al., 1997; Owman et al.,
1996; Takada et al., 1997). Furthermore, it has been reported that both wild‐type
and recombinant human GPR30 display high‐affinity, limited capacity, specific
estrogen binding characteristics of membrane estrogen receptors (mER) (Thomas
et al., 2005; Revankar et al., 2005; Pang et al., 2008).
Within the last decade, nuclear estrogen receptors have been identified in
ocular tissues (Ogueta, 1999; Bigsby, 1999; Wickham 2000; Cammarata, 2004).
Using reverse transcription‐polymerase chain reaction (RT‐PCR), transcipts were
detected for ERα in lenses from rat and rabbits (Bigsby, 1999; Wickham, 2004)
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and for ERβ in rat lenses (Bigsby, 1999). Using RT‐PCR followed by Southern
blot analysis of its products, ERα and ERβ messages were detected in human
lens epithelial cells (Cammarata, 2004) In addition to message, ERα protein was
detected in the human lens by western blot and immunocytochemistry (Ogueta,
1999). ER protein expression of all subtypes in the whole human lens and mouse
lens still remains unclear. The work outlined below will investigate whether the
mouse and human lens expresses ERα, ERβ, and/or GPR30 to determine the
potential of estrogen to provide protection by acting directly in the lens.

Mechanism of Action of Estrogen
Most steroid hormone receptors, including ERα and ERβ, form dimers to
activate transcription.

Transcriptional control by estrogen receptors requires

interactions with coregulator complexes, either coactivators or corepressors of
target gene expression (Klinge, 2000). These target genes contain a sequence that
is referred to as the estrogen response element (ERE). It is to this ERE sequence
on the DNA that activated ERs bind; however, estrogen receptors are also
capable of activating gene expression through AP‐1 sites or DNA sequences that
are primary targets for other transcription factors such as, cAMP‐responsive
elements and GC‐rich Sp‐1 binding sites (Safe, 2001). Selective action of ERα and
ERβ in vivo are a result of complex interplay between expression levels of each
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ER, the relative affinity for a specific response element, ligand and cofactor
availability, and interactions with other transcription factors.
Transcriptional activation of ERα is mediated by two distinct activation
functions: the constitutively active AF‐1, located in the N‐terminal domain of the
receptor protein, and the ligand‐dependent AF‐2, located in the C‐terminal
domain of the receptor protein. (Dahlman‐Wright et al., 2006). ERβ seems to
have a weaker AF‐1 function than ERα and, thus, depends more on the ligand‐
dependent AF‐2 for its transcriptional activation function (Delaunay et al., 2000).
In contrast to the genomic transcriptional regulation, estrogen can mediate
cellular processes non‐genomically in seconds to minutes. Reports suggest that
the estrogen‐responsive membrane receptor may be a modified version of ERα
translocated to the plasma membrane (Acconcia et al., 2004; Li et al., 2003), a
complex between the classical estrogen receptor and G‐proteins (Navarro et al.,
2003) or a complex with PI3 kinase (Simoncini et al., 2003). These rapid non‐
genomic estrogen signaling events are mediated by the generation of second
messengers including, Ca2+, cAMP, and nitric oxide (NO), as well as activation of
receptor tyrosine kinases, such as EGFR and IGF‐1R, and protein/lipid kinases
(Hall et al., 2001; Ho and Liao, 2002; Kelly and Levin, 2001; Levin, 2001, 2002;
Razandi et al., 2003).
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As mentioned earlier, little is known about GPR30 and what is known
appears to be contradictory. It has been reported that GPR30 associates with the
plasma membrane Gi proteins to mediate NO production (Wyckoff et al., 2001)
and cAMP inhibition (Navarro et al., 2003). Researchers have also shown that
human GPR30 is expressed on the plasma membrane and is coupled to a
stimulatory G‐protein (Gs) with characteristics of typical GPCRs (Pang et al.,
2008; Thomas et al., 2005; Filardo et al., 2007). In addition to the controversy
surrounding the G‐protein to which GPR30 is associated, the Prossnitz research
group reports that GPR30 is not expressed on the cell membrane, but is
expressed in the endoplasmic reticulum where its activation results in an
increase in intracellular free calcium (Revankar et al., 2005; Revankar et al., 2007).
In summary, if estrogen is capable of acting directly in the lens to maintain
lens transparency, one or more of the four pathways illustrated in Figure 2 may
be involved.

Briefly, estrogen can elicit its effect through the classical

mechanism, defined as estrogen binding to estrogen receptors in the cell nucleus
to form dimers that bind to an ERE to modify transcription of an estrogen‐
regulated gene.

The second mechanism is an ERE‐independent mechanism.

Essentially, estrogen binds to the ER and, instead of dimerizing, it interacts with
Jun and Fos by protein‐protein interactions to regulate AP‐1 genes or with SP1 or
CRE proteins to activate gene transcription. The third mechanism is estrogen‐
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Figure 2: Proposed Schematic of Estrogen Signaling Mechanisms. 1. Classical mechanism of ER
action in which nuclear ER dimers bind directly to EREs in target gene promoters. 2. ERE-independent
genomic actions in which nuclear E2-ER complexes are tethered through protein-protein interactions to Jun
and Fos at AP-1 binding sites to express AP-1 regulated genes. Similar interactions between E2-ER
complexes and SP1/CRE proteins can occur. 3. Ligand-independent genomic actions; growth factors (GF)
activate protein-kinase cascades, leading to phosphorylation (P) and activation of nuclear ERs at EREs. 4.
Nongenomic actions; membrane E2-ER complexes activate signaling cascades, leading to rapid cellular
effects without direct modulation of gene transcription.

independent; growth factors activate protein‐kinase cascades, leading to the
phosphorylation and activation of nuclear ER which can regulate transcription at
EREs.

Fourth, estrogen acts through non‐genomic signaling pathways by

binding with the membrane estrogen receptor (mER) to activate signaling
cascades which lead to rapid cellular effects with or without the activation of
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gene transcription. Another plausible explanation of estrogen action in the lens
is via an estrogen receptor‐independent mechanism. Estrogen has been shown to
provide neuroprotection by acting as a free‐radical scavenger, which does not
require an estrogen receptor (Prokai et al., 2003).

Functional Roles of ER in Physiology and Disease
Estrogens role in the female reproductive system has been known for
many decades. Estrogens stimulate growth of the endometrium, myometrium,
and vaginal and urethral epithelium (Couse et al., 2000). Estrogens are also
known to enhance vascular flow in the genital tract, increase cervical secretions,
and induce expression of progesterone and luteinizing hormone receptors.
Besides their influence on reproductive tissues, such as the mammary gland,
uterus, and ovary, estrogens also exert a multitude of effects on other organ
systems, including the skeletal system, cardiovascular system and adipose tissue
(Couse and Korach, 1999).
The specific phenotypes in estrogen receptor knockout (ERKO) models
lacking the expression of ERα, ERβ, or both have allowed researchers to begin to
understand the diverse functional roles of ER in peripheral tissues. Estrogens
have a diverse role in human physiology and disease, including gender specific
roles in several diseases, such as osteoporosis and coronary artery disease. The
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role of estrogens in these specific diseases is evident due to their increased
occurrence after menopause, when estrogen levels decline, and their
improvement with estrogen replacement therapy (Rossouw et al., 2007).
Cataracts are another disease state in which the risk is increased after a woman
goes through menopause (Klein, 1993; Klein et al., 1994; Cumming and Mitchell,
1997; Klein et al., 2000).
Numerous epidemiology studies suggest that estrogen plays a protective
role in cataract incidence. These studies report that the lack of estrogen, as a
result of menopause, may increase the risk for woman to develop cataracts
(Leske et al., 2004; Livingston et al., 1994). The incidence of age‐related cataracts
is higher in women as compared to males, which may potentially be due to the
decline in estrogen after menopause. In addition to menopause, cataracts are a
common side effect in women on the anti‐estrogen cancer therapy, tamoxifen
(Gail et al., 1999; Reeder et al., 2007; Li et al., 2008).
The correlation between estrogen and cataract incidence is also seen in
rodent models and in vitro studies. Estrogen has been shown to be protective
against TGFβ‐induced (Hales et al., 1997; Chen et al., 2004) and MNU‐induced
cataracts (Bigsby et al., 1999). In the ER∆3 mouse model, spontaneous cortical
cataracts develop in female mice as a result of estrogen receptor inhibition (Davis
et al., 2002). Long‐term treatment of the antiestrogen, tamoxifen, in rats was
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reported to increase the occurrence of cataracts (Greaves et al., 1993). Based on
the reported work, it is suggested that estrogen is protective; however, little is
known on how estrogen exerts protection against cataract development.
Additionally, there is a lack of data examining whether or not functional
estrogen receptors are present in the lens (mouse and/or human).

The specific

phenotypes in estrogen receptor knockout (ERKO) models lacking the expression
of ERα, ERβ, or both will help identify the roles of ER in the lens and determine
if loss of action via one or both of these receptors is critical in the maintenance of
lens transparency.

Estrogen Receptor Knockout and Transgenic Mouse Models

ERKO Mouse Models
As research progresses, the roles of estrogen in the physiology of non‐
reproductive systems are revealed. As early as the 1900s, researchers relied on
the ability of classical ablation experiments to identify an endocrine role for a
particular organ or tissue.

Three criteria were established: 1) removal or

destruction of the hormone synthesizing organ results in symptoms presumed to
be related to the absence of the hormone, such as ovariectomy (OVX); 2)
exogenous administration of the material synthesized and released from the
removed organ should relieve the symptoms, such as estrogen replacement
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therapies; and 3) the hormone should be present in and extractable from the
organ and blood. Currently, research relies on relatively new methodologies to
introduce a new modern approach to ablation experiments by removing specific
receptors involved in hormone action.

To generate mice lacking a specific

receptor (knock‐out mouse models), mouse embryonic stem cells are cultured in
vitro and targeted by homologous recombination for the precise disruption or
knockout of a particular gene of study.
The use of receptor‐specific knockout models allow for the study of the
function of a specific hormone rather than the function of a whole endocrine
organ that may produce multiple hormones.

Additionally, knockout mouse

models enable researchers to study the roles of particular receptors throughout
the life of the animal, including early developmental stages. This approach has
already made significant advances in our knowledge of particular genes
involved in development and reproduction (Camper et al., 1995; Nishimori and
Matzuk, 1996).
In the 1990’s, the generation of ERKO animals was pursued by Drs.
Lubahn, Korach, and Smithies. At this time, only ERα was known and there
were no reports of ER mutations in normal tissues. There was belief that loss of
ERα would prove to be lethal; however, animals without ERα expression were
viable, developed normally, and exhibited a life span comparable to wild‐type
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litter mates (Lubahn et al., 1993).

Therefore, an in vivo model of estrogen

insensitivity was developed. Although these ERKO animals develop normally
compared to wild‐types, the adult αERKO (ERα knockout) mouse exhibits
several abnormalities and deficiencies; the most remarkable is the phenotypic
syndromes of infertility in both sexes. After the discovery of ERβ in 1996, the
βERKO mouse model was generated to study the role of ERβ; like the αERKO
mice, the βERKO mice survive to adulthood while exhibiting unique phenotypes
from those of the αERKO mouse model (Krege et al., 1998).
The ERKO mouse models provide unique tools to investigate the role of
ER in the context of the whole animal during its entire lifespan. Utilizing the
ERKO models, researchers are able to address the role of ER in the development
and normal physiology of all organ systems, in carcinogenesis, toxicity, and
aging. Those models are unique from the “castrate” model in which several
hormones are removed from the system, as the ERKO mice retain the ability to
synthesize and secrete gonadal steroids, including 17β‐estradiol, the most potent
endogenous ligand for both ER subtypes (Couse and Korach, 1999). The αERKO
model can be used to identify ERβ‐mediated actions since these animals do not
exhibit an altered pattern of ERβ mRNA expression (Couse et al., 1997; Rosenfeld
et al., 1998) and estrogens are still produced to elicit action via ERβ.
Additionally, in the αERKO female mice, a disruption of the endocrine system is
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observed, including significantly higher serum 17β‐estradiol levels in the αERKO
females compared to wild‐type (Couse and Korach, 1999). However, there is no
observable difference in serum estradiol levels in αERKO males, mice
heterozygous of the ERα disruption, βERKO females and males (Couse and
Korach, 1999), and female and male mice lacking both ERα and ERβ (αβERKO)
compared to wild‐type mice (Couse et al., 2003). The ERKO mouse models
provide endless possibilities to discover ER‐dependent and ‐independent
pathways and/or to suggest the presence of a novel estrogen receptor. In the
work presented within, ERKO mouse models were utilized to study the actions
of ERα and ERβ in the lens since their actions in the lens are unknown.

ERΔ3 Transgenic Mouse Model
As noted previously, spontaneous cortical cataracts develop in female
mice expressing the ER∆3 repressor. Estrogen action is inhibited in these animals
via the ER∆3 receptor. The sections below will discuss the ER∆3 receptor and its
similarity to ERα and functional activity, generation of the ER∆3 transgenic
mouse model and the cataract‐associated phenotype.
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ER∆3 Receptor
Wang and Miksicek (1991) detected a human ERα variant with the
deletion of exon 3 in the T47D breast cancer cell line. The ERΔ3 receptor is a
natural variant of ERα resulting from the in‐frame deletion of exon 3 by
alternative splicing (refer to Figure 3). The region of the ERα receptor translated
from exon 3 is part of the DNA‐binding domain. Deletion of this region results
in the receptor lacking the second zinc finger while all other domains of ERα
remain intact. In mice, exon 4 corresponds to exon 3 in human ERα, since the
first exon of human ERα was discovered after exon numbering (the first exon of
human ERα is designated as exon 1’).

Figure 3: An Illustration of the Human ERΔ3 Receptor. Only coding sequences (exons) are
depicted; thus, exon 1’ is not included. The amino terminal end of the protein consists of the A/B
domains, the C domain which forms the DNA‐binding domain (DBD), while domains E/F
constitute the ligand‐binding domain (LBD). In humans, the ERΔ3 receptor lacks the second zinc
finger located in exon 3 from an in‐frame deletion by alternative splicing. All other domains are
identical to the ERα receptor.

The expected effect for an ER lacking the second zinc finger of the DNA‐
binding domain is loss of the affinity or specificity for the estrogen response
element.

Initially, the human ER∆3 receptor was investigated using in vitro
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methods to determine the effect of removal of the second zinc finger; researchers
observed the inability of ER∆3 dimers to bind DNA containing the consensus
ERE or to possess transcriptional activity (Wang and Miksicek, 1991).
Interestingly, the ER∆3 variant, in a transfected mammalian cell line, was
reported to have dominant negative activity when co‐transfected with ERα
(Wang and Miksicek, 1991). It is hypothesized that the major mechanism for
dominant negative activity with nuclear receptors occurs through the formation
of heterodimers; that is, the ER∆3 dominant negative variant could bind to and
form a complex with wild‐type estrogen receptors (Yen and Chin, 1994; Bollig
and Miksicek, 2000). In the ER∆3 repressor, the ligand‐dependent dimerization
domain is unaffected by the deletion, so it is homologous to ERα; therefore,
estrogen is essential for ER∆3:ER dimerization (Bollig and Miksicek, 2000). These
specific ER∆3:ERα heterodimers do not possess the ability to bind to an ERE
and/or transactivate an estrogen responsive gene based on in vitro studies (Wang
and Miksicek, 1991; Yen and Chen, 1994). Although not tested, ER∆3 would be
expected to have dominant negative activity for ERβ since ERβ has a higher
affinity to form dimers with ERα versus itself (Cowley et al., 1997) and ER∆3 is a
splice variant of ERα.
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ER∆3 Transgenic Mouse Model
Given the ability of the ER∆3 repressor to suppress estrogen action, the
generation of a transgenic mouse model would provide another method to
investigate estrogen inhibition. In order to insert the ERΔ3 gene into the normal
genetic background, ER∆3 mice were generated using mouse ERα cDNA with a
deletion of exon 4 to mimic the deletion of exon 3 in human ERα (Davis et al.,
unpublished). Exon 4 of ERα in the mouse encodes for the second zinc finger
critical for specific DNA binding and is homologous to exon 3 in human ERα.
Expression of the ERΔ3 cDNA was directed by the rat osteocalcin promoter,
truncated to approximately 200 bp of 5’‐flanking sequences, in conjunction with
a viral murine enhancer, Harvey murine sarcoma virus long terminal repeat
(Davis et al., 2002).

Typically, osteocalcin promoter directed expression is

specific to the bone; however, the truncation results in a loss of tissue specificity,
as expression of ERΔ3 transgene is detected in most tissues of ERΔ3 mice (Davis
et al., unpublished data).

ER∆3 Transgenic Mouse Model Phenotype
The ERΔ3 model is relevant in the research of cataracts since cataracts
spontaneously develop in ERΔ3 females at approximately 3 months of age.
Histopathology confirmed cortical cataracts were initiated by degenerative
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changes in the lens epithelial cells and elongating fiber cells at the equatorial
region of the lens. As these ERΔ3 females age, the cortical cataracts increase in
severity and become calcified until the lens capsule ruptures (Davis et al., 2002).
With OVXremoval of the ovaries prior to the onset of puberty, the lens of ER∆3
female mice is protected from opacification; whereas, cataracts still develop
when the ovaries were removed after puberty (Davis et al., 2002). Removal of
the ovaries after puberty does not protect the ERΔ3 lens from cataracts since the
process may have already been activated by endogenous estrogen produced after
puberty.

These data by Davis et al (2002) confirm estrogen is vital to the

activation of the ERΔ3 repressor in the development of cataracts and once the
mouse is exposed to estrogens, the process of cortical cataract development
begins.
Unlike in the ERΔ3 female mice, in ER∆3 male mice, the lens remains
transparent throughout adulthood; however, exogenous estrogen administration
after birth or prior to puberty was shown to induce cataracts in both sexes of
ER∆3 mice (Davis et al., 2002). When newborn ER∆3 mice were treated with the
potent estrogen, diethylstibesterol, at day 1 to 5 after birth, severe nuclear
cataracts with lens rupture are observed (Davis et al., 2002). Taken together,
these data support the required role of estrogen to induce ER∆3 cortical cataracts.
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As cataracts develop spontaneously in adult females, the inducible ERΔ3
cataract model provides a relevant model to study age‐related cataracts. With
this model, morphological changes can be observed in the lens since exogenous
administration of estrogens induces cortical cataracts within 4 days of treatment
(Davis et al., unpublished; see Result Section C). Another advantage of the ERΔ3
model is the ability to investigate the regulation of genes in the lens associated
with cataract development and/or estrogen‐regulation due to the rapid induction
of cataracts after estrogen exposure. Therefore, we will utilize the ERΔ3 model
as a means to screen for genes related to cataract development and to investigate
the regulation of these genes in both the ER∆3 and WT mice.

The Crystalline Lens
To fully understand the pathological events that occur in the crystalline
lens to result in cataracts, basic knowledge about the lens is critical.

Lens

research has dated back to as early as the 1950s with cataract research following
shortly thereafter.

The majority of the initial research investigated the

anatomical and histological features of the individual lens compartments; the
embryonic developmental processes and growth factors involved in lens cell
proliferation and differentiation; the role of the retina and other ocular tissues on
the lens tissue; the changes associated with the aging lens; and basic knowledge
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of the specific types of cataracts and risk factors associated with cataracts. A
summary of what was gained from the research in these specific areas is
addressed in this section.
The transparency and refractive properties of the lens directly depends
upon its cellular features, specifically the lens epithelial and lens fiber cells
(Figure 4). The lens epithelium is composed of simple cuboidal epithelial cells
found between the anterior lens capsule and the most superficial fiber cells in the
anterior region of the lens. The fiber cells are unique in their structure. In a
cross‐sectional profile, they appear as flattened hexagons, and their sharply
angled membranes enclose a transparent cytoplasm that lacks organelles
typically found in all other cells. The bulk of the lens is comprised of lens fiber
cells, which can be further classified as primary and secondary fiber cells.
Primary fibers are derived from the initial posterior lens epithelial cells that
elongate into the fiber cells during embryonic lens development. Secondary
fibers are lens epithelial cells that have differentiated into fiber cells that
surround the primary fibers comprising the embryonic nucleus.
The process of proliferation and differentiation are unique in the lens.
One reason is because the lens epithelial cells are the only cell type that
proliferates in the lens. The active process of differentiation is critical to the
overall maintenance of homeostasis in the lens. Three distinct types of cataracts
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are a result of abnormal fiber cell differentiation: 1) posterior subcapsular
cataracts 2) cortical cataracts and 3) PCO cataracts. Typical posterior subcapsular
cataracts are due to an accumulation of swollen cells beneath the posterior
capsule. The morphology of posterior subcapsular cataracts suggests that they
are caused by abnormal differentiation of lens fiber cells (Streeten and
Eshaghian, 1978; Eshaghian and Streeten, 1980). However, a study completed in
the last decade suggests that posterior subcapsular cataracts may be a result of
abnormal posterior suture growth (Kuszak et al., 1999). Cortical cataracts may
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Figure 4: Cross‐section of the Crystalline Lens. Key lens features are illustrated. Lens epithelial
cells are located along the anterior side of the lens, while lens fiber cells comprise the bulk of the
lens. Permission to use by Dr. Carmen M. H. Colitz.
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result from damage to the primary epithelial cells of the lens; however, this
damage is regulated by aberrant differentiation of lens fiber cells to express a
cataract (Worgul et al., 1989).

PCO cataracts are a complication of cataract

surgery. During the surgical process, the central portion of the lens epithelium is
peeled back and the entire lens fiber mass is removed.

This is not a clean

process, for numerous epithelial cells are still present and have a tendency to
migrate posteriorly on the denuded posterior capsule beneath the lens implant.
There they differentiate into small clusters of fiber cells or form plaques of
fibrous tissue, both of which inhibit lens transparency.
Not all epithelial cells proliferate. Cells found in the central zone (refer to
Figure 5) normally do not undergo mitosis, unless stimulated by various stimuli,
including injury (Weinsieder et al., 1973) and hormones (Rothstein and Worgul,
1973). It is the cells in the germinative zone, located in a preequatorial portion of
the lens, that actively divide (Sallmann, 1952).

As the epithelial cells migrate

equatorially to reside in the equatorial region (otherwise referred to as
transitional zone) they differentiate and elongate to make up the bulk of the lens.
Through this process, these cells mature and lose their organelles and nuclei.
The lens fiber cells are arranged in a concentric pattern lengthwise from the
posterior to anterior poles of the lens. Essentially, the elongation of these cells
proceeds until they fill the lumen of the lens vesicle.
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Figure 5: Diagrammatic Cross‐section of the Adult Crystalline Lens.
Defining the
supramolecular order: epithelium [central zone (CZ), preequatorial zone (PZ), germinative zone
(GZ), meridional rows (MR), and differentiating cells (DC)], bow and equator regions, capsule,
phase transition zone #1 (PTZ), PTZ #2, superficial fiber cells (SF), middle fiber cells (MF), deep
fiber cells (DF), secondary non‐nucleated fiber cells (SAF), and primary non‐nucleated fiber cells
(PAF). The epithelium is found along the anterior region of the eye lens and proliferation of the
epithelial cells is initiated at the CZ and the cells progress through PZ into GZ. The equatorial
region is the site in which differentiation takes place. With permission to use. Gagna et al., 1999.

Typically, the secondary lens fiber cells will migrate posteriorly, rotate 90°
and elongate bidirectionally. When the anterior and posterior ends of the newly
formed fiber break contract with the epithelium and lens capsule, elongation is
considered complete (Coulombre and Coulombre, 1963).

Once fiber cell

elongation is complete, the cells continue to terminally differentiate, eliminating
their nuclei, Golgi bodies, rough endoplasmic reticulum, and parts of their
smooth endoplasmic reticulum and mitochondria (Modak et al., 1968; Jurand
and Yamada, 1967; Papaconstantinou, 1967; Modak and Ballum, 1972; Kuwabara
and Imaizumi, 1974).

Microtubules are present only in the superficial fiber cells
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(Kuwabara, 1975). In the adult lens, intermediate filaments are found in the
superficial cortical fiber cells, which decrease in number in the deeper fibers, and
are absent in the nuclear fiber cells (Bloemendal, 1981). The degradation of such
organelles is considered essential for the lens to maintain its transparent nature.
The stratum of the lens is composed of the secondary lens fiber cells. As
mentioned previously, the cells in the transitional zone (refer to Figure 5)
differentiate to form the secondary fiber cells. It is at the site of the transitional
zone (or also referred to as the cortical region) that age‐related cortical cataracts
and ER∆3‐induced cortical cataracts develop.

Therefore, the occurrence of

cataracts at the site of differentiation suggests this process may be perturbed to
display the cortical cataract phenotype.
There is evidence that at both early (induction and morphogenesis) and
late (differentiation and growth) stages of lens development, growth factors
mediate and orchestrate at least some of the interactions that occur between the
developing lens and retina. Previous studies have identified platelet‐derived
growth factor (PDGF) and transforming growth factor beta (TGFβ) families to be
critical in the overall maintenance of the lens.

Additionally, expression of

growth factors belonging to these two growth factor families was examined in
the lenses of estrogen‐treated ER∆3 animals (see Results, Subsection D).
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Numerous researchers have found that PDGF is capable of stimulating
proliferation of bovine and chick lens epithelial cells in bovine and rat lens
epithelial explants (Wunderlich and Knorr, 1994; Hyatt and Beebe, 1993; Potts et
al., 1994; Potts et al., 1998; Kok et al., 2002). Expression of PDGFα is restricted to
the lens epithelium at all ages and becomes localized to the epithelial cells of the
germinative zone during postnatal development (Lovicu and Robinson, 2004).
Therefore, research indicates that PDGFα and its receptor are localized to the
region of the lens undergoing proliferation. If PDGFα was aberrantly expressed,
its misregulation may lead to abnormal proliferation to ultimately result in
cataracts.
Whereas the growth factors belonging to the PDGF family are considered
to be mitogenic since they stimulate proliferation, growth factors belonging to
the TGF family are inhibitory or negative regulators of proliferation. TGFβ is
known to inhibit the growth of various cell types (Akhurst and Derynck, 2001).
For TGFβ signaling, both TGFβ‐I and TGFβ‐II receptors are required; however,
only type I receptor is expressed in the epithelium throughout development. The
type II receptor is postnatally expressed in the epithelium and its expression
coincides with the development of the competence of LEC to respond to TGFβ
(de Iongh et al., 2001a).
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TGFβ is known to be abundant in the lens and ocular media (Gordon‐
Thomson et al., 1998) and has a role in the maintenance of lenticular processes
such as, differentiation. In whole lens cultures, an increase in TGFβ induces the
formation of punctuate opacities (Hales et al., 1995a). These opacities correspond
to plaques of spindle‐shaped cells that contain α‐smooth muscle actin and
desmin and extracellular matrix containing collagen types I and III, fibronectin
and tenascin (Hales et al., 1995b; Lovicu et al., 2002). Also, additional research
has shown TGFβ to induce cataracts (Lee and Joo, 1999; Lee et al., 2000; Saika et
al., 2001; Wormstone, 2002; Wunderlich et al., 2000). One study suggested that
excessive TGFβ disrupts the normal lens epithelium and induces epithelial‐
mesenchymal transition, while down‐regulating normal epithelial markers such
as PAX6, α‐crystallin, and connexin 43 (Lovicu et al., 2002). Lens epithelial cells
lose their normal cell‐cell and cell‐matrix associations due to TGFβ‐induced
inhibition of signaling pathways.

LEC also lose their normal polarity and

monolayered arrangement as they undergo a marked phenotypic change. TGFβ
is normally present in or near the lens, and because lens epithelial and fiber cells
express TGFβ receptors (de Iongh et al., 2001a; 2001b), bioavailability of this
growth factor must be tightly regulated; otherwise, all lenses would quickly
become cataractous. In summary, exogenous TGFβ is highly potent and can
induce cataracts if it is not tightly regulated. Work reported by Hales et al.,
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(1997) suggests estrogen may regulate pathways stimulated or inhibited by TGFβ
to protect the lens from TGFβ‐induced cataracts in rats.

Retinal Effects on the Lens
In addition to the innate nature of the lens, the retina is known to
influence lens differentiation and maintenance. In 1965, Coulombre and
Coulombre observed the cessation of lens fiber growth after removal of the retina
from chick embryos. They observed no new fibers, the epithelium migrated
from the anterior to the posterior of the lens to completely line the lens capsule
with epithelium, and ultimately, the lens became opaque in nature. Due to the
nature of the ER∆3 repressor and its broad expression patterns (Davis et al.,
2002), estrogens may act at the retina to indirectly influence the lens.
As mentioned earlier, the vitreous body also plays a major role in the
regulation of lens differentiation. Epithelial cells have been observed to elongate
into fiber cells when the orientation of the lens is reversed with the epithelial
cells placed proximal to the vitreous body (Coulombre and Coulombre, 1963).
The neural retina is known to release stimulatory factors into the vitreous that
regulate the differentiation of epithelial cells into fiber cells (Coulombre and
Coulombre, 1963; Coulombre, 1979), such as, fibroblast growth factor.
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A specific retinal factor, fibroblast growth factor (FGF), has been identified
(Chamberlain and McAvoy, 1987) which initiates fiber differentiation in lens
epithelial explants cultured in retina conditioned media (McAvoy, et al., 1985). It
has

been

observed

that

lens

epithelial

proliferation,

migration,

and

differentiation are FGF‐dependent (McAvoy, et al., 1991), suggesting that FGF
regulation in the retina and lens is essential for the normal maintenance of the
lens. The vitreous humor contains a significantly higher levels of FGF compared
to the aqueous humor (McAvoy et al., 1991) and possesses fiber cell
differentiating activity, which may explain why FGF is more abundant in the
vitreous humor.

In other tissues, such as the uterus, 17β‐estradiol induced

expression of FGF and its receptors (Wing et al., 2003). Therefore, estrogens may
mediate expression levels of FGF in the retina to influence lens cell
differentiation and this perturbation of differentiation may result in cataract
formation.
In summary, epidemiology and animal studies correlate estrogen to lens
transparency. More specifically, estrogens may provide protection against age‐
related cataract development. The mechanism in which estrogen acts to prevent
the loss of lens transparency remains unknown. Estrogen may directly act at the
lens or indirectly via neighboring tissues, such as the retina, to regulate genes
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associated

with

lens

development,

proliferation,

homeostasis.
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differentiation,

and/or

Statement of the Problem

Research Objective
Cataracts are the most commonly diagnosed eye disease inflicting the
elderly population and a major cause of visual impairment worldwide. The
World Health Organization (WHO) projected that approximately 75 million
individuals will suffer from blindness in 2020 and may cost the United States
more than $110 billion dollars to treat this disease (World Health Organization,
2005). In the Unites States, the National Eye Institute estimates that a 10‐year
delay in the onset of cataracts would result in a 50 percent reduction in the
prevalence of cataracts (Javitt et al., 1996), thus lowering the number of cataract
surgeries performed annually and the economical hardship associated with such
surgeries. A number of epidemiological studies have shown an increase in the
prevalence of cataracts in elderly women compared to men which suggests that
the decline in estrogen associated with menopause may increase the
susceptibility of the lens to cataract formation. Also, animal studies suggest that
estrogen provides protection in models of inducible cataracts. However, there is
only limited information on how estrogen and its receptors function in the lens.
For this reason, the present study was designed to examine whether estrogen
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and its receptors are required for maintenance of lens transparency and/or have a
cataract‐protective role.
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Hypothesis

Estrogen action in the mouse and human lens can occur via estrogen receptors,
including ERα, ERβ, and/or GPR30, and inhibition of its actions in transgenic
mouse models null for ERα, deficient in ERβ, and/or expressing the ER∆3
repressor induces cataracts and modifies expression of influential genes involved
in cataract development.

Specific Aims

I. Determine if the mouse and human lenses express estrogen receptors
capable of binding estrogen.
II. Examine the importance of the estrogen receptor on lens transparency
using mouse models with modified expression of ERα, ERβ, and/or ER∆3.
III. Identify estrogen‐regulated genes in the lens of a mouse model expressing
ER∆3, a dominant negative variant of ERα.
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Methods

Animal Husbandry

All animal procedures were in accordance with the Animal Welfare Act
and were approved by the Institutional Animal Care and Use Committee at
Duquesne University. All study mice, including αERKO, βERKO, αβERKO, and
wild‐type strains, FVB/n and C57Bl/6 hybrid, were produced from breeding
colonies established in our facility. Initial αERKO and βERKO breeding pairs
were provided by Dr. Kenneth Korach (from the colony housed at Charles River
Laboratories, Wilmington, MA ).
All animals were housed in a well ventilated, controlled environment;
temperatures ranging from 22‐25o C and humidity between 50‐75% with a
standard 12h:12h light:dark cycle. The breeding colonies were maintained on
standard rodent chow and water was available ad libitum.

A semi‐purified,

isoflavone‐free diet (Harlan Teklad, Indianapolis, IN) was used to generate and
maintain all study mice in order to eliminate the exposure to estrogenic soy
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isoflavones that are present in standard rodent chow (Thigpen et al., 1999; Degen
et al., 2002). Ear punches were used to designate animal numbers. All mice were
euthanized using carbon dioxide inhalation.

ER∆3 Colony
Dizygous male and female ER∆3 (FVB/n) were bred to sustain a colony
of dizygous ER∆3 mice. The progeny of the breeding colony were used for
breeding the mice for the ERKO/ER∆3 cataract development, cataract induction,
gene expression, and estradiol binding studies.

αERKO and βERKO Colonies
Heterozygous αERKO (ERα+/‐) male and female mice were bred to sustain
the colony with the disruption of the mouse ERα gene (ERα‐/‐) since homozygous
(αERKO) male and female mice are infertile (Course and Korach, 1999). Male
and female mice with the following genotypes were produced from this breeding
scheme: ERα‐/‐ (αERKO), ERα+/‐ (heterozygous), and ERα+/+ (wild‐type).
Homozygous

βERKO

(ERβ‐/‐)

females

are

subfertile;

therefore,

heterozygous βERKO (ERβ+/‐) females were bred with homozygous βERKO
males to sustain a colony. Male and female mice with the following genotypes
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were produced from this breeding scheme: ERβ+/‐ and ERβ‐/‐ (βERKO).

All

progeny were subjected to a standard tail biopsy for genotyping (See page 52).

ERKO Breeding and Study Design for Cataract Development Study
αERKO, βERKO, αβERKO, and wild‐type (control) mice for studies in
cataract development (Results, Section B) were generated using the following
two‐step breeding scheme (Figure 6). Briefly, ERα heterozygous (ERα+/‐) females
were bred with βERKO homozygous (ERβ‐/‐) males to generate male and female
breeders heterozygous for both ERs (ERα+/‐/ERβ+/‐).

The (ERα+/‐/ERβ+/‐) breeders

produced αERKO, βERKO, αβERKO and wild‐type control study animals. All
progeny were subjected to a tail biopsy for genotyping.
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A.

ERα+/‐
ERβ+/+
♀

ERα+/+
ERβ‐/‐
♂

ERα+/‐
ERβ+/‐
♀&
♂

ERα+/+
ERβ+/‐
♀&
♂

Breeders

Undesired genotype

B.

ERα+/‐
ERβ+/‐
♀

ERα+/‐
ERβ+/‐
♂

ERα+/+
ERβ+/+

ERα+/+
ERβ‐/‐

ERα‐/‐
ERβ+/+

ERα‐/‐
ERβ‐/‐

ERα+/‐
ERβ+/‐

ERα+/‐
ERβ‐/‐

ERα+/+
ERβ+/‐

ERα‐/‐
ERβ+/‐

ERα+/‐
ERβ+/+

♀&♂

♀&♂

♀&♂

♀&♂

♀&♂

♀&♂

♀&♂

♀&♂

♀&♂

Undesired Genotypes

Study Genotypes
(Section B)
3.125% occurrence/genotype/gender

Figure 6: Breeding Schematic for ERKO Cataract Development Study Mice. ERα+/+ and ERβ+/+
are wild‐type; ERα+/‐ and ERβ+/‐ are heterozygous for the disruption of the ER subtype; ERα‐/‐ and
ERβ‐/‐ are knockout mice that are homozygous for the disruption. Panel A: The block highlighted
in yellow indicates the desired breeding genotype for the generation of study animals. Panel B.:
Blocks highlighted in yellow can be used as breeders for this schematic and blocks highlighted in
pink are desired genotypes of study pups. Due to the nature of bi‐transgenic breeding the
occurrence of desirable genotypes is low, 3.125%/genotype/gender.
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Of the nine different genotypes produced, four were used for the cataract
development study: αERKO, βERKO, αβERKO and WT control (n= 6‐8/
genotype/sex). ERα+/‐/ERβ+/‐ animals were retained as breeders. Beginning at 4
months of age until 16 months of age, a minimum of three mice/genotype/sex
were monitored monthly for lens abnormalities by slit‐lamp biomicroscopy (see
page 61 for methods), including the region(s) in the lens in which cataract
abnormalities are noted (nucleus, cortical region, anterior, posterior, or lens
sutures); aberrant adhesions of the lens to the cornea; and alteration of the
overall transparency of the lens fibers, for example, lens haze, lens snowflakes,
and lens spots. At 16 months of age, all animals were euthanized and the eyes
were fixed in 10% neutral formalin for histological analyses (see page 62 for
methods).

ERKO/ER∆3 Breeding and Study Design for Cataract Development
Study
To determine the influence of ERα and ERβ on ERΔ3‐induced cataracts,
male and female mice with the disruption for ERα and/or ERβ and the presence
of ER∆3 were produced. Retinal degeneration (rd‐/‐) is a recessive phenotype
inherent to the FVB/n strain. The retinas of FVB/n mice begin to degenerate
during the 2nd postnatal week of life and disappear completely by 35 days (Caley
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et al., 1972). With the known influence of the retina on the lens, it is essential to
generate study animals on the hybrid background to keep the retina intact to
ensure cataract formation was not a result of retinal degeneration in the ER∆3
(FVB/n) mice. Breeding was designed so that all study animals generated will
result in hemizygous ERΔ3 mice on the hybrid strains C57Bl/6/129SV/FVB/n, to
ensure all study animals do not have retinal degeneration. To generate mice
with normal retinas in the desired genotypes, αERKO and βERKO mice
(C57Bl/6/129SV hybrid strains) were mated with ER∆3 animals on the FVB/n
background. From this point forward C57Bl/6/129SV background strains will be
referred to as C57H and C57Bl/6/129SV/FVB/n background strains will be
referred to as C57H/FVB. In both cases, C57Bl/6 is designated since it is the
primary strain in the C57Bl/6/129SV hybrid mice.
Separate breeding schemes were used to get the desired αERKO/ER∆3
mice and the βERKO/ER∆3 and αβERKO/ER∆3 genotypes. This is necessary due
to the fertility issues associated with animals homozygous for the disruption of
ERα to minimize the number of mice produced with the unwanted genotypes.
First, dizygous ERΔ3 (FVB/n) females were crossed with heterozygous αERKO
(C57H)

males

to

generate

the

(C57H/FVB) breeders (Figure 7).

heterozygous/hemizygous

αERKO/ERΔ3

These animals were then bred with
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heterozygous αERKO mates to result in wild‐type, ERΔ3, ERΔ3/ERα+/‐, and
ERΔ3/αERKO study mice (Figure 8).

ERΔ3+/+
(ERα+/+)
♀

ERα+/‐
(ER∆3‐/‐)

♂

ERα+/‐
ERΔ3+/‐
♀&♂

ERα+/+
ERΔ3+/‐
♀&♂

Breeder

Undesired

Figure 7: Generation of ERΔ3 Mice on a Hybrid Background Strain. ER∆3+/+ and ER∆3+/‐
designate mice dizygous and hemizygous for ER∆3 gene insertion, respectively; ERα+/‐ indicates
mice heterozygous for the ERα disruption and ERα+/+ ERα wild‐type mice. ERΔ3 (FVB/n) females
have retinal degeneration unlike the C57H strain for the αERKO mice; therefore, the generated
ERα+/+/ERΔ3 mice would not have retinal degeneration.
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ERα+/‐
ERΔ3+/‐
♀

ERα+/‐
ER∆3‐/‐
♂

ERα+/+
ERΔ3+/‐
♀&♂

ERα+/‐
ERΔ3+/‐
♀&♂

ERα‐/‐
ERΔ3+/‐
♀&♂

ERα+/+
ERΔ3‐/‐
♀&♂

ER∆3

ERα+/‐/ER∆3

αERKO/ER∆3

WT

Figure 8: Breeding Schematic for αERKO/ERΔ3 Cataract Development Study Mice. ER∆3+/‐ are
hemizygous for ER∆3 gene insertion; ERα+/+ are wild‐type; ERα+/‐ are heterozygous for the ERα
disruption; ERα‐/‐ are homozygous for the ERα disruption (αERKO). This breeding scheme
resulted in ERΔ3 mice on a hybrid background strain that does not have retinal degeneration.
Genotypes produced include wild‐type (WT), ERΔ3, αERKO/ERΔ3, and ERα+/‐/ERΔ3. These
terms will be used in Results Section B to refer to study mice. Blocks highlighted in pink are
study animals and yellow blocks indicate breeder and study genotypes. ERα+/‐/ER∆3 animals
occur 25% of this with this breeding scheme; while ER∆3, αERKO/ER∆3, and WT occur 12.5% of
the time. Additional genotypes not suitable for breeding or the study were also generated but
not shown above.

A two‐step breeding scheme was necessary to generate the final
ERΔ3/βERKO and ERΔ3/αβERKO mice. ERΔ3 (FVB/n) female mice were bred
with males heterozygous for the ERα and ERβ disruption (ERα+/‐/ERβ+/‐) to result
in the generation of animals heterozygous for ERα, ERβ, and ER∆3 (ERα+/‐/ERβ+/‐
/ER∆3; Figure 9, Part A). The ERα+/‐/ERβ+/‐/ER∆3 mice were bred with mice both
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heterozygous and homozygous for ERα and ERβ, respectively (ERα+/‐/ERβ‐/‐) to
generate the following genotypes: ERΔ3/βERKO, ERΔ3/αβERKO, ERΔ3/ERα+/‐,
and ERΔ3/ERα+/‐/βERKO study mice (Figure 9, Part B).
Beginning at 3 months of age until 10 months of age, a minimum of three
mice/genotype/sex for the study mice (as shown in Figures 8 and 9) were
monitored monthly for abnormalities associated with cataract development.
Animals were euthanized to obtain tissues for histological analyses at the
following ages: prepubescent (approximately 3 weeks of age), pubescent
(approximately 1 month of age), adults (4‐5 months of age), and older adults (10
months of age). The number of animals per group varied due to prevalence of
desired genotypes during breeding.
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A.

B.

ERΔ3+/+

ERα+/‐
ERβ+/‐

♀

ERα+/‐
ERβ+/‐
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♂

ERα+/‐
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♀

ERα+/‐
ERβ+/‐
ERΔ3+/‐
♀&♂

ERα+/+
ERβ‐/‐
ERΔ3+/‐
♀&♂

ERα‐/‐
ERβ‐/‐
ERΔ3+/‐
♀&♂

ERα+/‐
ERβ‐/‐
ERΔ3+/‐
♀&♂

βERKO/
ER∆3

αβERKO/
ER∆3

ERα+/-/
βERKO/
ER∆3
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genotype/gender

ERα+/‐
ERβ+/‐
ERΔ3+/‐
♀&♂
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genotype/gender

Figure 9: Breeding Schematic for αβERKO/ERΔ3 Cataract Development Study Mice. The
following abbreviations are used to designate the genotypes of mice in this figure: ER∆3+/‐,
hemizygous for ER∆3 gene insertion; ERα+/+ and ERβ+/+,wild‐type; ERα+/‐ and ERβ+/‐, heterozygous
for the ERα and ERβ disruption, respectively; ERα‐/‐ and ERβ‐/‐, homozygous for the ERα and ERβ
disruption, respectively. This breeding scheme resulted in ERΔ3 mice on a hybrid background
strain that does not have retinal degeneration. Genotypes produced for the cataract study (pink
blocks) include βERKO/ERΔ3, αβERKO/ER∆3, and ERα+/‐/βERKO/ERΔ3. Blocks highlighted in
yellow are the genotypes used for breeding. Additional genotypes not suitable for breeding or
the study were also generated, but not shown above.
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Tail Biopsy
After weaning, all progeny of the ERKO and ERKO/ER∆3 breeding
schemes underwent tail biopsies in order to obtain DNA for screening to
determine the genotype (wild‐type, heterozygous, or homozygous for the ER
disruption and/or presence of the ER∆3 transgene). Additionally, mice produced
in the αERKO and βERKO colonies were genotyped.

Briefly, animals were

anesthetized with 3% isoflurane by inhalation; a < 5 mm section was removed
from the tip of the tail with a surgical scalpel. The tips of the tails were taped to
minimize bleeding and animals were placed under a heat lamp to recover from
the anesthesia. Tail biopsy samples were stored at ‐80° C until DNA was isolated
using the protocol below.

DNA Isolation
DNA from tail biopsies was isolated and purified using the DNeasy Blood
& Tissue Kit (Qiagen, Valencia, CA). Briefly, tails were digested in Proteinase K
and lysis buffer in a 55° C water bath overnight. The next day, the lysate is
loaded onto the DNeasy mini‐spin column. DNeasy min‐spin columns were
centrifuged 60 seconds at 8000 rpm at room temperature in a microcentrifuge to
allow for selective DNA binding to the DNeasy membrane and remove any
contaminants.

Any remaining contaminants and enzyme inhibitors on the
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DNeasy membrane are removed following two wash steps (8000 rpm for 60
seconds; 13200 rpm for 3 minutes) with proprietary buffers provided in the kit
and the purified DNA was then eluted using DNase/RNase‐Free water (8000
rpm for 60 seconds). The isolated DNA samples were stored at ‐20° C prior to
genotyping using the protocols listed below.

Genotyping Assays
Genotyping assays were carried out by standard polymerase chain
reaction (PCR) using genomic DNA prepared from the tail biopsies from each
individual animal.

Genomic DNA was screened by PCR (Mastercycler®,

Eppendorf, New York, NY), using the specific primers sequences in Table 1, PCR
optimized buffer E (Invitrogen, Carlsbad, CA), Platinum® Taq DNA polymerase
(Invitrogen, Carlsbad, CA) and 10 mM dNTP Mix (Invitrogen, Carlsbad, CA).
PCR conditions specific to the individual primer sets are listed in Table 1. The
resulting PCR products were subjected to gel electrophoresis to visualize band
sizes and confirm the presence of the desired product. A primer set for the p53
gene was included as an internal control primer for the ER∆3 genotyping to
ensure that the DNA sample was amplifiable to prevent false negative results.
An internal control primer was not required for ERKO genotyping as the primers
designed correspond to part of the Neo cassette used in the generation of the
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knockout mice or to the wild‐type ER gene. Therefore, DNA quality will be
confirmed since all mice would have an amplified product from one of the
primer sets, regardless of genotype.
To visualize the resulting PCR products, gels [2% NuSieve® GTG®
Agarose (Cambrex, East Rutherford, NJ)/0.7% Agarose (Fisher Scientific,
Pittsburgh, PA)] were prepared in 1x TBE (0.09 M Tris Base, 0.09 M Boric Acid, 1
mM EDTA). Approximately 15 μL of the PCR product sample mixed with 6x
dye mix (0.1 mM bromophenol blue, 0.1 mM xylene cyanol FF, 6x TBE, and 35%
(vol:vol) glycerol) was loaded into the gel. Gel electrophoresis was run at 80
mVolts for approximately 1 to 1.5 hrs for adequate band separation. The PCR
product band size was verified using a 100 bp ladder (Invitrogen, Carlsbad, CA)
as a reference.
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Table 1: Oligonucleotide Primers and Anticipated Sizes of Amplified Genomic
DNA Products in the Genotyping PCR Procedures.

Gene

Orientation

Nucleotide Sequence

Mouse ERα

Forward
Reverse

CGG TCT ACG GCC AGT CGG
GCA TC
CAG GCC TTA CAC AGC GGC
CAC CC

Forward

TGA CCG CTT CCT CGT GCT
TTA C

Forward
Reverse

TGG ACT CAC CAC GTA GGC
TC
CAT CCT TCA CAG GAC CAG
ACA C

Forward

GCA GCC TCT GTT CCA CAT
ACA C

Forward
Reverse

TAT CCG GCA CAT GAG TAA
CA
CAC ACC AGC CAC CAC CTT
CT

Mouse
αERKO

Mouse ERβ

Mouse
βERKO

Mouse ERΔ3
(Davis et al.,
1994)

Mouse
Control
primer
p53 gene
(Davis et al.,
1994)

Forward
Reverse

TGT AAA ACG ACG GCC AGT
ACT CTC CTC CCC TCA
GAG GGC TTA CCA TCA CCA
TC
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Amplified
Product Size
(bp)
281

760

356

404

PCR
Conditions

94°C/3 min;
94°C/45 sec,
67.5°C/45 sec;
72°C/90 sec (35
cycles); 72°C/7
min; 4°C hold

94°C/3 min;
94°C/45 sec,
57°C/30 sec;
72°C/60 sec (40
cycles); 72°C/7
min; 4°C hold

94°C/3 min;
94°C/45 sec,
59°C/45 sec;
72°C/60 sec (35
cycles); 72°C/7
min; 4°C hold

Animal Treatments
Previous work by Davis et al., examined spontaneous cataract
development and DES‐induced cataracts in the ER∆3 mouse model. For cataract
induction and gene expression studies, male and female mice with (ER∆3) and
without (WT) the ER∆3 transgene were examined in both strains (FVB/n and
C57H) at different ages and reproductive stages. ER∆3 (FVB/n) study mice were
obtained from the breeding colony; therefore mice were dizygous for the ER∆3
transgene and homozygous for the retinal degeneration (rd‐/‐) gene.

ER∆3

(C57H/FVB) study mice were generated by breeding WT (C57H) male mice (from
the ERKO colony) with ER∆3 (FVB/n) female mice; therefore, mice generated
were hemizygous for the ER∆3 transgene without retinal degeneration.

All

study animals without the ER∆3 transgene were obtained from the WT (FVB/n)
and ERKO (C57H) colonies. All breeders and study animals were maintained on
an isoflavone‐free diet to prevent exposure to these estrogens. All study animals
were weaned at 21 days of age.

Cataract Induction Study
The following animals were used: 1) 17‐day‐old, intact prepubescent ER∆3
(FVB/n and C57H/FVB) male and female mice, 2) 25‐day‐old ER∆3 (C57H/FVB)
female mice ovariectomized (OVX) at weaning, 3) 6‐week‐old ER∆3 (C57H/FVB)
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OVX (at weaning) female mice, 4) 25 day‐old ER∆3 (C57H/FVB) male mice, 5) 6‐
week‐old ER∆3 (C57H/FVB)) male mice, 6) 17 day‐old, intact prepubescent WT
(FVB/n and C57H/FVB) male and female mice. Removal of the ovaries (the
primary source of endogenous estrogen) is critical for eliminating endogenous
estrogens which would result in cataracts developing spontaneously (Davis et
al., 2002) and confound the induction study. Therefore, removing the source of
estrogen prior to estrogen synthesis at puberty can prevent spontaneous cataract
development to allow for testing specific doses of 17β‐estradiol and their effects
on cataract induction.

All animals (n=3‐6 mice/group) were treated

subcutaneously with 17β‐estradiol or vehicle using a specific dosing regimen
followed by slit‐lamp examination at designated times (hrs post‐injection) as
outlined in Table 2. Eyes were collected at necropsy at the specific time outlined
in Table 2.
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Table 2:

Groups, Dosing Regimen, and Tissue Collection Schedule for

Cataract Induction Study
Animal Group

Treatment

Dose

Frequency

17‐18‐day‐old ERΔ3
(FVB/n) Male and Female
Mice

17β‐estradiol

1000
μg/kg

1x

17‐18‐day‐old ERΔ3
(C57H/FVB) Male and
Female Mice

17β‐estradiol

17‐18‐day‐old WT (FVB/n)
Male and Female Mice
17‐18‐day‐old WT
(C57H/FVB) Male and
Female Mice
Ovariectomized, 25‐day‐
old ERΔ3 (C57H/FVB)
Female Mice
25‐day‐old ERΔ3
(C57H/FVB) Male Mice

Vehicle
1000
μg/kg

1x

1x

1x

1x

17β‐estradiol

6‐week‐old ERΔ3
(C57H/FVB) Male Mice

17β‐estradiol

96 hrs
96 hrs

1000
μg/kg

1x

Vehicle

Ovariectomized, 6‐week‐
old ERΔ3 (C57H/FVB)
Female Mice

96 hrs
96 hrs

1000
μg/kg

Vehicle
17β‐estradiol

96 hrs
96 hrs

1000
μg/kg

Vehicle
17β‐estradiol

6, 14, 24, 48, and 96 hrs
96 hrs

1000
μg/kg

Vehicle
17β‐estradiol

6, 14, 24, 48, 72, and 96 hrs
96 hrs

Vehicle
17β‐estradiol

Slit‐Lamp Biomicroscopy
Time Points

96 hrs
96 hrs

500
μg/kg

Vehicle
500 or
1000
μg/kg

4x weekly for 3
weeks

Lenses were monitored weekly by slit‐
lamp, eyes were collected one month post
the last injection

3x weekly for 3
weeks

Lenses were monitored weekly by slit‐
lamp, eyes were collected one month post
the last injection

Vehicle

Gene Expression Study
To identify genes regulated by estrogen, RNA prepared from the lenses of
male and female mice expressing the ER∆3 transgene (ER∆3) or WT (FVB/n)
examined at different ages and stages of reproductive development.

The

following groups (n = 3‐9/gender/group) were examined: 1) 3‐week‐old,
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prepubescent ER∆3 (FVB/n) male and female mice, 2) 3‐week‐old, prepubescent
WT (FVB/n) male and female mice, and 3) 6‐week‐old ER∆3 (FVB/n) female mice,
OVX prepubertally at weaning. All animals were treated subcutaneously with
17β‐estradiol or vehicle using a specific dosing regimen as outlined in Table 3
and the eyes were enucleated 6 hrs post‐injection. Immediately post‐enucleation,
lenses were dissected, flash frozen with liquid nitrogen, and stored at ‐80° C
prior to RNA isolation (see page 66).

Table 3: Groups and Dosing Regimen for Gene Expression Study
Animal Group

Treatment

Dose

Prepubescent ERΔ3 (FVB/n) Male and
Female Mice

17β‐estradiol
Vehicle
17β‐estradiol
Vehicle
17β‐estradiol
Vehicle

1000 μg/kg

Prepubescent WT (FVB/n) Male and
Female Mice
Prepubertally OVX, 6‐week‐old ERΔ3
(FVB/n) Female Mice

1000 μg/kg
500 μg/kg

Frequency
1x
1x
1x

Ovariectomy Surgery
Female mice were anesthetized with 3% isoflurane in oxygen by
inhalation, the hair over each flank was shaved, a single incision was made in the
skin followed by bilateral incisions in the abdominal wall. Each ovary was
identified, the ovarian pedicle was ligated and the ovary was excised. The skin
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incision was closed by skin clips. Animals were administered subcutaneous
warmed saline to warm and rehydrate the animal. Additionally, animals were
administered an analgesic, buprenorphine hydrochloride, at a dose of 0.1 mg/kg
(2 μg/ 20 g mouse given as 0.1 mL) to ease pain. Skin clips were removed 7‐10
days post surgery. Female mice were allowed to recover for a minimum of 14
days prior to treatments.

Treatment Preparation
17β‐estradiol Treatment
A stock solution of 17β‐estradiol was prepared by dissolving 5 mg of 17β‐
estradiol (Sigma‐Aldrich, St. Louis, MO) in 1 mL of 95% ethanol. This stock
solution was used to prepare treatments for subcutaneous injection that were
used in the cataract induction and gene expression studies.
The 5 mg/mL 17β‐estradiol stock solution was diluted into corn oil to
prepare the following doses: 500 μg/kg and 1000 μg/kg 17β‐estradiol with the
volume to be administered based on 0.1 mL per 20 g mouse. As a control, 95%
ethanol (vehicle) was dissolved in corn oil at the same ratio of ethanol to corn oil
as with the appropriate 17β‐estradiol dose.
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Slit‐Lamp Biomicroscopy
All mice were restrained by hand and one drop of 1% tropicamide was
applied to each eye to dilate the pupils.

Approximately 20 minutes after

treatment, the eyes of the animals were examined by hand‐held portable slit‐
lamp (SL‐15 Portable Slit‐Lamp, Kowa, Torrance, CA) to evaluate the lens for
morphological changes in a darkened room. Both eyes were scanned from side
to side to observe all areas for abnormalities. Morphological observations that
can be observed include the location of origin of cataract formation (nucleus or
lens sutures); aberrant adhesions of the lens to the cornea; and alteration of the
overall transparency of the lens fibers. Slit‐lamp examinations were performed
in the ERKO and ERKO/ER∆3 cataract development study and the cataract
induction study in the ER∆3 mice.

Observations were recorded; images could

not be captured since a camera attachment for the slit‐lamp apparatus is not
commercially available.
For the ERKO cataract development study, slit‐lamp examinations were
completed monthly beginning at 4 months of age until 16 months of age in a
minimum of three animals/genotype/sex. All study animals, if not examined
monthly, were examined prior to necropsy (16 months of age). From 3 months of
age through 10 months of age, a minimum of three ERKO/ER∆3 study
animals/genotype/sex were examined monthly to observe morphological
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changes. Prepubescent and pubescent study mice, were examined at necropsy .
For all cataract induction work, lenses were assessed by slit‐lamp biomicroscopy
after euthanasia without administration of 1% tropicamide.

Histology
At necropsy, each animal was euthanized by CO2 inhalation. Eyes were
enucleated and processed for either RNA analysis or histology. For RNA, the
lenses were dissected and flash‐frozen in liquid nitrogen (refer to Mouse Lens
Collection method below).

For histology, eyes were fixed in 10% neutral

buffered formalin or 4% ice‐cold paraformaldehyde. Eyes that were fixed in
formalin were stored at room temperature until sent for processing, at this time
they were transferred to 70% ethanol prior to shipping. ERKO and ERKO/ERΔ3
formalin‐fixed eyes were shipped to Dr. Chi‐Chao Chan (National Eye Institute,
National Institutes of Health) where the eyes were embedded in methacrylate,
cut into 2 μm sections, and stained with hematoxylin and eosin.

As the

histopathologist for the study, Dr. Chan read the slides and recorded
morphological changes in the lens of all study animals.
For the eyes fixed in 4% paraformaldhyde, the fixative was prepared no
more than 2 weeks in advance and stored at 4°C until use. Eyes fixed in 4%
paraformaldhyde for 6 hrs at 4° C and then immediately processed and
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embedded. The fixed eyes from cataract induction studies were processed using
the Pathcentre (Shandon, ThermoFisher_Scientific, Waltham, MA) under the
following conditions (Table 4), embedded in paraffin (Tissue Infiltration
Medium, Surgipath®, Richmond, IL) using the Histocentre 2 (Shandon,
ThermoFisher Scientific, Waltham, MA), cut into 5 μm sections (HM 325
Microtome, Microm, ThermoFisher Scientific, Waltham, MA), and stained with
hematoxylin and eosin using the protocol below.

Table 4: Processing Conditions for Lens Samples
Reagent
70% Ethanol
80% Ethanol
90% Ethanol
95% Ethanol
100% Ethanol
100% Ethanol
Xylene
Xylene
Xylene
Paraffin
Paraffin
Paraffin

Time (hr)
1:00
0:30
0:30
0:30
0:30
0:30
0:30
1:00
0:30
0:30
0:45
0:45

Hematoxylin and Eosin (H&E) Staining
Hematoxylin and eosin staining is a common stain used to visualize the
nuclei and cytoplasm of tissues. First, 5 um tissue sections were deparaffinized
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in two changes of xylene. Slides were hydrated with decreasing concentrations
of ethanol (100%, 100%, 95%, 95% and 80%) and a change of distilled water
followed by staining with Mayer’s hematoxylin solution (Sigma‐Aldrich, St.
Louis, MO) for 15 minutes and washed for 2 minutes in running tap water. Next,
slides were dipped two times in 1% acid alcohol, a differentiator of hematoxylin,
and washed in water for 30 seconds. This wash step was followed by a 10‐
second change in weak ammonia and a thorough washing in running tap water
for 10 minutes.

Next, a 2‐minute change 80% ethyl alcohol was completed

followed by application of the counterstain, eosin‐phloxine (Volu‐Sol, Inc., Salt
Lake City, UT), for 2 minutes. Finally, slides were dehydrated and cleared with
ethanol (95%, 95%, 100%, 100%) and two changes of xylene.
coverslipped using Permount (Fisher Scientific, Pittsburgh, PA).

Slides were
Following

staining, nuclei were stained blue and the cytoplasm and other tissue structures
appeared pink to red in color.

Mouse Lens Collection
At necropsy, each animal was euthanized by CO2 inhalation. Enucleated
eyes were microdissected and the whole lens or the lens capsule and cortex were
collected. For whole lens collections, a stab incision using a 27 gauge needle was
made along the cornea. Using fine scissors, the corena and iris were removed
- 64 -

leaving the posterior cup. The whole lens was scooped out using curved forceps.
In order to collect the lens capsule with adhered lens epithelial cells and the lens
cortex comprised of lens fiber cells, the whole lens was collected as described
above. Once the entire lens was removed, the lens capsule, with adhered lens
epithelial cells, was collected using a 27 gauge needle to initiate an anterior
capsulotomy. The lens fiber mass (or lens cortex) was removed using curved
forceps. All tissues collected were flash‐frozen and stored at ‐80° C until RNA
extraction.

Human Lens Collection
All human lens tissues were obtained from the National Disease Research
Interchange, and stored at ‐80° C. Prior to death, all donors did not exhibit lens
pathology, and had no history of taking estrogen hormone replacement therapy
or chemotherapy that could affect the lens (i.e., tamoxifen, raloxifene, and/or
fulvestrant). All lens samples were harvested post‐mortem during tissue
recovery. Lenses from 2 females, ages 78 (postmortem enucleation time [PET] 10
hrs) and 57 (PET 2 hrs) were studied for ER transcripts and estradiol binding.
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Total RNA Isolation
Total RNA was isolated from ocular tissues (whole lens, lens capsule, or
fiber cells) using the Absolutely RNA® Miniprep Kit (Stratagene, La Jolla, CA)
according to the manufacturer’s small sample protocol.

Briefly, 5‐20 mg of

frozen lens tissue was homogenized in a ratio of 7 μL:1 mL β‐
mercaptoethanol:lysis buffer.

Tissue homogenates were centrifuged for 60

seconds at 13,200 rpm using a microcentrifuge filter spin‐cup provided in the kit.
Additional lysis buffer was added to the spin cup and spun again for 2 minutes
at 13200 rpm. The filtrate was combined with equal parts 70% ethanol and
transferred to the RNA spin‐cup to bind total RNA. The fiber was washed with a
low‐salt wash buffer and spun in the microcentrifuge for 60 seconds at 13200
rpm. Samples were then treated with RNase‐free DNase and incubated for 20
minutes in a 37°C air incubator to remove DNA contamination that may interfere
with amplification.
Following incubation, samples were washed with a high‐salt wash buffer
(60 seconds at 13,200 rpm) and two subsequent low‐salt wash buffer applications
(60 seconds at 13,200 rpm; 120 seconds at 13,200 rpm) to prepare them for down‐
stream PCR applications. RNA spin columns were transferred to RNase/DNase‐
free 1.5 mL microcentrifuge tubes. To elute total RNA, two‐50 μL aliquots of 60°
C elution buffer was added to the spin column and centrifuged at 13,200 rpm for
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60 seconds. RNA concentrations were determined spectrophotometrically and
RNA integrity was calculated using the 260:280 nm ratio. High quality‐RNA
possessing a ratio between 1.8 and 2.1 was used for the subsequent real‐time RT‐
PCR analysis (Results, Subsections A and D).

cDNA Microarray Analysis
A microarray analysis was completed to identify differentially expressed
genes after a 6 hr exposure to 17β‐estradiol versus vehicle (95% ethanol) in
prepubescent ER∆3 (FVB/n) female mice approximately 3 weeks of age. Lens
tissues were prepared according to the Total RNA Isolation protocol (see above
section). Individual total RNA samples were sent to the Functional Genomics
Core at Columbus Children’s Research Institute (Columbus, OH) for analysis of
RNA quality, pooling of samples, and microarray and data analyses. Two pools
were prepared from three RNA samples of good quality from each treatment
group (6 mice in total). Pools were prepared to account for the high variability
between individual samples. Each pool was run on a separate Affymetrix®
GeneChip Mouse Genome 430 2.0 Array (Affymetrix, Inc, Santa Clara, CA) to
result in a total of two microarrays for each treatment group (E2 and V).
Briefly, microarray analysis entails the following steps (Figure 10), using
an oligo(dT)T7 primer to synthesize first and seconds strand cDNA. The double‐
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stranded cDNA serves as a template for in vitro transcription to incorporate
biotinylated nucleotides. Synthesized cRNA is fragmented and hybridized to the
Affymetrix GeneChip® Mouse Genome 430 2.0 Array (Affymetrix, Inc, Santa
Clara, CA). A phycoerythrin‐rich biotin stains the cRNA bound to the probes on
the GeneChip. The chip is scanned and converted to an image that contains
information about the level of fluorescence bound to probes for the specific genes
on the GeneChip. From the data collected, statistical analyses are completed to
determine the EASE score.

Figure 10: Microarray Flow Chart. Image obtained from Columbus Children’s Research
Institute, ABRF Microarray Research Group.

The EASE score is a statistical tool to examine significant changes in gene
expression patterns. The EASE score is calculated for the likelihood of over‐
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representation of biological processes, molecular functions and cellular
component categories using the Gene Ontology (GO) public database. Over‐
representation describes a class of genes that have similar functions regardless of
expression level and appear more frequently in a list of interest than normally
predicted by their distribution among all gene assays.

Therefore, the EASE

analysis of the regulated genes would indicate molecular functions and
biological processes unique to the disorder, treatment, etc. EASE scores enable
researchers to elucidate signaling pathways that may serve as key master
regulating factors or potential therapeutic targets. Categories with an EASE
score of p<0.05 is considered to be significantly over‐represented; meaning, genes
in these categories may be influenced by estrogens in the lens of ER∆3 mice.

cDNA Reverse Transcriptase (RT) Reaction
First‐strand cDNA was synthesized from 500 ng total RNA using ABgene
Reverse‐iTTM 1st Strand cDNA Synthesis Kit (ABGene, Rochester, NY) under the
manufacturer’s suggested protocol. Briefly, the RNA template (500 ng total/20
μL reaction) and anchored oligo dT (500 ng/μL) in sterile RNase/DNase‐free
water was heated to 70°C for 5 minutes to remove any secondary structures. The
reaction was immediately returned to ice and the following components were
added: 5x First Strand Synthesis buffer, dNTP mix (5mM each), Reverse‐iTTM
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RTase Blend and 100 mM DTT. The mixture was incubated at 47°C for 50
minutes to synthesize the cDNA strand followed by 75°C for 10 minutes to
inactivate the reverse transcriptase. In addition to the RT reaction, a “No RT”
reaction consisting of RNA and all other reagents except the Reverse‐iTTM RTase
Blend (substituted with equal volume of sterile RNase/DNase‐free water) was
prepared to serve as a control to identify if the RNA sample had DNA
contamination. After incubation, multiple RT reactions per RNA sample were
pooled together to reduce variability in 1st stand cDNA synthesis levels for
examining multiple genes from each RNA sample. These pools provide a more
accurate representation of the individual sample being analyzed by real‐time RT‐
PCR. All reactions were stored at ‐20° C until use for real‐time RT‐PCR analysis
of gene expression.

Real‐Time RT‐PCR
Real‐time detection of relative RNA levels was performed using the
iCycler iQTM Real‐Time PCR detection system (Bio‐Rad Laboratories, Hercules,
CA) with SYBR green detection. cDNA samples from the RT reactions described
above were used for real‐time PCR analysis.

Lens tissue from OVX ERΔ3

(FVB/n) female and immature ER∆3 (FVB/n) and WT (FVB/n) male and female
mice were analyzed for expression of pax6, tcfap2a, tgfb2, six3, sox2, and pdgfa
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transcripts. Additionally, select lens tissues were analyzed for expression of
ERα, ERβ, and GPR30 mRNAs. Primers were designed to span at least one
intron/exon boundary to ensure the amplification of cDNA versus potential
contaminating genomic DNA. All reaction mixes (25 μL total volume) included
the following 2x SYBR green master mix, forward primer (200 nM), reverse
primer (200 nM), cDNA template (1/20 dilution of the RT reaction) and water.
Primer sequences are found in Table 5.
Real‐time RT‐PCR amplification of the cDNA from OVX ER∆3 (FVB/n)
female mice was performed using iQTM SYBR® Green Supermix (Bio‐Rad
Laboratories, Hercules, CA)

and analyses quantifying the expression levels of

the ER subtypes and GPR30 in the lens using B‐R SYBR® Green Supermix for
iQTM (Quanta BioSciences, Gaithersburg, MD) with the following PCR conditions:
enzymatic activation at 95 °C for 3 minutes followed by 50 cycles of denaturation
(95° C for 30 seconds) and annealing/extension (60° C for 30 seconds).
Determination of gene expression in cDNA products from the lenses of
prepubescent ER∆3 (FVB/n) male and female mice utilized AbsoluteTM QPCR
SYBR® Green Fluorescein Mix (ABgene, Rochester, NY). PCR conditions were
the same except, enzymatic activation at 95° C was extended to 15 minutes.
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Table 5: Oligonucleotide Primers and Anticipated Sizes of Amplified cDNA
Products using Real‐Time RT‐PCR.

Gene

Accession No.

Orientation

Nucleotide Sequence

Amplified
Product
Size (bp)

Mouse ERα

NM_007956

Forward
Reverse

TAT GCC TCT GGC TAC CAT TAT
CAT CAT GCC CAC TTC GTA AC

182

Mouse ERβ

NM_207707

Forward
Reverse

AAA TGT GCT ATG GCC AAC TTC
TTG GCG CTT GGA CTA GTA AC

200

Mouse GPR30

NM_029771

Forward
Reverse

AGA TCA GGA CAC CCA ACA GA
TTA AGG GGA GCA GAG TCC TT

171

Mouse ppia

NM_008907

Forward
Reverse

TAT CTG CAC TGC CAA GAC TG
ACA GTC GGA AAT GGT GAT CT

145

Mouse pax6

NM_013627

Forward
Reverse

TCT AAT CGA AGG GCC AAA TG
AGG AGG AGA CAG GTG TGG TG

151

NM_011547

Forward
Reverse

GGA GAC GTA AAG CTG CCA AC
TTC TTG CCA CTT GCT CAT TGG

168

Mouse tgfβ2

NM_009367

Forward
Reverse

CTT CGC CCT CTT TAC ATT GA
CTT CGG GAT TTA TGG TGT TG

166

Mouse six3

NM_011381

Forward
Reverse

GTT TAA GAA CCG GCG ACA G
CTG GAG GTT ACC GAG AGG AT

219

Mouse sox2

NM_011443

Forward
Reverse

ACT AGG GCT GGG AGA AAG AA
AGT GCA ATT GGG ATG AAA AA

281

Mouse pdgfa

NM_008808

Forward
Reverse

CAG GAA GAA GCC AAA ATT GA
TTT CAC GGA GGA GAA CAA AG

236

Human ERα

NM_000125

Forward
Reverse

TAC TAC CTG GAG AAC GAG CC
TGG TGG CTG GAC ACA TAT AG

286

Human ERβ

NM_001437

Forward
Reverse

TAT GCG GAA CCT CAA AAG AG
ATC CCT CTT TGA ACC TGG AC

141

Human GPR30

NM_001039966

Forward
Reverse

GAG ACT GTG AAA TCC GCA AC
AGC TGC TCA CTC TCT GGG TA

221

Human GAPDH

NM_002046

Forward
Reverse

GAG TCA ACG GAT TTG GTC GT
CAT TGA TGA CAA GCT TCC CG

192

Mouse tcfap2a
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All samples were run in triplicate and additional wells consisting of “no
RT” for each sample and no template (water in the place of the RT reaction) for
each gene tested to identify amplification of genomic DNA or other
contaminants. In addition to the experimental genes, a housekeeping gene was
examined. Housekeeping genes are used as an internal control for each set of
genes in each run; essentially, it allows normalization for data analysis by the
∆∆Ct method of relative expression (see section below). For the mouse RNA
analyses, the housekeeping gene was ppia (cyclophilin A), a gene that has been
validated in primary breast tissue (McNeill RE et al., 2007), mouse liver (Tatsumi
et al., 2008), in cell lines and tissues from brain, breast, colon, kidney, ovary,
pancreas, prostate, skin, and vascular origin (Feroze‐Merzoug et al., 2002) as an
endogenous control gene for real‐time RT‐PCR. The gene GAPDH was used as
the housekeeping gene for the RNA analysis in the human lens. A melting curve
was added following all real‐time RT‐PCR runs to confirm the presence of a
single product in each cDNA sample. Additionally, gel electrophoresis was
completed on a subset of the samples to visualize amplification of the correct
product based on base pair size for a select set of wells.
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Relative Gene Expression using the 2‐ΔΔCt method
Relative expression was calculated using the 2‐ΔΔCt method (Livak and
Schmittgen, 2001) with piaa (mouse) or GAPDH (human) as the housekeeping or
normalizing gene.

First, the ΔCt value was calculated by subtracting the

threshold value (Ct) for the housekeeping gene from the Ct value for the gene of
interest for each sample.

The Ct value is defined as the number of cycles

required for the fluorescent signal to cross the designated threshold value;
therefore, the fewer cycles needed to cross the threshold would indicate higher
levels of mRNA for that gene.

The ∆Ct value for each individual

sample/group/gene of interest was averaged to obtain the average ∆Ct ± standard
error of the mean (SEM).
Relative gene expression between treatment groups and the control group
was determined by the equation 2‐ΔΔCt; ΔΔCt values were calculated by
subtracting the average ΔCt value for the control group from the average ∆Ct
value for the treatment group. Values were expressed as a relative fold change,
2‐ΔΔCt. Statistical analyses were performed on the ∆Ct values.

Statistical Analysis for Gene Expression
Statistical analyses were performed using Microsoft® Excel and
GraphPad® Prism Version 5. A non‐parametric test, Mann‐Whitney U test and
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Kruskal‐Wallis Test, was used because it requires less restrictive assumptions
about the data.

Non‐parametric tests account for data not fitting a normal

distribution which is required for the more robust, powerful parametric tests.
The Mann‐Whitney U test was used to determine differences between two
groups and the Kruskal‐Wallis test for multiple groups. A Dunn’s Multiple
Comparison test was conducted to determine significance between specific
groups when a significant difference was observed between group medians. A
value of p ≤ 0.05 was considered significant.

Protein Extraction from Lens Tissues for Binding Analysis
All lens tissues were stored at ‐80° C prior to use. All steps were carried
out at 4° C unless otherwise noted.

Lens tissues were pooled to obtain

approximately 100 mg of tissue weight, diluted in TEMMG (10 mM Tris, 1.5 mM
EDTA, 1 mM monothioglycerol, 25 mM sodium molybdate, and 10% (v/v)
glycerol + Protease Inhibitor (PI) Cocktail (Roche, Nutley, NJ), pH 7.4, 1:5
(wt:vol), and homogenized. The homogenate was centrifuged at 4° C for 10
minutes at 1200xg in a Beckman Avanti‐J20XP centrifuge to obtain the nuclear
pellet. The supernatant was aspirated and then centrifuged at 4° C for 1 hr at
106,000xg in a Beckman Coulter XL‐70 ultracentrifuge (Fullerton, CA) to obtain
the cytosol (supernatant) and membrane fraction (pellet). The nuclear fraction
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was resuspended in 7 mL TEMMG + PIs +0.5 M KCl and incubated for 1 hr to
extract the nuclear proteins, while being vortexed every 15 min. The cytosol and
membrane fractions were resuspended in 7 mL of TEMMG + PIs. All fractions
were stored on ice until use in the binding assay.

Protein Quantification from Tissues for Binding Analysis
Protein concentrations for the nuclear, cytosolic and membrane fractions
were determined using a 96‐well format of the BCA protein assay kit (Pierce
Biotechnology, ThermoFisher Scientific, Waltham, MA). Wells containing the
protein standards (bovine serum albumin at concentrations ranging from 25 to
2,000 μg/mL), samples (nuclear, cytosol, and membrane fractions), and negative
control (TEMMG buffer containing protease inhibitors) were all plated out in 25
μL volumes, in triplicate. A two hundred microliter aliquot of BCA working
reagent was added to each well and the plate was incubated at 37° C for 30
minutes. Optical density readings were taken at 590 nm using a Perkin Elmer
HT7000 Bio Assay microplate reader (Waltham, MA). A standard curve was
generated using Microsoft Excel®.

Sample protein concentrations were

calculated from the standard curve equation.
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Estrogen Receptor Binding Study
Full‐Curve Saturation Binding
Nuclear, cytosolic, and membrane extracts from WT (C57H and FVB/n)
female mouse lenses or female human lenses (200 μL) were incubated for 1 hr at
room temperature with varying concentrations of 16α‐[125I]‐iodo‐3,17β‐estradiol
(2,200 Ci/mmol; Perkin‐Elmer, Boston, MA) in the absence (total binding) or
presence (non‐specific binding) of 100‐fold excess inert diethylstilbestrol (Sigma‐
Aldrich, St. Louis, MO) for a 260 μL total volume. The reaction was stopped by
addition of 50 mM ice‐cold Tris‐HCl buffer and rapid filtration over glass‐fiber
filters (Whatman, Piscataway, NJ) soaked in 0.5% polyethylenimine glycol
solution. Each filter was washed twice with 5 mL of ice‐cold Tris‐HCl buffer and
counted on a liquid scintillation counter. The saturation assay was performed in
duplicate on two to three independent samples. The specific binding of 16α‐
[125I]‐iodo‐3,17β‐estradiol was calculated by subtracting the nonspecific binding
from the total binding. All data were analyzed by non‐linear regression analysis
using GraphPad Prism® software where KD and Bmax values were calculated.

Single Point Saturation Binding
Nuclear, cytosolic, and membrane extracts from pools of 6‐10 lenses from
WT (C57H) female mice or 6‐10 lenses from WT (C57H) male mice were
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incubated for 1 hr at room temperature with 16α‐[125I]‐iodo‐3,17β‐estradiol
(approximately 19.5 nM) in the absence (total binding) or presence (non‐specific
binding) of 100‐fold excess inert DES (Sigma‐Aldrich, St. Louis, MO) for a total of
260 μL volume. The reaction was stopped by addition of 50 mM ice‐cold Tris‐
HCL buffer and rapid filtration over glass‐fiber filters (Whatman, Brandel,
Gaithersburg, MD) soaked in 0.5% polyethylenimine glycol solution. Each filter
was washed twice with 5 mL of ice‐cold Tris‐HCL buffer and counted on a liquid
scintillation counter. The specific binding of 16α‐[125I]‐iodo‐3,17β‐estradiol was
calculated by subtracting the nonspecific binding from the total binding.
Samples with a positive specific binding number were considered to be positive
for binding.

All data were analyzed by unpaired, two tailed t‐test using

GraphPad Prism® software and significance was defined as p < 0.05.

Competition with DES and GTPγS
Competition with various concentrations of DES (0.1 pM – 1 μM) for 16α‐
[125I]‐iodo‐3,17β‐estradiol (approximately 250 pM concentration) binding to
mouse lenses was determined in the absence or presence of 5 μM GTPγS.
Membrane extracts (200 μL) from WT (C57H) female mice were incubated for 1
hr

at

room

temperature

with

16α‐[125I]‐iodo‐3,17β‐estradiol,

various

concentrations of inert DES, with or without GTPγS in a total volume of 260 μL.
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The reaction was stopped by addition of 50 mM ice‐cold Tris‐HCl buffer and
rapid filtration over glass‐fiber filters (Whatman, Brandel, Gaithersburg, MD)
soaked in 0.5% polyethylenimine glycol solution. Each filter was washed twice
with 5 mL of ice‐cold Tris‐HCl buffer and counted on a liquid scintillation
counter. Values were plotted as Log [DES] (M) versus 16α‐[125I]‐iodo‐3,17β‐
estradiol bound (% total).

Data is represented as mean ± SEM of three

independent samples performed in duplicate. All data were analyzed by paired,
two‐tailed t‐test using GraphPad Prism® software and significance was defined
as p < 0.05.
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Results

The main goal of the work presented within is to begin to elucidate
mechanisms in which estrogen may provide protection against lenticular
changes associated with cataracts. In order to determine if estrogen is capable of
eliciting protection directly in the lens, the first goal of the present study is to
identify the presence of estrogen receptors (ERα, ERβ, and/or GPR30) in the
mouse and human lens to determine if the lens expresses specific proteins
capable of binding estrogens (Subsection A). Next, mouse models without ER
expression (estrogen receptor knock‐out mice; ERKO) were used to determine if
loss of ERα and/or ERβ in the lens results in the development of spontaneous
cataracts or cataracts induced by the ER∆3 repressor (Subsection B). If cataracts
occur spontaneously in the ERKO mice, these results would demonstrate that the
missing ER is required to maintain lens transparency.

Separately, cataract

induction in mice expressing the ERΔ3 repressor was examined to determine the
timeframe in which morphological changes in the lens are observable in
prepubescent‐, pubertal‐, and post‐pubertal‐aged mice (Subsection C). The
cataract induction study is needed to identify a time point suitable for
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investigation of genes modified to correlated cataract development with gene
expression in Subsection D.

Finally, lenticular genes that are modified by

estrogen in the ERΔ3 transgenic model will be identified in order to begin to
elucidate molecular pathways involved with the development of the ERΔ3‐
induced cataract phenotype (Subsection D). Furthermore, these genes may be
valuable tools for future investigations in other animal models of cortical
cataracts as well as potential biomarkers in human or animal studies. Overall, the
work will provide insight regarding the ability of estrogen to act directly on the
lens by binding to specific estrogen receptors localized in the cells of the lens and
regulating expression of genes previously identified to be associated with
cataract development, such as genes known to influence lens development,
proliferation, and differentiation.
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A. Identification of Estrogen Receptors in the Mouse and Human
Lens
To begin elucidating the role of estrogen in cataract prevention, the first
goal was to identify if the lens of the mouse and human contain estrogen binding
sites consistent with the nuclear and/or membrane estrogen receptors found in
other tissues. The presence of estrogen binding sites in the lens will demonstrate
if estrogen is capable of acting via estrogen receptors in the lens to elicit
protection.

Furthermore, utilizing real‐time RT‐PCR, the expression of ERα,

ERβ, and/or GPR30 transcripts will be examined due to the inability of the
binding studies to distinguish between receptor subtypes.

Additionally, the

mouse lens will be dissected into two different regions, the epithelial cell‐rich
lens capsule and fiber cell‐rich lens cortex, to determine if ERα, ERβ, and/or
GPR30 are differentially expressed based on cell type. Lastly, sex and/or age‐
dependent expression of transcripts for ERα, ERβ, and GPR30 will be determined
in the mouse lens.

17β‐Estradiol Binding Characteristics to the Wild‐Type Mouse Lens and
Uterus
To assess whether or not 17β‐estradiol binding sites exist in the normal
mouse lens, saturation binding analyses using [125I]‐17β‐estradiol on pools of
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lenses from adult female mice from two separate strains, C57Bl/6 hybrid (C57H,
refers to animals of the C57Bl/6/129SV background strain which are the WT mice
for the ERKO models) and FVB/n, were performed. Both strains are used in
other sections of this project, such as C57H for the ERKO cataract study
(Subsection B) and FVB/n for the ER∆3 mice in Subsections C and D.
Furthermore, 17β‐estradiol binding was characterized in both strains to
determine if estrogen binding sites vary between mouse strains with differences
in ocular phenotypes. Retinal degeneration and albino eyes are characteristic of
the FVB/n mouse strain, whereas, the C57H mice have normal retinas and
pigmented eyes. As the C57Bl/6 mice age, the retina releases dialdehyde toxins
(Zeigler and Hess, 1984; 1985; Ziegler et al., 1983) which explains the subcapsular
cataract phenotype observed in older C57Bl/6 mice (Wolf et al., 2000).
Extracts prepared from wild‐type (WT) C57H female mouse lenses
(nuclear, cytosolic and membrane) showed specific binding of [125I]‐17β‐estradiol
(Figure 11). Examination of the affinity (Kd) and the density of binding sites
(Bmax) revealed that the membrane fraction was biphasic with two affinity states
of the receptor (Figure 11C). In the membrane fraction of the C57H female lens,
the affinities were Kd = 0.075 nM and 0.7 nM with Bmax values of 12.8 and 155
fmol/mg protein, respectively. The nuclear and cytosolic fractions of the C57Bl/6
female lens showed specific binding of [125I]‐17β‐estradiol with a single affinity
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state of the receptor (Figure 11A and B). The binding affinities for the nuclear
and cytosolic fractions were Kd = 0.1 nM and 0.06 nM, respectively. Receptor
density was Bmax = 19.5 fmol/mg protein for the nuclear fraction. The cytosolic
fraction contained very low levels of [125I]‐17β‐estradiol binding, Bmax = 0.02
fmol/mg protein.

The Kd from all three fractions is characteristic of values

obtained for ERα and ERβ in other tissues.
As a positive control, saturation binding analysis was performed in the
uteri of female mice. As shown in Figure 11E, [125I]‐17β‐estradiol bound with
high‐affinity (Kd=0.02 nM) and revealed a receptor density of 6.8 fmol/mg
protein.

These data are consistent with other binding affinity reports.

For

example, Kuiper et al., (1997) reported Kd values of 0.1 nM and 0.4 nM for in vitro
synthesized human ERα and rat ERβ proteins, respectively. At concentrations
greater than 1.0 nM, specific binding in the C57H uteri increases to 146 fmol/mg
protein suggesting an additional binding site (data not shown).
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Figure 11: High Affinity 17β‐Estradiol Binding Sites are Present in C57H Female Mouse
Lenses. Lens nuclear, cytoplasmic, and membrane fractions and uterine nuclear fraction were
prepared from approximately 3‐month‐old C57H mice as described in the Methods section.
Aliquots of 200 μL of each fraction were incubated with increasing concentrations of [125I]‐17β‐
estradiol (total binding) or [125I]‐17β‐estradiol plus 100‐fold excess of diethylstilbestrol (non‐
specific binding) for 1 hr at room temperature. Specific binding was determined by subtracting
non‐specific binding from total binding. Specific binding was normalized to the concentration of
the protein of each individual extract. Specific binding (fmol/mg protein) is shown as mean ±
SEM. Kd and Bmax values were generated from the composite curves using GraphPad® Prism
software, non‐linear regression analysis. Panels A ‐ C: Binding affinity and receptor density were
determined in the nuclear (A), cytoplasmic (B) and membrane (C) fractions from pooled C57H
female lenses (n=3 pools). Panel D (inset of panel C): Binding affinity and receptor density in
membrane fractions from pooled C57H female lenses (n=3) shown with increasing concentrations
of [125I]‐17β‐estradiol between 0 and 0.6 nM. Panel E: Binding affinity and receptor density were
determined in the nuclear fraction from individual C57H mouse uteri in estrus (n=5).
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In addition to the WT C57H female mice, WT female mice from the FVB/n
strain were examined for [125I]‐17β‐estradiol specific binding (Figure 12). No
concentration‐dependent increase in [125I]‐17β‐estradiol binding was detected in
FVB/n female lenses (nuclear and cytosolic fractions) until the concentration
reached levels of 0.58 nM and 3.45 nM.

As the concentration of [125I]‐17β‐

estradiol increased, detectable binding sites were more pronounced.

At a

concentration of 0.58 nM [125I]‐17β‐estradiol binding in the nuclear fraction was
29.9 fmol/mg protein and increased to 143.5 fmol/mg protein at 3.45 nM [125I]‐
17β‐estradiol.

In the cytosolic fraction, at a concentration of 0.58 nM [125I]‐17β‐

estradiol binding was 2.6 fmol/mg protein and increased to 10.0 fmol/mg protein
at 3.45 nM [125I]‐17β‐estradiol. Additionally, in the FVB/n female lens membrane
fraction, the binding characteristics of [125I]‐17β‐estradiol were monophasic,
saturable (Bmax = 19.6 fmol/mg protein) and high‐affinity (Kd=0.4 nM).
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Figure 12: [125I]-17β-Estradiol High Affinity Binding Sites in the FVB/n Female Mouse Lens. Lens
nuclear, cytoplasmic, and membrane fractions were prepared from approximately 3‐month‐old
WT (FVB/n) female mice as described in the Methods section. Aliquots of 200 μL of each fraction
were incubated with increasing concentrations of [125I]‐17β‐estradiol (total binding) or [125I]‐17β‐
estradiol and 100‐fold excess of diethylstilbestrol (non‐specific binding) for 1 hr tissue at room
temperature. Specific binding was determined by subtracting non‐specific binding from total
binding. Specific binding was normalized to the concentration of the protein of each individual
extract. Specific binding (fmol/mg protein) is shown as mean ± SEM. Binding affinity and
receptor density was determined in the membrane fractions from pooled FVB/n female lenses
(n=3). Affinity (Kd) and total binding (Bmax) values were obtained on membrane fractions from
composite curves using GraphPad Prism® software, non‐linear regression analysis; shown as
mean ± SEM. Detectable binding was observed in all three fractions.
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Besides analyzing the binding characteristics in female mice, [125I]‐17β‐
estradiol total binding was analyzed in the lenses from male mice (Figure 13).
Although estrogen is commonly referred to as a female sex hormone, adult males
also have circulating estrogen, albeit at lower levels (Saladin, 2006). Therefore,
C57H male mice were also examined to determine if [125I]‐17β‐estradiol binding
is present in the lens or if it differs between the genders. As shown, there were
no significant differences in [125I]‐17β‐estradiol binding between male or female
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mice in any of the lens fractions examined (Figure 13).

Figure 13: Similar [125I]‐17β‐Estradiol Binding in C57H Female and Male Lenses. Lens nuclear,
cytoplasmic, and membrane fractions were prepared from approximately 3‐month‐old
C57H/FVB female or male mice (n= 5 pools/sex) as described in the Methods section. Aliquots of
200 μL of each fraction were incubated with approximately 1.5 nM concentration of [125I]‐17β‐
estradiol (total binding) or [125I]‐17β‐estradiol and 100‐fold excess of diethylstilbestrol (non‐
specific binding) for 1 hrhr tissue at room temperature. Specific binding was determined by
subtracting non‐specific binding from total binding. Specific binding is shown as mean ± SEM.
Using GraphPad® Prism software, no significant statistical difference was observed in specific
binding between the female and male lenses (Mann‐Whitney U test, p > 0.05).
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To further characterize estradiol binding in the membrane fraction of the
C57Bl/6 female mouse lens, competition binding analysis was performed using
DES, an estrogen agonist with higher affinity for both ERα and ERβ than 17β‐
estradiol.

As shown in Figure 14, DES did not displace [125I]‐17β‐estradiol

binding using concentrations ranging from 0.01 pM to 0.1 nM. To assess whether
or not membrane receptors may be acting via G‐proteins as would be expected
for GPR30, competition assays using DES were performed in the absence or
presence of GTPγS, a non‐hydrolyzable analog of GTP (Manning, 1999). As
shown in Figure 14, the presence of GTPγS did not modify the ability of DES to
displace [125I]‐17β‐estradiol binding to mouse lens at all concentrations of DES
tested. These data suggest that DES is not an agonist for estrogen receptors
detected in the membrane extract of mouse lenses.
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Figure 14: DES Competition and G‐Protein Activation of Membrane Receptors in the C57H
Mouse Lens. Membrane fractions were prepared from approximately 3‐month‐old C57H/ female
lenses as described in the Methods section. Aliquots of 200 μL were incubated with
approximately 268 pM concentration of [125I]‐17β‐estradiol (total binding) with increasing
concentrations of DES with or without 5 μM concentration of GTPγS. Data are shown as a
percentage of total [125I]‐17β‐estradiol binding with 0.1 pM diethylstilbestrol (DES). Each value
represents the mean ± SEM of three individual samples run in duplicate. No significant statistical
difference was observed (GraphPad® Prism, unpaired t‐test, p < 0.05).

In summary, we are able to detect 17β‐estradiol binding sites in all three
fractions (nuclear, cytoplasmic, and membrane) in wild‐type mice. These results
suggest the presence of both classical nuclear estrogen receptors as well as
membrane estrogen receptors in the mouse lens. Therefore, estrogen should be
able to produce its effects in the lens through estrogen receptor‐dependent
mechanisms. Additionally, specific 17β‐estradiol binding occurred in both male
and female lenses (Figure 13) with similar levels of expression indicating that
receptor mediated effects could occur in both genders.
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Since DES did not

compete with estradiol for the binding sites in the membrane fraction in the
competition binding assay (Figure 14), these data would be consistent with other
studies reporting that DES has poor binding affinity to GPR30 (Filardo et al.,
2007). Therefore, based on the lack of DES binding and the presence of estradiol
binding sites in the membrane fraction, GPR30 receptors may exist in the lens.

17β‐Estradiol Binding Characteristics to the Female Human Lens
To assess whether 17β‐estradiol binding sites exist in the human lens,
saturation binding analyses using [125I]‐17β‐estradiol were performed in two
individual human lenses from women aged 78 and 57 years.

Monophasic,

saturable, and high‐affinity binding sites for [125I]‐17β‐estradiol were detected in
the nuclear, cytosolic, and membrane fractions of the lens. (Figure 15). The
nuclear fraction of the female human lens had the highest level of [125I]‐17β‐
estradiol binding (78.7 fmol/mg protein). The level of [125I]‐17β‐estradiol binding
sites was approximately ten‐fold lower in the cytoplasmic fraction (Bmax = 7.5
fmol/mg protein) than in the nuclear fraction and was lower in the membrane
fraction (Bmax values of 1.0 fmol/mg protein) than in both the nuclear and
cytosolic fractions. The binding affinity of 17β‐estradiol for ERα and ERβ are
reported to be 0.1 nM and 0.4 nM, respectively (Kuiper et al., 1997). The affinity
of [125I]‐17β‐estradiol binding in the human lens was similar to the reported
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literature, with the affinity of [125I]‐17β‐estradiol to the membrane fraction at Kd =
0.06 nM.

In the nuclear and cytosolic extracts, the binding affinity of 17β‐

estradiol (Kd = 1.1 nM and 1.1 nM, respectively) was 10‐fold lower than the
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Figure 15: [125I]‐17β‐Estradiol High Affinity Binding Sites in Human Lenses. Lens nuclear,
cytoplasmic, and membrane fractions were prepared from two individual female donors (aged 57
and 78 years) as described in the Methods section. Aliquots of 200 μL of each fraction was
incubated with increasing concentrations of [125I]‐17β‐estradiol (total binding) or [125I]‐17β‐
estradiol and 100‐fold excess of diethylstilbestrol (non‐specific binding) for 1 hr at room
temperature. Specific binding was determined by subtracting non‐specific binding from total
binding. Kd and Bmax values were generated using GraphPad® Prism software, non‐linear
regression analysis. Detectable binding was observed in all three fractions from both donor
samples. Data shown are all individual data points plotted for both donors.
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Identification of Estrogen Receptor mRNA in the Mouse and
Human Lens
To determine which estrogen receptor(s) could be responsible for the
binding in the nuclear, cytoplasmic, and membrane fractions of the mouse and
human lens, the presence of the specific estrogen receptor transcripts (ERα, ERβ,
and GPR30) was assessed. Expression of the nuclear estrogen receptors, ERα and
ERβ were examined by real‐time reverse transcriptase polymerase chain reaction
(real‐time RT‐PCR) in C57H female mice (n=3) between the ages of 6 and 12
weeks.

Examination of receptor expression in young adults from the C57H

strain was chosen to correlate with the binding data (Figure 11) and cataract
studies in subsection B. In addition, the presence of message for GPR30 was also
investigated due to identifying 17β‐estradiol binding in the membrane fractions
of mouse and human lenses. To confirm that the specific transcript for each
primer was amplified, product size was verified using gel‐electrophoresis.

As

shown in Figure 16, the chosen primer pairs amplified the appropriately sized
product from ERα, ERβ and GPR30 mRNA from the mouse lenses.
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Figure 16: Female and Male Mouse Lens Tissues Express ERα, ERβ, and GPR30 mRNA. Total
mRNA was prepared from individual lens samples from 4‐wk‐old females (1 ♀), 3‐mo‐old
females (2 ♀), >12‐mo‐old females (3 ♀), 3‐mo‐old males (♂), and LECs (capsule) and fiber cells
(cortex) from 3‐mo‐old female mice of the C57H background as described in the Methods section
to test for expression by real‐time RT‐PCR. RT‐PCR products after 50 cycles were run on a
NuSieve/Agarose gel and visualized with ethidium bromide. The following products were
amplified from lens mRNA: Panel A, 182 bp product for ERα; Panel B, 200 bp product for ERβ;
Panel C, 171 bp product for GPR30; and Panel D, 145 bp product for ppia (cyclophilin A;
housekeeping gene as a positive control). A 100‐base‐pair ladder was included as a reference
point for amplified product size. All samples (except fiber cells with the ERβ‐specific primers)
produced CT values, amplified curves, and had the appropriate melting temperature. Due to
camera sensitivity issues, ERα and GPR30 in the fiber cells and ERβ in the male lens are not as
visible in the photograph as they were on the gel.

Next, estrogen receptor expression was examined in the human lens since
specific 17β‐estradiol binding was detected in the nuclear, cytoplasmic, and
membrane fractions (Figure 15). Individual lens mRNA samples were prepared
from the same females tested in the binding studies. Unlike in the mice, only one
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of the human lens samples (female donor aged 78 years) expressed GPR30 by
real‐time RT‐PCR (results not shown).

The second sample (female donor aged

57 years) did not express transcripts for ERα, ERβ, and GPR30 by real‐time RT‐
PCR. The human lenses from both women expressed the housekeeping gene,
GAPDH.

In the older female, GAPDH was more abundantly expressed in

comparison to GPR30 (results not shown). As human lenses are obtained post‐
mortem and frozen several hours after death, the quality of the tissue is not
optimal as is possible with the mouse tissue. The sample without detectable
estrogen receptor message had considerably lower RNA yields than the human
lens with estrogen receptor expression suggesting that RNA quality may have
been compromised. As a result the RNA may have been degraded or damaged
while awaiting tissue procurement and storage prior to shipment. Future studies
will need to examine additional female, as well as male, samples to determine
whether both men and women express these receptors in the lens.

Localization of ER in the C57Bl/6 Female Lens
To assess the localization of the specific ER mRNAs in the lens, the LEC
(capsule) and the lens fiber cells (cortex) were microdissected from 6‐12 week old
C57H female mice (n=3 pools/tissue type). Testing for the presence of nuclear
(ERα and ERβ) and membrane (GPR30) estrogen receptors in these two specific
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regions of the wild‐type (C57H) female mouse lens is designed to predict which
cell type may express each receptor type.

Since ERα and ERβ are classical

nuclear receptors, their presence is expected to coincide in the nucleated
epithelial cells associated with the lens capsule. ERα has also been reported to be
associated in the membrane and possess non‐genomic actions (Björnström L and
Sjöberg M, 2005); therefore, it may too be present in the non‐nucleated lens fiber
cells. The cortex contains fiber cells without nuclei which would be expected to
only express the membrane receptors, which could be products of GPR30 or
ERα. From the total RNA extracted from the fiber cells or capsule regions,
products specific for ERα, ERβ, and GPR30 were amplified by real‐time RT‐PCR.
As shown in Figure 16, the product size was confirmed to correspond to the
product size specific to the primers for each gene (see Table 5 for primers).
Expression of ERα and GPR30 mRNA was detected in both the LEC and
cortical fibers (Figure 17). The lower ΔCT values (Figure 17) for the fiber cells
versus the LEC suggests higher steady state levels of message since less PCR
cycles are required to amplify the product above a detectable threshold cycle (CT)
in samples with more abundant RNA (cDNA) levels. Specifically, ERα mRNA
was relatively expressed 6.25‐fold lower and GPR30 mRNA was 4.4‐fold lower in
the lens cortical fibers compared to the lens epithelial cells, although these
differences were not significant. ERβ was detected solely in the lens epithelial
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cells (Figure 16) as no CT value was obtained by real‐time RT‐PCR in the cortex
any of the three samples examined and no band was detected by gel‐
electrophoresis after 50 cycles. Although the band for ERα in the fiber cells is
barely visible by gel electrophoresis (Figure 16), real‐time RT‐PCR produced a Ct
value at the appropriate melting temperature to indicate this message is present
in the fiber cell‐rich fraction of the lens in all three samples tested.
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Figure 17: ERα and GPR30 Messages are Expressed in the Mouse LEC and Cortex. Total RNA
was extracted from pools of LECs and cortexes from 3‐month‐old C57H female mice and
converted to cDNA as described in the Methods section to test for expression by real‐time RT‐
PCR. All samples (except fiber cells with ERβ‐specific primers) produced CT values, amplified
curves, and had the appropriate melting temperature. ∆CT values for ERα and GPR30 were
determined by normalization with ppia to control for variation between samples and the ∆CT
values for each lens region were calculated. ∆Ct values are inversely proportional to the level of
expression; therefore a lower ∆Ct value is indicative of higher expression. No significant
difference in mRNA expression between the LEC and fiber cells for ERα (p = 0.1) or GPR30 (p =
0.1) was detected with the Mann‐Whitney U test. Results are graphed as mean ± SEM.; n=3
pools/lens region.
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Relative ER Expression Between Male and Female WT (C57H) Lenses
Since no significant differences in the 17β‐estradiol binding affinity
between lenses from C57H females and males is observed, the expression of the
three estrogen receptor messages in the males is expected to mimic the female
lens. To confirm the presence of ERα, ERβ, and GPR30 mRNA in the C57H male
lens, real‐time RT‐PCR was performed. Real‐time RT‐PCR produced a CT value
at the appropriate melting temperature in all female and male lens samples
examined. Expression levels of ERα, ERβ, and GPR30 mRNA are lower in the
male lens relative to the female lens by 1.51‐fold, 1.26‐fold and 2.32‐fold,
respectively; however, the difference in expression between males and females is
not significant (Figure 18). The representative gel confirms that the resulting
bands correspond to the expected product size for each amplified message
(Figure 16).
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Figure 18: All Three Estrogen Receptor Transcripts are Expressed in Male and Female Mouse
Lenses. cDNA, transcribed from total RNA extracted from 3‐month‐old male and female C57H
lenses was amplified by real‐time RT‐PCR to examine estrogen receptor gene expression. All
samples produced CT values, amplified curves, and had the appropriate melting temperature for
each specific primer. The product sizes were confirmed by gel electrophoresis (see Figure 16 for
representative gel photograph). Relative gene expression levels were calculated using the ∆∆CT
method as described in the Methods section. ΔCT values were determined by normalization with
ppia to control for variation between samples. ΔCT values are inversely proportional to the level
of expression, which means a lower ΔCT value is indicative of higher expression. No significant
differences were detected in estrogen receptor mRNA expression between female and male
lenses (Mann‐Whitney U Test, GraphPad® Prism). Results are represented as mean ± SEM;
n=3/sex.

Age‐specific ER Expression in Lenses from C57H Female Mice
The Blue Mountain (BMES) and Beaver Dam (BDES) human epidemiology
studies suggest that age of menstruation and menopause correlate to cataract
risk. Women who begin to menstruate at a younger age have a decreased risk of
developing nuclear sclerosis (Klein et al., 1994), while menstruation onset at an

- 99 -

older adolescent age increases cataract risk (Cumming et al., 1991). Additionally,
the older a women is at menopause, the lower the risk of cortical cataract
development (Klein et al., 1994). These reports suggest that the longer a woman
is exposed to estrogen, the lower the risk of developing cataracts. Whether
estrogen receptor expression varies at different ages to influence cataract risk has
not been examined. Therefore, lenses from adolescent, young adult, and old
female mice will be analyzed for estrogen receptor expression to determine if it
varies at different ages.
To determine if ERα, ERβ, and GPR30 mRNA were present and/or
differentially expressed in the lens at different ages, real‐time RT‐PCR was
performed on RNA obtained from lenses of 1‐month‐old, 3‐month‐old, and >12‐
month‐old C57H female mice to correlate to adolescent, young adult, and old
ages, respectively. All three ER transcripts are expressed in all three ages of mice
and mRNA expression levels were not significantly different with age (Figure
19). Expression levels of ERα in the lens were relatively lower, 0.29‐fold and
0.69‐fold, in the 1 month and >12 months of age female mice, respectively,
compared to 3‐month‐old female mice (Table 6).

Although not significantly

different, transcript levels for ERβ were relatively higher in lenses obtained from
females over the age of 12 months, 1.88‐fold, compared to young adult females
(Table 6). The trend in relative levels of GPR30 mRNA suggests its expression
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may decrease with age. Specifically, GPR30 message was expressed 1.30‐fold
higher in lenses obtained from 1‐month‐old female mice and 0.57‐fold in mature
adults compared to young adults (Table 6).
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Figure 19: Expression of ERα, ERβ and GPR30 Transcripts in the Mouse Lens with Age.
Estrogen receptor expression levels were determined in RNA extracted from lens tissues of 1‐
month‐old, 3‐month‐old, and over 12‐month‐old WT (C57H) female mice by real‐time RT‐PCR.
ΔCt values were determined by normalization with ppia to control for variation between samples.
∆Ct values are inversely proportional to the level of expression; therefore, a lower ∆Ct value is
indicative of higher expression. No significant differences in estrogen receptor expression were
found between the ages (Kruskal‐Wallis Test, GraphPad® Prism). Results are represented as
mean ± SEM; n=3/age group. The product sizes for ERα, ERβ, and GPR30 were confirmed to
correspond to the expected amplified product for the primer used in all samples; a representative
gel is shown in Figure 16.
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Table 6: Estrogen Receptor Gene Expression Changes in the Lens of Aging
C57H Female Mice
Ages

ERα

ERβ

GPR30

1 month

0.29
(0.17 – 0.50)
1.00
(0.76 – 1.31)
0.69
(0.48 – 0.99)

0.95
(0.77 – 1.17)
1.00
(0.88 – 1.14)
1.88
(1.82 – 1.95)

1.30
(1.11 – 1.52)
1.00
(0.97 – 1.03)
0.57
(0.43 – 0.75)

3 months
>12 months

Relative fold differences between all age groups are shown compared to the 3‐month‐old WT
(C57H) female lens. Relative fold changes were calculated using the ∆∆CT method and statistical
significance was determined using the ∆CT values. No significant differences were found
between the ages and estrogen receptor subtype (Kruskal‐Wallis Test, GraphPad® Prism).

In summary, transcripts for all three estrogen receptors were detected in
the mouse lens with the exception of ERβ not being detected in the fiber cells.
Expression of all three subtypes suggests estrogen may be capable of acting
directly in the lens via both nuclear and membrane estrogen receptors to provide
protection against the loss of lens transparency. Differential expression trends
suggest expression of GPR30 to be more abundant when compared to expression
of ERα in all ages and gender with a significant difference in the 1‐month‐old
C57H female lenses (Figure 20 and Table 7). There was no significant difference
calculated between ERα and ERβ expression with age and gender; however, ERβ
was slightly more abundant in 1‐, 3‐, and >12‐month old female, and 3‐month‐
old male C57H lenses compared to ERα (Figure 20 and Table 7).
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Together,

these results are the first to demonstrate the expression of GPR30, the novel
membrane estrogen receptor, in both the human and mouse lens. Furthermore,
these results are the first to demonstrate estrogen receptor expression is similar
in lenses with age and gender.
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Figure 20: Expression of ERα, ERβ and GPR30 Transcripts in the Mouse Lens. This figure is a
composite graph of estrogen receptor mRNA levels in mouse lens tissues from 1‐month‐old
females, 3‐month‐old females and males, >12 month‐old females, and 3‐month‐old female LECs
and cortex of C57H mice. ΔCt values were determined by normalization with ppia to control for
variation between samples. ∆Ct values are inversely proportional to the level of expression;
therefore, a lower ∆Ct value is indicative of higher expression. A significant difference between
ERα and GPR30 expression was observed in the 1‐month‐old C57H female lenses and no
significant differences in estrogen receptor expression were found between other sample groups
(GraphPad® Prism, Mann‐Whitney U test, * p < 0.05). Results are represented as mean ± SEM;
n=3/group.
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Table 7: Estrogen Receptor Gene Expression Changes in the Mouse Lens

ERα

Genes
ERβ

GPR30

3 mo. Female Lens

1.00
(0.76 – 1.31)

1.17
(1.03 – 1.33)

3.85
(3.72 – 3.98)

3 mo. Male Lens

1.00
(0.87 – 1.15)

1.41
(1.08 – 1.85)

2.51
(1.68 – 3.74)

3 mo. Female
LEC

1.00
(0.66 – 1.52)

0.88
(0.84 – 0.93)

2.11
(1.46 – 3.04)

3 mo. Female
Lens Fibers

1.00
(0.58 – 1.72)

Not Detectable

3.00
(2.13 – 4.22)

1 mo. Female Lens

1.00
(0.59 – 1.71)

3.82
(3.09 – 4.71)

17.21*
(14.76 – 20.08)

>12 mo. Female Lens

1.00
(0.70 – 1.43)

3.19
(3.08 – 3.30)

3.17
(2.41 – 4.18)

Groups

Composite table of the relative fold differences in estrogen receptor expression (compared to
ERα) for all C57H experimental groups. Relative fold changes were calculated using the ∆∆CT
method and significant differences were determined using the ∆CT values (see Figure 20). A
significant difference in the differential expression between ERα and GPR30 was detected in the
1‐month‐old female lens (GraphPad® Prism, Mann‐Whitney U test, *p < 0.05). No significant
difference between receptor subtype in the other groups was detected (GraphPad® Prism, Mann‐
Whitney U test, p <0.05).

Together, the binding studies and mRNA expression work are the first
evidence of both nuclear and membrane estrogen receptors in the mouse and
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human lens. The [125I]‐17β‐estradiol binding sites in the nuclear, cytoplasmic,
and membrane fractions of the mouse and human lens suggest the presence of
functional estrogen receptors. Functional estrogen receptors, that is lens proteins
capable of specifically binding estrogen, are expressed in the lens. Additionally,
the results from the real‐time RT‐PCR detected the presence of nuclear estrogen
receptors, ERα and ERβ, in the mouse lens and the novel membrane estrogen
receptor, GPR30, in both the mouse and human lens. Therefore, these data
suggest estrogen is capable of eliciting its action directly in the lens by binding to
specific nuclear and membrane estrogen receptors.
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B. Absence of Specific Estrogen Receptors in the Development of
Cataracts
With the confirmation of estrogen receptors in the lens (by binding and
real‐time RT‐PCR analyses), the next step was to determine the specific role of
each nuclear estrogen receptor in the lens in relation to cataract development.
Estrogen has been shown to be protective against cataracts induced by
transforming growth factor β (Hales et al., 1997) and methylnitrosurea‐induced
(Bigsby et al., 1999); however, the specific estrogen receptor responsible for its
effect is not known. In the estrogen receptor knockout (ERKO) mouse models,
ERα and ERβ genes are mutated to prevent translation of a functional receptor in
order to identify their tissue‐specific roles in regards to normal and abnormal
tissue physiology (Couse and Korach, 1999). To examine the specific role of each
nuclear ER subtype in the lens, slit‐lamp examinations were performed on aging
male and female mice that were null for either ERα and/or ERβ or both in
comparison to wild‐type litter mates to detect lens abnormalities. The following
terms denote the genotypes of mice investigated: αERKO (no ERα), βERΚΟ (no
ERβ), αβERKO (no ERα and ERβ), and WT (both ERα and ERβ are expressed).
Slit‐lamp

examinations

were

performed

monthly

beginning

at

approximately 4 months of age until animals were 16 months of age. The use of
the slit‐lamp biomicroscopy allows visualization of the ocular surface and
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anterior segment of the eye such that abnormalities or opacifications in specific
regions of the lens can be detected prior to the cataracts being evident by gross
inspection.

Regardless of their genotype and gender, morphological

abnormalities on the anterior surface of the lens were observed at 100% incidence
in αERKO, βERKO, αβERKO, as well as WT mice (Table 8). These changes were
first observed at approximately 8 months of age in all genotypes of the living
mice and progressed in severity up until the maximum age of 16 months. The
observable anterior abnormalities in the lenses from all of the genotypes,
including WT, suggest that they are not a result of the loss of ER. There was no
evidence of nuclear or cortical cataracts in either gender by slit‐lamp
biomicroscopy or gross inspection (Table 9).

Table 8: Incidence of Anterior Abnormalities in 16‐month‐old ERKO Mice by
Slit‐Lamp Biomicroscopy

Genotype

Female

Male

αERKO

100% (n= 6)

100% (n=8)

βERKO

100% (n= 6)

100% (n= 7)

αβERKO

100% (n= 7)

100% (n=8 )

WT

100% (n= 6)

100% (n= 6)

Along with WT female and male mice, lenses from mice lacking ERα and/or ERβ were examined
by slit‐lamp biomicroscopy and gross inspection for abnormalities associated with cataracts.
Anterior abnormalities were detected by slit‐lamp biomicroscopy in all genotypes and both
genders. There was no evidence of cortical or nuclear cataracts by slit‐lamp biomicroscopy or
gross inspection.
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Histopathology of 16‐month‐old eyes from all genotypes and both
genders was completed to confirm slit‐lamp observations.

The anterior

subcapsular vacuoles observed by slit‐lamp biomicroscopy (Table 8) were also
detected by histopathology (Figure 21) in all lenses examined irrespective of
genotype since the wild‐type mice also exhibit similar lenticular phenotypes as
the ERKO mice. Previous reports have shown that aging C57Bl/6 mice (Wolf et
al., 2000) exhibit the same phenotype as the ERKO mice, which is the main strain
of the ERKO mice. Hence, the age of detectable anterior lens abnormalities and
subcapsular vacuoles appear to be inherent lenticular changes associated with
the mouse strain versus the loss of either ER subtype. Therefore, loss of one or
both ER subtypes does not induce spontaneous cataract development.

Table 9: Gross Cataract Incidence in 16‐month‐old ERKO Mice
Genotype

Female

Male

αERKO

0% (n= 6)

0% (n=8)

βERKO

0% (n= 6)

0% (n= 7)

αβERKO

0% (n= 7)

0% (n=8 )

WT

0% (n= 6)

0% (n= 6)
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A.
ASV

ASV

αβERKO

αERKO

ASV

ASV

βERKO

WT

B.

ASV

ASV

αβERKO

αERKO

ASV

ASV

βERKO

WT

Figure 21: Anterior Subcapsular Vacuoles in the Lenses from 16‐Month‐Old ERKO Female
and Male Mice. ERKO and WT animals were generated on the C57Bl/6/129SV (C57H)
background. Panels in A illustrate representative female mouse lens sections; Panels in B
illustrate representative male mouse lens sections. The genotypes are noted at the bottom of each
photograph. All genotypes exhibit anterior subcapsular vacuoles (ASV); designated by the arrow
in each panel. All histological sections (5 μm thick) were stained using hematoxylin & eosin stain
(H&E). All images are shown at 200x magnification.
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Roles of ERα and ERβ in the ER∆3 Transgenic Mouse Model
The ERKO studies determined that loss of ERα and/or ERβ does not result
in spontaneous cataract development; however, ERα and/or ERβ may still
provide protection in the lens against cataract risk factors. Therefore, ERKO
(C57BL/6/129SV or C57H) mice were bred with ER∆3 (FVB/n) to generate
ERKO/ER∆3 (C57Bl/6/129SV/FVB/n or C57H/FVB) mice to examine the role of
ERα and ERβ in the ER∆3 model of inducible cataracts. Animals with reduced or
no ERα and/or no ERβ expressing ER∆3 were compared to WT (no ER∆3) and
ER∆3 expressing both ERα and ERβ (Table 10). Female mice homozygous for the
ERα disruption (αERKO) are reported to have significantly higher endogenous
estrogen levels (Couse et al., 2002).

Davis and colleagues reported that a

sufficient level of endogenous estrogen is required for the development of
spontaneous ER∆3 cataracts since ER∆3 male mice remain cataract‐free unless
supplemental estradiol is administered to induce the phenotype (Davis et al.,
2002). Therefore, if an observable difference in the incidence of ER∆3‐induced
cataracts occurs between αERKO/ER∆3 and ER∆3 female mice; this increased risk
may be due to higher levels of circulating estrogens to activate the ER∆3
repressor versus to the lack of ERα. For that reason, animals heterozygous for
the disruption of ERα (ERα+/‐) were generated and examined to identify the effect
on cataract incidence in animals with diminished levels of ERα without the
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increase in endogenous estrogen.

When interpretating the data, an increase in

the incidence of ERΔ3‐induced cataracts in ERKO/ER∆3 mice compared to ER∆3
may indicate that the specific receptor (ERα or ERβ) is essential for maintaining
lens transparency. In contrast, a decreased incidence may indicate the specific
receptor is required or contributes to ER∆3 cataract formation.
Lens abnormalities in the ERKO mice expressing the ER∆3 repressor were
detected by gross inspection, slit‐lamp biomicroscopy, and histopathology.
Anterior surface abnormalities characteristic of the C57Bl/6 strain were detected
in ERKO/ER∆3 female and male mice by slit‐lamp examination and confirmed by
histopathology (results not shown) as seen in the WT and ERKO (C57H) mice
(see Figure 21). The age of onset for the anterior surface abnormalities was
similar to that observed in ERKO and WT mice, approximately 8 months of age,
indicating the dominance of this phenotype even in the C57H/FBV background.
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Table 10: Estrogen Receptor Expression in ERKO/ERΔ3 Animals
ER Genotype

ERα

ERβ

ERΔ3

Comments

αERKO/ERΔ3

‐

+

+

♀‐high estrogen levels*; ERΔ3 inhibition of
ERβ only

ERα+/‐/ERΔ3

+/‐

+

+

Reduced ERα expression**

ERα+/‐/
βERKO/ERΔ3

+/‐

‐

+

Reduced ERα expression**; ERΔ3 inhibition of
ERα only

βERKO/ERΔ3

+

‐

+

ERΔ3 inhibition of ERα only

αβERKO/ERΔ3

‐

‐

+

ERΔ3 activity in absence of ERα and ERβ

ERΔ3

+

+

+

ERΔ3 inhibition of ERα and/or ERβ

WT

+

+

‐

Normal ERα and ERβ activity

* Couse and Korach, 1999; ** Park et al., 2005.

Previous works by Davis and colleagues observed gross cataracts in
ER∆3 (C57Bl/6 and FVB/n hybrid strains) at 6 months of age (unpublished);
however, these animals were not monitored at earlier age. Therefore, ER∆3
(C57H/FVB) mice were examined monthly by gross inspection and slit‐lamp
biomicroscopy for cataracts. Gross cataracts were detected as early as 4 months
of age in ERΔ3 female mice on the C57H/FVB hybrid background after dilation of
the pupil (Table 11). Cortical vacuoles, which are characteristic of the ER∆3‐
induced cataract, were observed in the lens of ER∆3 female mice as early as 2
months of age by slit‐lamp examination. However, the incidence is not 100% (see
Table 11) as occurs in FVB/n mice expressing ER∆3 (Davis et al., 2002). These
data suggest that later onset of cortical cataracts may be due to the presence of
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the normal retina in the C57H/FVB mice unlike in the FVB/n strain mice.
However, other strain‐related differences may be responsible, such as dissimilar
endogenous estrogen levels between the two strains (not tested). Histopathology
on lenses from ER∆3 (C57H/FVB) mice at 4‐5 and 10 months of age, confirmed
slit‐lamp observations of anterior surface abnormalities and the presence of
cortical vacuoles (Figure 22). The lens remained transparent in the ER∆3 male
mice (C57H/FVB) up to 10 months of age (results not shown) which mimics the
results in the ER∆3 (FVB/n) male mice.
Another factor that may explain the delay in the onset of cortical cataracts
in ER∆3 mice on the C57Bl/6/FVB/n (Davis et al., unpublished) and C57H/FVB
(Table 11) backgrounds compared to FVB/n strain is the expression level of the
ER∆3 repressor. ER∆3 mice of the FVB/n background are dizygous for the ER∆3
repressor; whereas, animals of the C57Bl/6’FVB/n and C57H/FVB are
hemizygous for the ER∆3 repressor. Therefore, ER∆3 (FVB/n) mice may express
higher ER∆3 repressor levels (not examined) which accounts for the earlier onset
of cortical cataract detection.

-113-

Table 11: Gross Cataract Incidence in ERKO/ER∆3 Female Mice
Genotype

2 months

4‐5 months

7 months

10 months*

ERΔ3

0% (n=9)

9% (n=11)

0% (n=5)

25% (n=8)

βERKO/ ERΔ3

0% (n=7)

0% (n=5)

0% (n=3)

0% (n=3)

ERα±/βERKO/ERΔ3

0% (n=7)

9% (n=11)

22.2% (n=9)

25% (n=8)

ERα±/ERΔ3

0% (n=9)

30.8% (n=13)

33.3% (n=6)

66.7% (n=9)

αβERKO/ ERΔ3

50% (n=4)

80% (n=5)

ND

ND

αERKO/ ERΔ3

0% (n=8)

0% (n=9)

100% (n=3)

100% (n=5)

WT

0% (n=9)

0% (n=10)

0% (n=6)

0% (n=6)

Eyes from animals with the above genotypes were dilated with 1% tropicamide and inspected for
gross cataracts with the naked eye. The lack of detectable gross cataracts in some mice may be
due to a decrease in severity of the cataract (cataract has not progressed to be visible by the
unaided eye); therefore, the lack of gross cataracts does not rule out the possibility of immature
cortical cataracts. To confirm the presence or lack of cataracts, eyes were also examined by slit‐
lamp biomicroscopy and/or histopathology. A minimum of three animals/genotype/gender were
observed monthly beginning at 2 months of age until 10 months of age. Incidence is defined as
one and/or two lenses per animal which appear cataractous. An observed decline in the
incidence of gross cataracts in ER∆3 female mice between the 4‐5 and 7 month time point is due
to the animal with observable gross cataract being euthanized at 4‐5 months of age. Using
GraphPad® Prism software (Chi‐Squared test, *p<0.05), an observable difference in the incidence
of gross cataracts is observed between all genotypes at 10 months of age. No observable gross
cataracts were observed in male counterparts at all ages up to 10 months of age.
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A. 5 months of age

B. 10 months of age

Figure 22: Cortical Cataracts in Aging ERΔ3 (C57H/FVB) Female Mice. Cortical vacuoles
indicative of ER∆3‐induced cataracts were observed in 5 and 10 months of age female mice by
histopathology. Tissue sections (5 μm thick) from 5‐month (upper panels) and 10‐month‐old
(lower panels) female mice (ER∆3), shown at 40x (left panels) and 400x (right panels)
magnification. The right panel magnifies the cortical region of the lens within the box from the
left panel. All histological sections were stained using hematoxylin & eosin stain (H&E) in eyes
fixed with formalin.

To determine the role of ERβ in ER∆3‐induced cataracts, animals
expressing ER∆3 and lacking ERβ (βERKO/ER∆3) were generated.

βERKO

female mice are reported to have comparable serum estradiol levels as WT
female mice (Couse et al., 2002).

Gross cataracts were not detected in the

βERKO/ER∆3 female (Table 11) and male (results not shown) mice up to the age
of 10 months. Additionally, phenotypical changes associated with ER∆3‐induced
cataracts were not observed by slit‐lamp examination or by histology (Figure 23).
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Due to low number of the female mice with the βERKO/ER∆3 genotype (n=3) at
10 months of age and the low incidence of cataracts in similarly aged ER∆3
female mice (2 in 8 females), these data cannot confirm that loss of ERβ protects
the lens from ER∆3‐induced cataracts. Investigation of additional genotypes
(αβERKO/ER∆3 and ERα+/‐/βERKO/ER∆3, both described below) will provide
insight as to whether or not ERβ has a role in the induction of cortical cataracts in
the ER∆3 model.
a. 5 months of age

b. 10 months of age

Figure 23: Histological Analysis of ER∆3‐Induced Cortical Cataracts in βERKO/ER∆3 Female
Mice. Cortical vacuoles indicative of ER∆3‐induced cataracts were not observed in 5 and 10
months of age βERKO)/ER∆3 (C57H/FVB) female mice. Tissue sections (5 μm thick) are from 5‐
month‐old (upper panels) and 10‐month‐old female mice shown at 40x (left panels) and 400x
(right panels) magnification. The cortical region within the box (left panels) is magnified in the
right panel. All histological sections were stained using hematoxylin & eosin stain (H&E) in
formalin‐fixed eyes.

-116-

To determine the role of ERα in the ERΔ3 model of induced cataracts, the
incidence of cataracts in ERΔ3 mice that lacked ERα (αERKO/ERΔ3) was
examined. Gross cortical cataracts were detected at approximately 7 months of
age in αERKO/ER∆3 females with 100% incidence (Figure 24) and confirmed by
slit‐lamp biomicroscopy. At 10 months of age, lenses collected for histopathology
confirmed the presence of cortical cataracts in αERKO/ER∆3 female mice (Figure
24). Unlike the female mice, no detectable gross cortical cataracts were observed
in αERKO/ER∆3 male counterparts up to 10 months of age (results not shown).
The age of onset for the first ER∆3‐induced cataract was delayed in ER∆3 female
mice without ERα (αERKO/ER∆3) compared to ER∆3 female mice; however, the
percent incidence at 7 months of age is significantly increased with loss of ERα
(Table 11).

The increased incidence suggests the loss of ERα results in

heightened susceptibility to ER∆3‐induced cortical cataracts.

However, the

change may also be a result of increased endogenous estrogen from the loss of
negative feedback in the hypothalamic‐pituitary‐gonadal axis of αERKO females
(Couse and Korach, 1999) which would likely cause an increased activation of
the dominant negative receptor.

Results from the ER∆3 female mice with

reduced levels of ERα (ERα+/‐/ER∆3) and ones that lacked both ERα and ERβ
(αβERKO/ER∆3) will help address whether ERα loss or estrogen levels are the
determining factors in the onset and severity of cataracts in the αERKO/ER∆3
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female mice since endogenous estrogen levels should be comparable to WT in
ERα+/‐/ER∆3 and αβERKO/ER∆3 female mice.

a. 4 months of age

b. 10 months of age

Figure 24: αERKO/ERΔ3 Female Mice Develop Cortical Cataracts. Cortical vacuoles indicative
of ER∆3‐induced cataracts were observed in 10 months of age αERKO/ER∆3 (C57H/FVB) female
mice. Sections are from 4‐month‐ (upper panels) and 10‐month‐old (lower panels) αERKO/ER∆3
female mice shown at 40x (left panels) and 400x (right panels) magnification. The right panel
magnifies the cortical region of the lens within the box from the left panel. All histological
sections (5 μm thick) were stained using hematoxylin & eosin stain (H&E) from eyes fixed in
formalin.

To determine if the increased incidence of gross cataracts observed in 7‐
month‐old αERKO/ERΔ3 female mice is due to the loss of functional ERα in the
lens versus an increase in endogenous estradiol levels, ERΔ3 female mice
heterozygous for the disruption of the ERα gene (ERα+/‐/ER∆3) were investigated
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for cataract occurrence along with their αERKO/ER∆3 bitransgenic littermates.
Previous studies have demonstrated similar endogenous estrogen levels in ERα+/‐
and WT (C57H) female mice (Couse and Korach, 1999). Park and colleagues
(2005) reported that mice heterozygous for the disruption of ERα also express
approximately one half the levels of ERα protein in the uterus compared to WT
mice; therefore, ERα levels may also be 2‐fold lower in the lenses of ERα+/‐ mice
compared to WT mice. ERα+/‐/ER∆3 female mice, with the predicted diminished
levels of ERα in lenses and normal estrogen levels, the age of first gross cataract
detection (4 months of age) was similar compared to ER∆3 female mice (Table
11). These opacities were confirmed by histopathology to be cortical cataracts
(Figure 25). At 10 months of age, the incidence of ER∆3‐induced gross cataracts
in ERα+/‐/ER∆3 female mice was 66.7%, which was higher than ER∆3 (with WT
ERα and ERβ), but lower than the αERKO/ER∆3 female mice (Table 11). These
results suggest ERα levels are lower in female mice heterozygous for ER and
these potentially diminished levels of ERα may increase the incidence of ER∆3‐
induced cataracts or possibly accelerate the onset. Similar to the αERKO/ER∆3
and ER∆3 male mice, cortical cataracts were not detected by gross and slit‐lamp
examination and confirmed by histopathology in ERα+/‐/ER∆3 male mice (results
not shown).
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a. 4 months of age

b. 10 months of age

Figure 25: Cortical Cataracts are Detectable by Histopathology in the Lenses of ERα+/‐/ERΔ3
Female Mice. Cortical vacuoles indicative of ER∆3‐induced cataracts were observed in 4‐month‐
old (upper panels) and 10‐ month‐old (lower panels) of age ERα+/‐/ER∆3 (C57H/FVB) female mice.
Eye sections are shown at 40x (left panels) and 400x (right panels) magnification. The right panel
magnifies the cortical region of the lens within the box from the left panel. All histological
sections (5 μm thick) were stained using hematoxylin & eosin stain (H&E) from formalin‐fixed
eyes.

To determine if loss of ERβ protects the lens from ER∆3‐induced cataracts
in female mice with reduced levels of ERα, ERα+/‐/βERKO/ER∆3 mice were
generated. ERα+/‐/βERKO/ER∆3 male littermates were also examined by gross
inspection,

slit‐lamp

biomicroscopy,

and

histopathology

for

lenticular

abnormalities and, with these methods, no abnormalities associated with the
ER∆3 model were observed (results not shown).

If the presence of ERβ is

essential for the induction of ER∆3 cataracts in female mice, the observed effect
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in this genotype would be similar to that of βERKO/ER∆3 with no cataracts
observed.

Interestingly, when compared to detectable gross cataracts in

βERKO/ER∆3 female mice, the age of onset in ERα+/‐/βERKO/ER∆3 female mice
(between 4‐5 months) was similar to that of ER∆3 females with or without ERα
(Table 11). Additionally, morphological characteristics associated with the ER∆3
model were detected at 3 months of age by slit‐lamp biomicroscopy and
confirmed by histopathology (results not shown). The incidence of the ER∆3
phenotype is also the same (1 out of 11) in the ERα+/‐/βERKO/ER∆3 and ER∆3
female mice (Table 11).

However, when comparing the incidence of ER∆3‐

induced cortical cataracts between female mice with diminished levels of ERα
with or without ERβ, the incidence of gross cataracts is higher in ERα+/‐/ER∆3
(with ERβ) female mice (4 out of 13) compared to 1 out of 11 in ERα+/‐
/βERKO/ER∆3 (without ERβ) female mice (Table 11). Thus, these results suggest
ERβ has an important role in the lens.
To examine if nuclear ER are required for ER∆3‐induced cataracts, ER∆3
mice null for both ERα and ERβ were investigated.

The data from the

αβERKO/ERΔ3 animals will determine if ER∆3 inhibition in the lens only occurs
when it dimerizes with ERα and/or ERβ. Due to inherent difficulties associated
with generating triple transgenic animals, only a few αβERKO/ER∆3 mice were
produced.

At 2 months of age, gross cortical cataracts were observed and
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confirmed by slit‐lamp examination and histopathology in αβERKO/ER∆3
female mice (Figure 26). Between 4‐5 months of age, the gross cataract incidence
in these triple transgenic female mice was 80% (Table 11). Therefore, cataract
development was only investigated up to this age to eliminate the potential loss
of study animals due to unexpected death with age.

Similar to the other

genotypes investigated, αβERKO/ER∆3 male mice remained cortical cataract free
(results not shown).

a. 4 months of age

Figure 26: Histological Evidence of Cortical Cataracts in αβERKO/ER∆3 Female Mice Lens.
Eyes from 4‐month‐old αβERKO/ER∆3 (C57H/FVB) female mice were collected and fixed in
formalin. Histological sections (5 μm thick) stained with hematoxylin & eosin stain (H&E).
confirm the presence of cortical vacuoles indicative of ER∆3‐induced cataracts. The tissue
sections of the eye show the presence of cortical vacuoles (left panel, 40x magnification). The
right panel (400x) magnifies the cortical region of the lens within the box in the left panel.

WT (C57H/FVB) littermates served as a control for the interpretation of
the lens pathology from ERKO/ER∆3 male and female mice in this study. Their
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use was critical in the interpretation of model‐specific versus strain‐specific
morphological changes in the lens that occur with age. Slit‐lamp examinations
and histopathology in aging wild‐type female and male mice indicate the lack of
cortical vacuoles while subcapsular vacuoles associated with the C57H
background strain were present (refer to Figure 27 for representative WT female
lens sections).

These results in the WT (C57H/FVB strain, Table 11) are in

agreement with the observations in the WT mice (C57H, Table 9) from the ERKO
spontaneous cataract study.
In summary, in male ERKO/ER∆3 mice (up to age of 10 months), gross
cortical cataracts were not detected regardless of ER subtype and ER∆3
expression (results not shown). Thus, loss of nuclear estrogen receptors, ERα
and/or ERβ, does not increase the propensity of ER∆3 male mice to
spontaneously develop cataracts. Gross cortical cataracts characteristic of the
ER∆3 model were observed in female ER∆3 (C57H/FVB) mice (Figure 22);
however, the incidence of these cataracts is not 100% as observed in FVB/n strain
(Davis et al., 2002). Additionally, loss of ERα in female mice expressing ER∆3
increased the incidence of gross cortical cataracts compared to ER∆3 female mice
with WT ERα (Table 12). Loss of both ERα and ERβ accelerated the onset of
gross cortical cataracts in the ER∆3 female mice compared to αERKO/ER∆3 and
βERKO/ER∆3 female mice (Table 12) to suggest ER∆3 homodimers are capable of
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inducing cortical cataracts in the absence of both ER subtypes. In ER∆3 female
mice with reduced levels of ERα and WT ERβ, the occurrence of gross cortical
cataracts was greater at 4‐5 and 10 months of age in comparison to ER∆3 female
mice with WT ERα (Table 12). These results suggest that loss of ERα in female
mice increases the propensity of inducing ER∆3 cortical cataracts. Therefore,
estrogen action via ERα may play a protective role in the lens against cataract
development.

Table 12: Female Gross Cataract Incidence in ER∆3 Females with Diminished
Levels of ERα Expression

ER∆3
ERα+/‐/βERKO/ER∆3
ERα+/‐/ER∆3
αERKO/ER∆3
αβERKO/ER∆3

Age
4‐5 months
+ (n=11)
+ (n=11)
++ (n=13)
‐ (n=9)
++++ (n=5)

2 months
‐ (n=9)
‐ (n=7)
‐ (n=9)
‐ (n=8)
++ (n=4)

10 months
+ (n=8)
+ (n=8)
+++ (n=9)
+++++ (n=5)
ND

Cataract incidence determined by gross inspection is indicated by – (0% incidence); + (9‐25%
incidence); ++ (25‐50% incidence); +++ (66.7‐75% incidence); ++++ (80‐99% incidence); +++++ (100%
incidence). ND indicates cataract incidence could not be determined at this age since animals
were euthanized at earlier ages. The n represents only the number of animals examined for gross
cataracts at the specific age since not all study animals were monitored at all ages listed. Eyes
were examined either after dilation with 1‐2 drops of 1% tropicamide 15‐20 minutes prior to gross
inspection in live mice or at euthanization without treatment since the pupils dilate naturally at
death.
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a. 5 months of age

b. 10 months of age

Figure 27: Cortical Vacuoles Characteristic of ER∆3‐induced Cataracts Are Not Evident in
Aging WT Female Mice. Cortical vacuoles indicative of ER∆3‐induced cataracts were not
observed in 5 (upper panels) and 10 months of age (lower panels) WT female mice (C57H/FVB).
The left panels are of the entire eye (40x magnification) and right panels (400x magnification)
magnify the cortical region of the lens within the box of the panel on the right. Tissue sections
(5μm thick) were prepared from formalin‐fixed WT female eyes stained with hematoxylin‐eosin.
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C. Cataract Induction in ERΔ3 Male and Female Mice
Previous work completed by Davis and colleagues (2002) has
demonstrated the following in the ERΔ3 transgenic mouse model: 1) intact ERΔ3
(FVB/n) female mice spontaneously develop cortical cataracts that are grossly
visible at approximately 3 months of age, 2) ovariectomy prior to puberty
protects ERΔ3 female mice from developing cataracts unlike, ovariectomy after
puberty, 3) cataracts can be induced in ERΔ3 males with exogenous estrogen
supplementation, 4) the potent estrogen, diethylstilbestrol (DES), subcutaneously
administered daily on days 1‐5 after birth induced cortical cataracts in male and
female mice, and 5) cataracts occur after subcutaneous administration of 500
μg/kg 17β‐estradiol in immature ERΔ3 (FVB/n) male and female mice (Davis,
unpublished).

However, the above work does not answer two important

questions, 1) when do morphological changes associated with cortical cataracts
begin after estrogen treatment and 2) is the age of estrogen exposure (exogenous
or endogenous) critical for ER∆3‐induced cataract formation?

In the ER∆3

model, male and female mice will not develop cataracts without estrogen to
activate the estrogen repressor receptor (ER∆3). For this reason, cortical cataracts
are evident in ER∆3 female mice after puberty and with supplemental estrogen
administered to the ER∆3 males.

Therefore, to further examine cataract

induction in this model, immature male and female ER∆3 mice (d17‐d19 of age)
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were administered exogenous estrogen prior to the synthesis of natural estrogen
to determine how soon morphological changes associated with ER∆3‐induced
cataracts could be detected by slit‐lamp examination.
To verify and generate a time course of lenticular changes, 1000 μg/kg
17β‐estradiol was subcutaneously administered to male and female mice
between 17 to 19 days of age. Initially, morphological changes were examined 4‐
days post‐treatment by slit‐lamp examinations in both male and female ER∆3
mice to confirm cataractous changes occur as observed previously. A higher
dose of 17β‐estradiol dose was tested to determine if a more rapid effect would
be observed with a higher dose compared to the dose (500 μg/kg 17β‐estradiol)
previously examined by Davis et al., (unpublished). These results confirm that
1000 μg/kg 17β‐estradiol administered subcutaneously to immature ER∆3 female
and male mice can induce spontaneous cataracts with morphological changes
observed 4 days‐post treatment by slit‐lamp biomicroscopy (data not shown).
Since cataractous changes were present at 4 days post‐treatment with both
doses, 500 μg/kg 17β‐estradiol (Davis et al., unpublished) and 1000 μg/kg 17β‐
estradiol (results not shown), earlier time points were examined to determine
when the first evidence of cortical cataract is visible by slit‐lamp biomicroscopy.
Therefore, 17 to 19‐day‐old, sexually immature ER∆3 (FVB/n) female and male
mice (16‐20 eyes/time point) were examined at 6, 14, 18, 24, 48, 72 and 96 hrs
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post‐treatment with 1000 μg/kg 17β‐estradiol. Additionally, for a control, vehicle
was administered to a subset of ER∆3 animals and examined by biomicroscopy
at 72 and 96 hrs to verify that any resulting phenotypes observed were a result of
17β‐estradiol treatment.
As early as 48 hrs post‐treatment with 1000 μg/kg 17β‐estradiol, cortical
vacuoles characteristic of ER∆3 cataracts were observed by slit‐lamp
biomicroscopy (Figure 28). 100% incidence of bilateral cortical cataracts were
observed in groups examined 48, 72, and 96 hrs after 1000 μg/kg 17β‐estradiol
treatment, and at earlier time points, morphological changes in the lens (0%
incidence) were not observed (Table 13). These data suggest that detectable
cortical cataracts occur between 24 and 48 hrs after estrogen treatment. At 48 hrs,
vacuoles covered approximately 12.5% of the lens and the severity increased
with time (Figure 28).

Cortical vacuoles were not detected in vehicle‐treated

immature ER∆3 male and female mice up to 96 hrs after exposure. These results
suggest ER∆3 cataracts are rapidly induced by 17β‐estradiol in immature ER∆3
female and male mice with observable cortical vacuoles detected at 48 hrs post‐
treatment by slit‐lamp biomicroscopy.
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Figure 28: 17β‐Estradiol Induces Cortical Vacuoles in Immature ER∆3 Mice which Increase in
Severity with Time. Rate of morphological changes to the lens associated with ER∆3‐induced
cataracts was determined by slit‐lamp examinations in 17‐ to 19‐day‐old ER∆3 (FVB/n) male and
female mice treated with a single dose of 1000 μg/kg 17β‐estradiol or vehicle (95% ethanol
dissolved in corn oil); the severity of cortical vacuole coverage of the lens was estimated in both
lenses and graphed as % coverage versus time (hrs). Animals were dizygous for the ER∆3
repressor. Eyes were examined by slit‐lamp biomicroscopy at death; therefore, the pupils dilated
naturally as a result of death. Using GraphPad® Prism software, a statistical difference was
observed between the presence of detectable cortical cataracts at 48, 72 and 96 hrs between 17β‐
estradiol‐treated mice compared to vehicle‐treated (2‐Way ANOVA, Bonferroni post test,
*p<0.05). Data is represented by mean ± SEM, n=16‐20 eyes/treatment/timepoint.
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Table 13: Incidence of Cortical Vacuoles in 17‐ to 19‐day‐old ER∆3 (FVB/n)
Mice with Time After 17β‐Estradiol or Vehicle Treatment
Time (hrs)
6
14
18
24
48
72
96

1000 μg/kg 17β‐estradiol
0%
0%
0%
0%
100 %
100 %
100 %

Vehicle
ND
ND
ND
ND
ND
0%
0%

The incidence of cortical vacuoles was determined by slit‐lamp biomicroscopy in 17‐ to 19‐day‐
old ER∆3 (FVB/n) ER∆3 male and female mice treated with a single dose of 1000 μg/kg 17β‐
estradiol or vehicle (95% ethanol dissolved in corn oil) at various time points (n= 16‐20
eyes/treatment/time point). Both eyes were examined at death by slit‐lamp biomicroscopy;
therefore, pupils dilated naturally. Each eye was counted as a single sample and incidence is
defined as the presence of cortical vacuoles. ND, not determined.

In addition to the vehicle‐treated ERΔ3 male and female mice, immature
wild‐type (FVB/n) mice were used as an additional control to confirm the effect
observed in the ER∆3 male and female mice was related to ER∆3 expression
versus 17β‐estradiol toxicity in the lens. WT animals were given the same dose
of 17β‐estradiol (1000 μg/kg) or vehicle as the ERΔ3 mice of the same age. Slit‐
lamp biomicroscopy of WT (FVB/n) male and female mice treated with 17β‐
estradiol or vehicle remained vacuole‐free up to 96 hrs post‐injection.
Collectively, these results suggest the cortical vacuoles induced by 17β‐estradiol
in the ER∆3 mice are due to activation of the ER∆3 repressor.
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Cataract Induction in ERΔ3 (C57H/FVB) Male and Female Mice
A delay in the detection of spontaneous gross cataracts was observed in
ER∆3 female mice in the C57Bl/6/FVB/n (Davis et al., unpublished) and
C57H/FVB strains (Results Section B) compared to ER∆3 mice in the FVB/n strain
(Davis et al., 2002).

Therefore, a delay in the onset of morphological

abnormalities in the lens, such as cortical vacuoles, may also occur with E2‐
induced cataracts in immature ER∆3 (C57H/FVB) mice compared to ER∆3 mice
of the FVB/n strain.

To determine if the onset of lenticular abnormalities

associated with ER∆3 cataracts were delayed in immature ER∆3 (C57H/FVB)
mice, 17‐19‐day‐old mice were administered 1000 μg/kg 17β‐estradiol
subcutaneously and examined by slit‐lamp biomicroscopy.

Animals were

examined at 6, 14, 24, 48, and 96 hrs post‐treatment (n=4‐7 animals/time‐point).
Slit‐lamp examinations show 100% incidence of vacuoles at 48 hrs post‐
treatment, which is similar to that observed in ER∆3 (FVB/n) mice (results not
shown).

Vehicle‐treated immature ER∆3 (C57H/FVB) mice were confirmed

vacuole‐free at 48 and 96 hrs post‐treatment (results not shown). These results
suggest that background strain does not influence vacuole onset in immature
ER∆3 mice treated with 17β‐estradiol. However, at 96 hrs post‐treatment, the
percent of the lens covered with cortical vacuoles (estimated by slit‐lamp
examination) is significantly different between strains, indicating increased
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severity in ER∆3 animals on the C57H/FVB background (Figure 29).

As

mentioned previously, ER∆3 mice on the FVB/n background strain are dizygous
for the ER∆3 repressor whereas, animals on the C57H/FVB background are
hemizygous for the repressor. Given the increase in severity observed in the
hemizygous, C57H/FVB strain ER∆3 mice, the data suggest that the copy number
of the ER∆3 transgene (dizygous or hemizygous) appears unrelated for
predicting cataract severity after estrogen treatment and inhibition of estrogen
action propagated through ERα and/or ERβ is more critical.
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Figure 29: Strain Differences in Cortical Vacuole Severity in the Lens of Immature ER∆3 Mice.
The estimated percent of the lens occupied by vacuoles in the lens was examined in immature
ER∆3 mice from the FVB/n (dizygous) and C57H/FVB (hemizygous) background strains. ER∆3
mice were administered 17β‐estradiol (1000 μg/kg) and examined 48 and 96 hrs post‐treatment.
Naturally dilated eyes as a result of death were examined by slit‐lamp biomicroscopy at
necropsy. A statistical difference was observed between the severity of cortical cataracts at 96
hrs after 17β‐estradiol treatment between the two background strains by the same individual
examiner (2‐Way ANOVA, Bonferroni post test, * p<0.05). Data is represented by mean ± SEM,
n=5‐7 animals/strain/time point.
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To determine if the age of exposure influences the onset or severity of
ER∆3‐induced cataracts, female mice were ovariectomized prior to puberty and
allowed to age to prevent exposure to endogenous estrogen produced after
puberty. ER∆3 (C57H/FVB) female mice were ovariectomized between days 17
and 19. At day 25, OVX female and intact male mice (not castrated due to
naturally low circulating estradiol levels) were treated with 1000 μg/kg 17β‐
estradiol or vehicle and then examined 96 hrs later by slit‐lamp biomicroscopy
for lenticular changes (n=10 animals/treatment) associated with early cataract
formation.

Age 25 days was chosen because it coincides with the approximate

age of the onset of puberty in mice, which is designated by vaginal opening in
female mice and preputial separation in male mice. At 96 hrs post‐treatment,
cortical vacuoles were observed only in the 17β‐estradiol‐treated group as the
vehicle‐treated groups remained vacuole‐free (results not shown).

Although

both groups had 100% incidence at 96 hrs post injection, the severity of vacuoles
is significantly different between immature ER∆3 and estrogen‐deficient 25‐day‐
old ER∆3 mice treated with the same dose of 17β‐estradiol. These results suggest
the age of exposure may influence the sensitivity of the lens to ER∆3‐induced
cataracts (Figure 30).
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Figure 30: Increase in Cortical Vacuole Severity in Lenses from Prepubertal Versus Pubertal
ER∆3 Mice.
Prepubertal and pubertal mice (C57H/FVB) hemizygous for ER∆3 were
administered a single subcutaneous injection of 1000 μg/kg 17β‐estradiol (E2) and examined 96
hrs later by slit‐lamp biomicroscopy. Prepubertal male and female mice were between 17 and 19
days of age. Pubertal aged mice were 25‐days‐old and female mice were OVX at weaning while
male mice remained intact (not castrated). The severity of ER∆3‐induced cortical vacuoles was
assessed as % cortical vacuoles coverage of the lens. At 96 hrs post‐treatment the incidence of
cortical vacuoles was 100% regardless of initial age at E2 injection. The severity of ER∆3‐induced
cortical vacuoles was examined and graphed as % cortical vacuole coverage. Data is represented
by mean ± SEM, n=10 mice/group. A statistical difference was observed between the severity of
cortical cataracts at 96 hrs between prepubertal and pubertal ER∆3 mice (Unpaired, T‐test,
*p<0.05).

Since the severity was reduced in pubertal‐aged mice, older ages were
examined to determine if age plays an important role in ER∆3 cataract
development. At 6 weeks of age, a single dose of 500 μg/kg 17β‐estradiol was not
able to induce cataracts detectable by slit‐lamp and histopathology within 96 hrs
after 17β‐estradiol treatment in OVX ER∆3 (FVB/n) female mice (results not
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shown). Therefore, repeated exposures to 17β‐estradiol were examined in ER∆3
female and intact male mice. Beginning at 6 weeks of age, prepubertally OVX,
ER∆3 (FVB/n) female mice were administered daily treatments of 500 μg/kg 17β‐
estradiol (or vehicle) for four days/week for three consecutive weeks. Since
cortical cataracts spontaneously develop in normal cycling ER∆3 female mice
(Davis et al., 2002), this dosing schedule was chosen to mimic the cyclical nature
if estrogen exposure in intact mice related to the estrous cycle. The average
length of the estrous cycle in female mice is approximately 4‐5 days, with serum
estradiol levels peaking during estrus (Wood et al., 2007). No lens abnormalities
characteristic of ER∆3 cataracts were detected by slit‐lamp biomicroscopy at 10
weeks of age in OVX ER∆3 female mice which initially began treatment with
repeated doses of 17β‐estradiol at 6 weeks of age (result not shown). The lack of
inducible cataracts in the older ER∆3 female mice suggests that the age of initial
estrogen exposure may be critical to elicit an observable effect.
Since cortical vacuoles occurred in prepubertal and pubertal aged ER∆3
female and male mice after a single dose of 1000 μg/kg 17β‐estradiol (Figure 30),
yet could not be induced in 6‐week‐old ER∆3 mice (OVX) with a single or
repeated injections of 500 μg/kg 17β‐estradiol (results not shown), the dose of
estrogen exposure was investigated. Intact ER∆3 (FVB/n) male mice at 6 weeks
of age were administered 0 (vehicle), 500, or 1000 μg/kg 17β‐estradiol daily for
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three days per week for 3 consecutive weeks. Since a single injection of 1000
μg/kg 17β‐estradiol can induce cataracts in immature and pubertal‐aged ER∆3
mice (Figures 29 and 30), this dose was tested to determine if the absence of
cortical vacuoles in the 6‐week‐old, OVX female mice was a result of insufficient
estrogen levels to activate the ER∆3 repressor.
The male postpubertal mice did not developed cataracts after 3 weeks of
repeated estrogen treatments. Even though the male postpubertal mice were
given one less dose per week, slit‐lamp examinations at 10 weeks of age in the
ER∆3 (FVB/n) male mice (one week after the last treatment) support the finding
with the OVX ER∆3 female mice treated with multiple doses of 17β‐estradiol
over a 3 week period (results not shown). These results imply that age of initial
estrogen exposure is critical for the rapid induction of cataracts associated with
the ER∆3 model, given that a single dose of 17β‐estradiol was sufficient to induce
cortical cataracts in prepubertal and pubertal aged ER∆3 mice (Figures 28‐30;
Table 14). These data suggest that there is a small window of time in which the
lens is most sensitive to the effects of the ER∆3 repressor since cataracts are
induced in prepubertal‐ and pubertal‐aged ER∆3 mice and not post pubertal‐
aged ER∆3.
In summary, the findings on the rapid induction of ER∆3 cataracts,
suggest the formation of cortical vacuoles characteristic of ER∆3‐induced
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cataracts are not strain‐ or gender‐specific since the incidence of induction of
cortical cataracts occurs in both strains, FVB/n and C57H/FVB, of immature ERΔ3
male and female mice within 48 hrs post‐treatment (Figure 29).

Briefly, cortical

cataracts characteristic of the ER∆3 model rapidly developed only in prepubertal
and pubertal aged male and female mice (Figures 28 and 29) and not in
postpubertal male and female mice (Table 14). Therefore, these data suggest that
age of initial estrogen exposure modifies the incidence of ERΔ3‐induced cortical
cataracts in male and female mice.
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ERΔ3

ERΔ3

WT

ERΔ3

ERΔ3

ERΔ3

ERΔ3

Prepubertal

Prepubertal

Prepubertal

Pubertal

Pubertal

Postpubertal

Postpubertal

C57H/FVB

C57H/FVB

C57H/FVB

C57H/FVB

C57H/FVB

C57H/FVB

FVB/n

Strain

Male

OVX Female

Male

OVX Female

Female and Male

Female and Male

Female and Male

Gender

500 μg/kg

500 or 1000 μg/kg

3 daily doses
for 3 weeks

1000 μg/kg

1000 μg/kg

1000 μg/kg

Vehicle

E2

Vehicle

0%

0%

0%

0%

0%

E2

100%

E2

0%

Vehicle

Vehicle

100%

0%
E2

0%

E2
Vehicle

0%

Vehicle

0%
100%

E2

Vehicle
1000 μg/kg

100%

E2

1000 μg/kg

Incidence of ERΔ3‐
induced cataracts

Treatment

Dose

4 daily doses
for 3 weeks

1x

1x

1x

1x

1x

Frequency

The terms prepubertal, pubertal, and postpubertal define mice of the following ages:17‐ to 19‐day‐old, 25‐day‐old, and 6‐week‐old, respectively. Pubertal
and postpubertal ERΔ3 female mice were OVX at weaning (3 weeks of age). Both FVB/n and C57H/FVB strain male and female mice were examined for
the incidence of cortical cataratcs characteristic of the ERΔ3 model by slit‐lamp biomicroscopy. Prepubertal and pubertal aged mice were given a single
dose of 17β‐estradiol (E2), while postpubertal aged mice were given repeated doses of 17β‐estradiol (E2). Incidence is defined by one lens/mouse
exhibiting cortical cataracts, however, bilateral cataracts were observed in all prepubertal and pubertal aged FVB/n and C57H/FVB ERΔ3 male and female
mice.

Genotype

Age

Animal Group

Table 14: Incidence of Cataracts in ER∆3 Mice at Different Stages of Reproductive Development

D. Estrogen Regulation of Gene Expression in the Lens of ERΔ3
Mice

Identification of Differentially Expressed Genes in ER∆3 Female Mice Using
Microarray Analysis
To identify gene expression changes related to the lens pathology
observed in the ER∆3 transgenic mouse model, a cDNA microarray was
implemented to rapidly screen over 14,000 known mouse genes. Microarrays are
commonly used as a screening mechanism to identify differential expression of
genes between two or more groups. A single microarray chip can analyze
thousands of genes versus analyzing one gene at a time using real‐time RT‐PCR.
This is extremely advantageous because it allows for quick scanning of
numerous genes at once without requiring a high volume of total RNA isolated
from the specific sample. Microarrays enable scientists to identify coordinated
gene expression across many gene families; essentially, it detects expression
patterns of genes associated with known pathways as well as individual genes
with differential expression.

To identify differentially expressed genes

associated in pathways that may be involved in the development of ER∆3
cataracts, microarray analyses compared 17β‐estradiol‐ and vehicle‐treated ER∆3
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female mice at age 21 days (immature) when cataracts are inducible with
estrogen treatment (see Results Subsection C).
Since cortical cataracts characteristic of the ER∆3 model were rapidly
induced within 48 hrs post‐treatment with 1000 μg/kg 17β‐estradiol in
prepubertal and pubertal aged mice (refer to Cataract Induction Study, Results
Subsection C), the microarray was completed to identify differentially expressed
genes in the lens between 21‐day‐old ER∆3 (FVB/n) female mice treated with
1000 μg/kg 17β‐estradiol (E2) or vehicle. In order to identify genes that may be
modified prior to cataract formation, lens tissues were collected between 5.5 and
6 hrs post‐treatment, a time point that preceded detection of cortical vacuoles in
ER∆3 (FVB/n) female mice (refer to Cataract Induction Study, Results, Subsection
C).

RNA was prepared from both lenses from individual mice for future

analysis. From the microarray analysis, the lens RNAs from three individual
mice were pooled and two individual pools per treatment group were prepared.
The Functional Genomics Core at Columbus Children’s Research Institute
performed the microarray analysis using the Affymetrix® GeneChip Mouse
Genome 430 2.0 Array. Conversion of RNA samples to cDNA, the microarray
hybridization, and subsequent data analyses were completed by this core facility.
Twenty‐seven genes with more than a 2‐fold higher expression in the E2‐
treated group were identified in the lens RNA compared to vehicle‐treated ERΔ3

-140-

(FVB/n) female mice; whereas, only 3 genes displayed more than a 2‐fold
decrease after the 6‐hr estrogen exposure. In addition to specific genes with
differential expression, the microarray software identified groups of genes that
function similarly, suggesting pathways or functions which may be involved in
cataract development in the ER∆3 model. A subset of the up‐regulated categories
is shown in Table 15. No categories were found to be down‐regulated.
From the candidate genes identified as up‐regulated 6 hrs after 17β‐
estradiol treatment in the immature lenses, six genes known to be essential in the
lens development, proliferation, and differentiation were selected for further
characterization in the individual mice. These genes were selected because of
their known roles in lens development, proliferation, differentiation, or
maintenance of lens homeostasis as described below. In the lenses from 21‐day‐
old ER∆3 female mice treated with 17β‐estradiol compared to vehicle, the pax6,
tcfap2a, tgfβ2, six3, sox2, and pdgfa genes, were up‐regulated 2.03‐, 2.32‐, 1.48‐,
1.63, 2.02‐, and 1.65‐fold in the microarray, respectively.
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Table 15: Gene Categories Modified by Estrogen Treatment in the Lens of 21‐
day‐old ER∆3 Female Mice

Number of List
Hits

Number of List
Total

EASE score
(significance)

8

16

0.00216

Signal transduction

7

16

0.0412

Cell communication

8

16

0.0423

7

16

0.00194

Gene Category
Increased with
Treatment
Regulation of
transcription

Transcription
regulator activity

The pax6 gene, a tissue specific DNA binding factor, was chosen for
further testing in individual lens RNA samples because of its known role in the
induction, growth, and maintenance of the lens (van Raamsdonk and Tilghman,
2000) and, especially, its regulatory role of crystallins in the embryonic lens
(Cvekl and Piatigorsky, 1996; Kondoh, 1999; Kamachi et al., 2001; Cvekl et al.,
1995; Gopal‐Srivastave, 1996; Kralova et al., 2002). Additionally, pax6 possesses
tissue‐restricted roles in the lens based on interactions with transcription factors
which are tissue‐specific (AP‐2α and Sox2) and ubiquitously expressed. Plus, it
is able to regulate expression of other transcription factors, Six3 and Sox2
(Ashery‐Padan et al., 2000; Sakai et al., 2001; Goudreau et al., 2002; Reza et al.,
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2002), which were also differentially expressed in the microarray.

Pax6

expression in the lens fiber cells is tightly controlled, with a decreased expression
required for normal lens development (Duncan et al., 2004).

There is also

compelling evidence which suggests Pax6 is essential in the regulation of
crystalline genes involved in the lens differentiation process (Cvekl and
Piatogorsky, 1996; Duncan et al., 1998). Therefore, the increase in expression of
Pax6 observed in the microarray may suggest it has a role in ER∆3‐induced
cataracts, possibly by modifying a critical developmental pathway in the lens.
Another transcription factor, tcfap2a, was selected because it encodes for
activating protein 2 (AP‐2α), a protein involved in lens development and
differentiation.

Specifically, AP‐2α acts as a negative regulator of fiber cell

differentiation in the lens (West‐Mays et al., 2002). In the ER∆3 model, cortical
vacuoles are observed in the transitional zone (the region where lens epithelial
cells lose their nuclei and differentiate to form fiber cells); therefore, genes that
regulate differentiation and are modified by estrogen may influence cataract
induction in the ER∆3 model. Additionally, previous reports suggest Pax6 and
AP‐2α may share a similar pathway in ocular epithelial development and
coregulate genes within similar cell signaling cascades, such as sox2 (Makhani et
al., 2007; Lengler et al., 2005).

-143-

The transcriptional repressor gene, six3 (Kobayashi et al., 1998; Zhu et al.,
2002; Lopez‐Rios et al., 203), was investigated further because it regulates pax6
and sox2 gene expression during lens induction (Lui, 2006). The sox2 gene was
also selected for subsequent analyses since it is regulated by other genes
identified by the microarray, as well as its implicated roles in the initiation of
lens cell differentiation (Kamachi, 2001; Furuta and Hogan, 1998; Kamachi et al.,
1998; Nishiguchi et al., 1998) and regulation of lens crystallins (Kamachi et al.,
2001).
As mentioned previously, TGFβ2, a member of transforming growth
factor family is reported to regulate growth and differentiation in numerous
biological systems (Laiho and Keski‐Oja, 1992) and is capable of inducing
pathological changes associated with various lens abnormalities, including
cataracts (Font and Brownstein, 1974, Novotny and Pau, 1984; Wormstone et al.,
2002; Lovicu et al., 2002; Lovicu et al., 2004;). Furthermore, aberrant lens fiber
differentiation, which is characteristic of TGFβ2‐induced anterior subcapsular
cataracts, is dependent on reduced levels of Pax6 (Lovicu et al., 2004).
Interestingly, estrogen has been reported to protect the rat lens from TGFβ2‐
induced cataracts (Hales et al., 1997). Since estrogen is reported to protect the
lens from TGFβ2‐induced cataracts and the tgfβ2 gene is observed to be up‐
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regulated in the lenses of ER∆3 mice, it is of interest to investigate estrogen
modification of this gene in the ER∆3 lens.
The gene that encodes PDGFα was investigated in individual samples
because the PDGF family of growth factors is known to activate signaling
pathways leading to cell proliferation and motility, which are key events that are
critical to the lens. One study demonstrated that PDGF is required to maintain
lens transparency and growth in organ culture (Brewitt and Clark, 1988).
Whereas, Reneker and Overbeek (1996) reported PDGFα stimulates proliferation
of lens epithelial cells in vivo and elevated levels will enhance proliferation and
induce some aspects of the lens fiber cell differentiation pathway. Since ER∆3
cortical cataracts occur primarily in the region undergoing lens fiber
differentiation and PDGFα can stimulate this process, the observed differential
expression of pdgfa in the microarray may suggest that differentiation is being
affected in the ER∆3 model.
In summary, the pax6, tcfap2a, sox2, six3, tgfβ2, and pdgfa genes were
selected to be investigated in individual lens samples because of their distinctive
roles in lens development, proliferation, and differentiation. Additionally, these
genes possess the ability to regulate each other and/or similar cell signaling
cascades.

Therefore, significant differential expression of these genes may

suggest pathways involved in ER∆3‐induced cataracts.
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Relative Expression of Selected Genes in ER∆3 (FVB/n) and WT (FVB/n) Mice
Due to their observed up‐regulation in the microarray, differential gene
expression of pax6, tcfap2a, tgfβ2, six3, sox2 and pdgfa were analyzed in individual
lens RNA samples from prepubertal (21‐day‐old) ER∆3 (FVB/n) female mice
treated with 1000 μg/kg 17β‐estradiol mice compared to vehicle‐treated mice.
The 1000 μg/kg 17β‐estradiol dose induced lenticular abnormalities in
prepubertal‐ and pubertal‐aged ER∆3 mice as early as 48 hrs post‐treatment (see
Cataract Induction Study, Results Subsection C). All genes analyzed showed a
significant upregulation with 1000 μg/kg 17β‐estradiol compared to vehicle
(p<0.05). With 17β‐estradiol treatment, mRNA levels for the genes (pax6, tcfap2a,
tgfβ2, six3, sox2 and pdgfa) were approximately 2‐ to 4‐ fold higher in ER∆3 female
lenses (Figure 31 and Table 16).
To compare with the female ER∆3 (FVB/n) mice, the same six genes were
examined in RNA prepared from lenses from immature (21‐day‐old) male ER∆3
mice treated with 1000 μg/kg 17β‐estradiol or vehicle (Figure 31). All 6 genes
(pax6, tcfap2a, tgfb2, six3, sox2, and pdgfa) investigated were significantly
upregulated (2.5‐ to 5‐fold higher) in the male lenses treated with 17β‐estradiol
(Table 16).

Since significant expression differences were identified in both

immature male and female mice (Figure 31) and cataracts are inducible in both
genders at this age (see Cataract Induction Study, Results Subsection C), these
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Figure 31: Differential Expression in Immature ER∆3 Mice. Lens RNA was prepared from both
lenses from immature (21‐day‐old) ER∆3 (FVB/n) female and male mice 6 hrs after treatment with
1000 μg/kg 17β‐estradiol (black bars) or vehicle (gray bars). Expression levels of pax6, tcfap2a,
tgfβ2, sox2, six3, and pdgfa were determined by real‐time RT‐PCR. ∆Ct values were obtained by
normalizing the specific genes above to the housekeeping gene, ppia (cyclophilin A), to control for
variation in RNA levels among samples. The lower average ∆Ct value observed with 17β‐
estradiol treatment indicates that the expression of these genes is higher (refer to Table 16 for
transformed data to present relative fold‐changes). 2‐way ANOVA with Bonferroni post tests
revealed 1) no significant interaction between treatment and gender, meaning 17β‐estradiol had
the same effect in male and female mice; 2) a significant difference (*p<0.05) in the expression of
all genes examined between vehicle‐ and 17β‐estradiol‐treated male or female mice; and 3) a
significant difference in the expression of pax6, tcfap2a, tgfβ2, sox2, and pdgfa between male and
female mice (*p<0.05).
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Table 16: Relative Expression Levels of Candidate Genes in Immature ER∆3
(FVB/n) Lenses.
Female

Male

Gene
Vehicle

17β‐estradiol

Vehicle

17β‐estradiol

Pax6

1.00
(0.94 – 1.07)
n=6

2.33*
(2.12 – 2.56)
n=6

1.00
(0.84 – 1.19)
n=6

2.67*
(2.26 – 3.15)
n=4

Tcfap2a

1.00
(0.89 – 1.12)
n=6

5.51*
(5.19 – 5.84)
n=6

1.00
(0.68 – 1.47)
n=6

2.83*
(2.33 – 3.43)
n=4

Tgfβ2

1.00
(0.92 – 1.09)
n=5

1.94*
(1.83 – 2.04)
n=4

1.00
(0.82 – 1.23)
n=6

2.48*
(2.12 –2.89)
n=4

Six3

1.00
(0.91 – 1.10)
n=6

3.05*
(2.55‐ 3.67)
n=6

1.00
(0.82 – 1.21)
n=6

2.59*
(2.25 – 2.99)
n=4

Sox2

1.00
(0.88 – 1.13)
n=6

4.00*
(3.56 – 4.50)
n=5

1.00
(0.91 – 1.10)
n=6

4.82*
(3.74 – 6.21)
n=5

Pdgfa

1.00
(0.88 – 1.14)
n=6

3.35*
(2.97 – 3.78)
n=6

1.00
(0.74 – 1.36)
n=6

5.08*
(4.73 – 5.46)
n=4

Relative expression levels of pax6, tcfap2a, tgfβ2, six3, sox2, and, pdgfaα genes in vehicle‐ and 1000
μg/kg 17β‐estradiol‐treated, immature ER∆3 (FVB/n) mice were calculated using the 2‐∆∆Ct method
as described in the Methods section. The relative fold‐changes were calculated using the ∆Ct
data found in Figure 31, ∆∆Ct vales for each gender were determined by normalizing the ∆Ct
value from mice treated with 17β‐estradiol to vehicle, and a range was determined using the SEM
from the experimental groups. 2‐way ANOVA with Bonferroni post tests of the average ∆CT
revealed a significant difference in the expression of pax6, tcfap2a, tgfβ2, six3, six2, and pdgfa with
17β‐estradiol treatment. * p<0.05
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data imply that pax6, tcfap2a, tgfβ2, sox2, six3, and pdgfa may have potential roles
in ER∆3 cataract development.
Wild‐type (FVB/n) immature mice do not develop cataracts after
administering 1000μg/kg 17β‐estradiol (see Cataract Induction Study, Result
Subsection C). If the upregulation of the above genes in the ER∆3 mice is due to
inhibition of estrogen action by the repressor, then a decrease in expression
would be expected in the lenses from immature WT (FVB/n) mice treated with
17β‐estradiol. However, if the level of expression is not modified by 17β‐estradiol
in the lenses from immature WT mice, unlike in the ER∆3 mice, these results
might suggest that the genes are being regulated by the morphological events
associated with cataractogenesis in the ER∆3 model. Therefore, immature (21‐
day‐old) WT (FVB/n) male and female mice were treated with the same dose of
17β‐estradiol (1000 μg/kg) or vehicle and examined of expression of pax6, tcfap2a,
tgfβ2, six3, sox2 and pdgfa genes. Expression of the selected genes in the lens was
not significantly different between WT females and males treated with 17β‐
estradiol compared to vehicle (Figure 32). However, the results suggest that
tcfap2a, sox2, and Pdgfα genes are differentially expressed in WT male and female
mice with higher expression levels of tcfap2a and sox2 transcripts in the WT male
mice (Figure 32). The relative fold‐changes of the genes of interest in WT mice
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treated with 17β‐estradiol are similar to the control group (Table 17) suggesting
these genes are not regulated by estrogen in the normal lens.
Additional statistical analyses were completed to determine if there is a
significant difference in the basal expression and estrogen‐induced expression of
pax6, tcfap2a, tgfb2, six3, sox2 and Pdgfα in the lenses of WT versus ER∆3 male and
female mice. Such analyses would indicate if the ER∆3 repressor modifies gene
expression with or without activation by estrogen. After 17β‐estradiol treatment,
if the expression of any of the above genes demonstrates opposite regulation in
the WT versus ER∆3 mice, these results may suggest these genes are estrogen‐
regulated since the ER∆3 repressor should inhibit estrogen action. Furthermore,
comparing the levels of expression in the ER∆3 mice with 17β‐estradiol, which
induces cortical cataracts, to the basal or estrogen‐induced levels in WT mice will
help determine if the gene may be correlated to cortical cataract development.
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Table 17: Relative Expression Levels of Candidate Genes in Immature WT
(FVB/n) Lenses.
Female

Male

Gene
Vehicle

17β‐estradiol

Vehicle

17β‐estradiol

Pax6

1.00
(0.95 – 1.05)
n=5

1.19
(1.10 – 1.29)
n=6

1.00
(0.89 – 1.13)
n=4

1.27
(1.05 – 1.52)
n=5

Tcfap2a

1.00
(0.86 – 1.17)
n=5

1.25
(1.09 – 1.43)
n=6

1.00
(0.92 – 1.08)
n=3

1.21
(1.10 – 1.32)
n=3

Tgfβ2

1.00
(0.90 – 1.11)
n=5

1.16
(1.02 – 1.31)
n=6

1.00
(0.93 – 1.07)
n=4

1.10
(1.01 – 1.20)
n=5

Six3

1.00
(0.92 – 1.08)
n=5

1.08
(0.98 – 1.18)
n=6

1.00
(0.87 – 1.14)
n=4

1.14
(0.96 – 1.35)
n=5

Sox2

1.00
(0.91 – 1.09)
n=5

1.31
(1.26 – 1.36)
n=6

1.00
(0.90 – 1.11)
n=4

1.01
(0.93 – 1.11)
n=5

Pdgfa

1.00
(0.65 – 1.55)
n=5

0.65
(0.58 – 0.72)
n=6

1.00
(0.83 – 1.21)
n=4

1.03
(0.89 – 1.20)
n=5

Using the 2‐∆∆Ct method, relative fold‐changes in the expression of pax6, tcfap2a, tgfβ2, six3, sox2,
and, pdgfa genes in the lenses of immature, WT (FVB/n) male and female mice treated with
vehicle or 1000 μg/kg 17β‐estradiol. Relative expression levels and ranges were based on the
average ∆Ct values and SEM, respectively, for each gene, gender, and treatment in Figure 32. No
significant differences were observed between 17β‐estradiol and vehicle based on analyses from
the ∆CT values (see Figure 32).
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Figure 32: The Expression of pax6, tcfap2a, tgfb2, six3, sox2 and pdgfa Genes in Immature WT Mice.
RNA was prepared from both lenses from immature (21-day-old) WT (FVB/n) female and male mice 6 hrs
after being treated with 1000 µg/kg 17β-estradiol (black bar) or vehicle (gray bar). ΔCt values were
determined by normalization to ppia (cyclophilin) to control for variation among samples. Differential
gene expression was calculated using the 2-∆∆Ct method. ∆Ct values are inversely proportional to the level
of expression; therefore a lower ∆Ct value is indicative of higher expression. Refer to Table 17 for relative
fold changes. There was no significant difference in gene expression as a result of 17β-estradiol treatment;
however, there is a significant difference in the expression of tcfap2a, sox2, and pdgfa between female and
male mice (GraphPad® Prism, 2-way ANOVA, Bonferroni post test, *p<0.05). Data was graphed as mean
± SEM (n = 3 – 6 animals/gender/gene/treatment group).
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Figure 33: Effect of Genotype Differences and 17β‐Estradiol Treatment on Gene Expression in
the Lenses of Immature Female Mice. Lenses were dissected 6 hrs after vehicle (gray bar) or
1000 μg/kg 17β‐estradiol (black bar) treatment in immature (21‐day‐old) WT and ER∆3 female
mice (FVB/n). RNA was prepared from both lenses and subjected to real‐time RT‐PCR for
analysis of pax6, tcfap2a, tgfβ2, six3, sox2, and pdgfa gene expression levels. ΔCt values were
determined by normalization to ppia (cyclophilin) to control for variation among samples. Two‐
way ANOVA revealed significant interaction (p<0.05) between the presence of ER∆3 and
treatment for pax6, tcfap2a, tgfβ2, six3, and sox2 (F=18, 39, 5.3, 18, and 30, respectively). Kruskal‐
Wallis tests with Dunn’s multiple comparisons indicated a significant difference in the basal
expression of pax6 and pdgfα between vehicle‐treated WT and ER∆3 immature female lenses.
Asterisks (*) denote a significant difference (p<0.05).
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Statistical analyses examining both genotype (WT vs. ER∆3) and treatment
(vehicle vs. 17β‐estradiol) as main factors were completed to determine if there
was an interaction between genotype and treatment.

Two‐way ANOVA

confirmed a significant interaction between genotype and treatment for all of the
genes examined except pdgfa (Figure 33), indicating that for those genes, the
effect of 17β‐estradiol treatment is significantly different in WT and ER∆3 female
lens. A significant difference in the expression of all six genes in ER∆3 mice with
treatment (Figure 33) and in the induction of cortical cataracts in similarly aged
mice (refer to Cataract Induction Study, Results Subsection C) suggests the
potential of these genes to be involved in a pathway associated with cataract
development (with the exception of pdgfa since statistical analyses do not indicate
a difference in pdgfa expression in WT and ER∆3 mice treated with 17β‐estradiol).
Statistical analyses of basal gene expression between WT and ER∆3 immature
female mice indicate that the inactive ER∆3 repressor may be capable of
modifying pax6 and pdgfa expression in the lens and upon activation of the ER∆3
repressor, pax6 is further upregulated (Figure 33 and Table 18). Like the female
mice, 17β‐estradiol can induce cortical cataracts in immature ER∆3 male mice,
but not in WT male mice (refer to Cataract Induction Study, Results Subsection
C). Therefore, it is important to examine if gene expression is affected by both
the presence of the ER∆3 transgene and 17β‐estradiol treatment in male mice.
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The relative expression levels of pax6, tcfap2a, tgfβ2, six3, sox2, and pdgfa mRNAs
were examined by 2‐way ANOVA to identify the transgene, treatment, and/or an
interaction between the transgene and treatment effects. A significant interaction
between the presence of the ER∆3 transgene and treatment in the male mice was
observed in the expression of pax6, tgfβ2, six3, sox2, and pdgfa, demonstrating the
effect of 17β‐estradiol treatment on the expression of these genes, but not tcfap2a,
in the lens is significantly different between WT and ER∆3 immature male mice
(Figure 34). These data may imply 4 of the 6 genes (pax6, tgfβ2, six3, and sox2)
may be involved in a pathway associated with cortical cataract development.
Comparisons between the relative expression levels of pax6, tgfβ2, six3,
sox2, and pdgfa in 17β‐estradiol‐treated WT and ER∆3 female and male mice
(Table 18) suggest that pax6 and sox2 are associated with cataract development
since both of these genes were statistically different in both ER∆3 male and
female mice that develop cataracts with the dose of 17β‐estradiol (1000 μg/kg)
administered. The genes tcfap2a and six3 were statistically different between 17β‐
estradiol‐treated WT and ER∆3 female mice and tgfβ2 and pdgfa were
upregulated significantly in ER∆3 male mice compared to WT to suggest these
genes regulation may be cataract‐related, however, gender‐specific.
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Figure 34: Effect of ER∆3 and 17β‐Estradiol Treatment on Gene Expression in the Lenses of
Immature Male Mice. Lenses were dissected 6 hrs after vehicle (gray bar) or 1000 μg/kg 17β‐
estradiol (black bar) treatment in immature (21‐day‐old) WT and ER∆3 male mice (FVB/n). RNA
was prepared from bilateral lenses and subjected to real‐time RT‐PCR for analysis of pax6, tcfap2a,
tgfβ2, six3, sox2, and pdgfa gene expression levels. ΔCt values were determined by normalization
to ppia (cyclophilin) to control for variation among samples. Two‐way ANOVA revealed
significant interaction (p<0.05) between the presence of ER∆3 and treatment for pax6, tgfβ2, six3,
sox2, and pdgfa (F=5.1, 6.8, 5.4, 32, and 12, respectively). Asterisks (*) denote a significant
difference (p<0.05) between vehicle‐ and 17β‐estradiol‐treated ER∆3 male mice. Kruskal‐Wallis
analyses with Dunn multiple comparisons indicate a significant difference in the expression of
pdgfα with 17β‐estradiol activation of the ER∆3 repressor.
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Table 18:

Relative Expression Levels between Vehicle‐ and 17β‐Estradiol‐

Treatment in the Lenses of Immature WT and ER∆3 Mice.
Gene
pax6

Vehicle‐Treated
ER∆3 Female
ER∆3 Male
1.69*
1.19
(1.51 – 1.91)
(1.00 – 1.41)

17β‐Estradiol‐Treated
ER∆3 Female
ER∆3 Male
3.31*
2.51
(3.01 – 3.63)
(2.13 – 2.96)

tcfap2a

0.89
(0.84 – 0.95)

0.33
(0.22 – 0.48)

3.89*
(3.66 – 4.12)

0.76
(0.63 – 0.92)

tgfβ2

0.71
(0.65 – 0.78)

0.90
(0.73 – 1.09)

1.20
(1.13 – 1.26)

2.00
(1.71 – 2.33)

six3

0.62
(0.57 – 0.69)

0.67
(0.55 – 0.82)

1.77
(1.48 – 2.13)

1.54
(1.34 – 1.77)

sox2

0.70
(0.62 – 0.79)

0.59
(0.54 – 0.66)

2.12
(1.89 – 2.39)

2.84
(2.20 – 3.66)

pdgfa

0.25*
(0.22 – 0.28)

0.93
(0.69 – 1.27)

1.29
(1.14 – 1.45)

4.61*
(4.29 – 4.95)

Relative fold‐changes in the expression of pax6, tcfap2a, tgfβ2, six3, sox2, and, pdgfa genes were
calculated in the lenses 6 hrs after 17β‐estradiol‐treated (1000 μg/kg) WT and ER∆3 female and
male mice. Relative expression levels and ranges were based on calculated ∆∆Ct values from the
average ∆Ct values of WT and ER∆3 female and male mice and SEM, respectively, for each gene
and gender in Figures 33 and 34. WT expression levels were normalized to 1.00 (not shown) and
fold‐changes in ER∆3 mice are shown. Asterisks (*) indicate a p<0.05 (Kruskal‐Wallis with
Dunn’s Multiple Comparisons) between ER∆3 and WT mice for the respective treatment group.

Morphological changes associated with the development of ER∆3‐induced
cataracts were not observed by slit‐lamp biomicroscopy in 6‐week‐old ER∆3
female mice (OVX prior to puberty) treated with 500 μg/kg 17β‐estradiol,
whereas, cortical cataracts were evident in immature ER∆3 female mice treated
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with 1000 μg/kg 17β‐estradiol. Since the two subpopulations, immature and 6‐
week‐old ER∆3 female mice, were treated with different doses, 1000 μg/kg and
500 μg/kg 17β‐estradiol, respectively, direct correlations cannot be derived
between the presence of cortical cataracts and differential expression. However,
these comparisons may implicate genes that should be examined further as
estrogen‐regulated genes, if differentially expressed in both age groups of female
ER∆3 mice.
Real‐time RT‐PCR results indicate a significant up‐regulation with 17β‐
estradiol treatment compared to vehicle in the lenticular expression of pax6 and
sox2 mRNA in the 6‐week‐old (OVX prepubertally) ER∆3 female mice which
were ovariectomized prior to puberty (Figure 35). The relationship of tcfap2a was
approaching significance (p = 0.0574) with an n=9/treatment.

Therefore, an

increase in the sample number may also result in a significant up‐regulation in
tcfap2a in 17β‐estradiol‐treated females compared to vehicle.

There is no

significant difference in tgfβ2, six3, and pdgfa with treatment. The increased level
of expression with 17β‐estradiol treatment versus control was generally less than
2‐fold, except for sox2 (Table 19), unlike in the immature ER∆3 female mice
(Table 14).
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Figure 35: Expression of pax6, tcfap2a, tgfb2, six3, sox2 and pdgfa in 6‐Week‐Old ER∆3 Female
Mice Lenses. Lenses from 6‐week‐old (prepubertally OVX) ER∆3 (FVB/n) female mice were
dissected approximately 6 hrs after treatment with 500 μg/kg 17β‐estradiol (black bar) or vehicle
(yellow bar). RNA was prepared from bilateral lens from individual female mice. Using real‐
time RT‐PCR and the 2‐∆∆CT method of analysis (as described in the Methods section) relative
gene expression of pax6, tcfap2a, tgfβ2, six3, sox2, and pdgfa was calculated. Briefly, ΔCt values
were normalized to the housekeeping gene, cyclophilin a (ppia) to control for variation among
samples. ∆Ct values are inversely proportional to the level of expression; therefore a lower ∆Ct
value is indicative of higher expression. Refer to Table 19 for relative fold‐changes. Significant
differences were observed in pax6 (p = 0.0169) and sox2 (p = 0.0107). tcfap2a was approaching
significance (p = 0.0574) and no significant difference was observed in tgfβ2 (p = 0.4363), six3 (p =
0.6665), and pdgfa (p = 0.2479). Significance was determined using Mann‐Whitney U test; data
was plotted as mean ± SEM (n=9‐10 animals/treatment). * p < 0.05 in 17β‐estradiol treated
females compared to vehicle.
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Table 19: Relative Gene Expression in the Lenses from 6‐Week‐Old (OVX)
ER∆3 Female Mice.

Gene
pax6

Control (vehicle)
1.00
(0.78 – 1.28)
n=9

500 μg/kg 17β‐estradiol
1.85*
(1.74 – 1.97)
n=9

tcfap2a

1.00
(0.78 – 1.28)
n=9

1.64
(1.50 – 1.80)
n=9

tgfβ2

1.00
(0.84 – 1.19)
n=9

1.35
(1.01 – 1.79)
n=9

six3

1.00
(0.87 – 1.15)
n=9

1.02
(0.78 – 1.33)
n=9

sox2

1.00
(0.76 – 1.31)
n=8

2.22*
(1.90 – 2.59)
n=9

pdgfa

1.00
(0.87 – 1.15)
n=8

1.18
(0.99 – 1.40)
n=9

Using the 2‐∆∆Ct method as described in the Methods section, relative fold‐changes in the
expression of pax6, tcfap2a, tgfβ2, six3, sox2, and, pdgfa genes were calculated in the lenses of 6‐
week‐old (prepubertally OVX) ER∆3 (FVB/n) female mice treated with vehicle or 500 μg/kg 17β‐
estradiol at 6 hrs post‐injection. Relative expression levels and ranges were based on the average
∆Ct values and SEM, respectively, for each gene and treatment in Figure 35. Asterisks (*) indicate
a p<0.05 (Mann‐Whitney U test).
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In summary, all six genes were significantly up‐regulated in the lenses of
immature (21‐day‐old) ER∆3 female and male mice treated with 17β‐estradiol
(Figure 31) and not significantly regulated in immature (21‐day‐old) WT female
and male mice treated with 17β‐estradiol (Figure 32). At approximately the same
age (17‐ to 19‐days‐old), cortical cataracts are inducible with 17β‐estradiol in
ER∆3 female and male mice and not WT female and male mice (Results Section
C). Together, these data may suggest the potential of these genes (pax6, tcfap2a,
tgfβ2, six3, sox2, and pdgfa) to be involved in pathways associated with cortical
cataract development. However, the significant regulation of pax6 and sox2 in
the lenses of 6‐week‐old, OVX ER∆3 female mice (Figure 34) may suggest that
these genes are modified early in estrogen‐regulated cascades in the ER∆3 mice .
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Discussion

With more than 400,000 new cataract cases a year (Research to Prevent
Blindness, NISE, NSF), the development of a therapy to lower the incidence is
critical to both quality of life and the economy. The World Health Organization
(WHO) estimates that by 2020 more than 75 million individuals will be
diagnosed with a cataract and 110 billion U.S. dollars will be used for cataract
surgeries (WHO, 2005).

With therapies designed to delay the onset of age‐

related cataracts, the number of cataract surgeries performed annually will
decrease. The WHO proposes that a 10‐year delay in the onset of age‐related
cataracts will reduce the incidence of cataracts to 50%, thus reducing the burden
to the U.S. economy.
Along with numerous animal studies (Greaves et al., 1993; Hales et al.,
1997; Bigsby et al., 1999; Davis et al., 2002; Wang et al., 2003) and human
epidemiological studies (Cumming and Mitchell, 1997; Klein et al., 1993; Klein et
al., 1994; Younan et al., 2002), the presented work suggests estrogen can regulate
responses in the lens that may protect its transparency.

If the protective

mechanism of estrogen action in the lens to prevent or delay the development of
age‐related cataracts is elucidated, such a therapy may combat the economical

-162-

hardship that will result from the increase in required cataract surgeries. The
following questions were investigated in pursuit of identifying potential
mechanisms of action for estrogen in the lens:
1. Are mouse models of cataract development applicable for the study
of estrogen protection against human age‐related cataracts?
2. Does the lens express estrogen receptors?
3. Does estrogen action via a specific nuclear estrogen receptor
influence lens transparency?
4. Does estrogen regulate genes of known pathways associated with
lens development, proliferation, differentiation, and/or homeostasis
which have been reported to be important in maintaining lens
transparency?
The results presented in this dissertation will provide the foundational blocks
necessary to begin to elucidate possible mechanisms of estrogen action in the
lens to elicit protection against cataract development and to initiate the
development of estrogen therapies.

Identification of Estrogen Receptors in the Lens
If estrogen provides protection in the lens against the development of age‐
related cataracts, more than likely its actions will be mediated through its
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receptors. The results in section A, demonstrate that the mouse and human lens
possess high‐affinity, saturable binding sites for 17β‐estradiol. Moreover, ERα,
ERβ, and GPR30 mRNAs were detected in the mouse lens. These data and
previous studies which detected nuclear estrogen receptors in cultured human
lens epithelial cells (Cammarata, 2004) and lens (Ogueta, 1999) suggest the
potential of estrogen to act directly via estrogen receptors expressed in the lens.
Currently, there are four known mechanisms which involve estrogen
receptor activation to directly elicit an effect within the cell (refer to Figure 36), 1)
classical mechanism via nuclear estrogen receptors to initiate gene transcription
via the estrogen response element (ERE), 2) ERE‐independent mechanism in
which nuclear estrogen receptors interact with proteins, Jun and Fos, to induce
AP‐1 regulated genes, 3) ligand‐independent pathways, where growth factors
activate protein‐kinase cascades to active estrogen receptors, and 4) membrane
estrogen receptors activation of non‐genomic signaling cascades.

Since the

current studies demonstrate that ERα, ERβ and/or GPR30 are present in the lens,
any or all of these four mechanisms of action may be responsible for estrogen
action in the lens. However, the protective nature of estrogen may be a result of
estrogen action in a neighboring cell which in turn induces changes that are
observed in the cells of the lens. For example, estrogen may be acting at the
retina, a known ocular tissue that influences lens cell differentiation. In addition
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to estrogen receptor‐dependent mechanisms, the actions of estrogen in the lens
may also occur by estrogen receptor‐independent mechanisms, where estradiol
acts as an antioxidant.

4.

E2

GPR30

3.

2.

G

1.
Gα

GFR

Gβ
Gγ

ER

P
ER

ER

P
ER

Non‐genomic
Signaling Cascades

ERE

ERE
ER
P

Jun

Fos
AP‐1

Figure 36: Proposed Schematic of Estrogen Signaling Mechanisms. 1. Classical mechanism of ER
action. Nuclear E2-ERs bind directly to EREs in target gene promoters. 2. ERE-independent genomic
actions. Nuclear E2-ER complexes are tethered through protein-protein interactions to Jun and Fos at AP-1
binding sites to express AP-1 regulated genes. 3. Ligand-independent genomic actions. Growth factors
(GF) activate protein-kinase cascades, leading to phosphorylation (P) and activation of nuclear ERs at
EREs. 4. Nongenomic actions. Membrane E2-ER complexes activate non-genomic signaling cascades,
leading to rapid cellular effects.

Three of the four known mechanisms of receptor‐dependent actions of
estrogen lead to the direct regulation of gene transcription (Figure 36). 17β‐
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estradiol binding in nuclear, cytosolic, and membrane extracts from lenses from
C57H (Figure 11) and FVB/n (Figure 12) mice and women (Figure 15) indicate the
presence of estrogen receptors in the lens; however, such data do not specify the
specific subtype present. Two common methods of detection of specific proteins
are western blot and immunohistochemistry (IHC) analyses. Due to sensitivity
issues common with IHC and western blot analysis, saturation binding and real‐
time RT‐PCR were chosen to detect estrogen binding sites and estrogen receptor
transcripts, respectively, in the mouse and human lens. Additionally, real‐time
RT‐PCR is advantageous because it allows for the analysis of individual mouse
lens samples versus pools of lenses that would be required for western blot
analyses. In this study, two complementary techniques, saturation binding and
real‐time RT‐PCR, provide evidence which suggests the presence of estrogen
receptors in the mouse and human lens (see Results Subsection A).
ERα, ERβ, and GPR30 mRNAs were detected in the lenses from
individual mice (Figure 16) of the same age and strain (C57Bl/6 hybrid, C57H) as
the animals used in the binding studies. One of two female human lens samples
expressed detectable levels of GPR30 mRNA (results not shown).

Previous

research has detected transcripts for ERα in the rabbit and rat lens (Wickham et
al., 2000) and expression of ERα and ERβ in cultured human lens epithelial cells
(Cammarata et al., 2004). Ogueta and colleagues (1999) detected the presence of
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ERα in LEC (by IHC) and in the retinal tissues from young female donors by RT‐
PCR, western blot, and IHC analyses and suggested its expression is gender‐ and
age‐related. However, expression of ERα and ERβ mRNA in the mouse lens and
ERβ in human lens has not been reported. Identification of estrogen receptors in
the mouse provides evidence to support the use of mice in the studies of
estrogen’s role in cataract development.
Given tissue limitations, the highly sensitive analysis of gene expression
using real‐time RT‐PCR allowed investigation of the specific estrogen receptor
subtypes that may be responsible for the 17β‐estradiol binding sites detected in
the mouse and human lenses. Poor RNA quality may explain the lack of ERα
and ERβ mRNA detection in the human lenses. The stability of estrogen receptor
mRNA in the lens is unknown; therefore, factors associated with tissue
procurement may have resulted in low quality RNA. Since lens tissues were not
collected and frozen immediately after death, the time it took to collect the lens
tissues may have resulted in degradation or damage to RNA in the lens tissue.
Additional samples will be analyzed to determine whether ERα and/or ERβ are
expressed in the human lens.
Estrogen receptors may be expressed in both the nucleated lens epithelial
and/or non‐nucleated fiber cells as suggested by the detection of estrogen
binding sites in all three fractions, nuclear, cytosolic, and membrane, (Figures 12,
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13, and 17) along with the amplification of gene transcripts for ERα, ERβ, and
GPR30 in the mouse lens (Figure 16). Therefore, 17β‐estradiol may be acting via
any of the four proposed mechanisms, since all four cascades involve nuclear or
membrane estrogen receptors. However, only three of these four mechanisms
require estrogen to bind directly to its receptor (Figure 36).
In the fourth signaling pathway (Figure 36; pathway 4), estrogens act via
membrane receptors, which may include G‐protein coupled receptors (GPCR).
As detectable binding sites were observed in the membrane extracts of the mouse
and human lens (Figures 11, 12, and 14), this signaling pathway may also be
important in the lens. Additionally, expression of GPR30 mRNA in the mouse
(Figure 16) and human lens (Results, Subsection A) is the first evidence of this
novel transmembrane estrogen receptor in the lens of any species. Therefore,
these results suggest estrogen may also act through non‐genomic pathways to
elicit its reported protection on lens transparency.
Besides detection of GPR30 transcripts, additional evidence for GPR30 in
the lens is the inability of diethylstilbestrol (DES) to compete with [125I]‐17β‐
estradiol in the membrane fraction (Figure 14).
compete for

125

The fact that DES did not

I‐17β‐estradiol is consistent with other reports in breast cancer

cells (Thomas et al., 2005), ovarian membranes (Pang et al., 2008), and HEK cells
expressing GPR30 (Thomas et al., 2005; Pang et al., 2008) and suggests that
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estrogens may be acting through this membrane estrogen receptor to modulate
signaling cascades in the lens important for lens physiology. Along with GPR30,
ERα has been reported to be expressed in the plasma membrane (Ranzandi et al.,
2004; Acconcia et al., 2005). However, if ERα is expressed in the cell membrane
in the lens, DES would be expected to compete for these estrogen binding sites.
Therefore, the little to no binding affinity of DES in the plasma membrane
suggests that the membrane binding of estradiol may not be due to an interaction
with ERα. Due to the inability of DES to displace [125I]‐17β‐estradiol in the
membrane fraction of the mouse lens (Figure 14), additional competition binding
analyses using another estrogen ligand, such as 17β‐estradiol, which is known to
bind with high affinity to GPR30, (Prossnitz et al., 2008) needs to be tested in the
absence and presence of GTPγS to confirm that estrogen may act via a GPCR,
such as GPR30, in the lens.
Transcripts for ERα and GPR30 were expressed in the lens epithelial cells
(LEC) and fiber cells of the mouse lens; whereas, ERβ was solely expressed in the
LEC (Figure 16). Knowing that ERα and ERβ are considered nuclear receptors,
their presence was originally assumed to be specific to the epithelial‐rich LEC.
However, the detection of ERα in the fiber cells suggests ERα may be localized in
the membrane of these non‐nucleated cells. Previous studies have reported that
truncated variants of ERα localized to the membrane can elicit estrogen action (Li
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et al., 2003; Pietras and Márquez‐Garbán, 2007). It is important to note that the
presence of transcripts for each estrogen receptor subtype in the lens and cortex
does not provide definitive evidence for the presence of these three translated
receptor proteins in the separate cell types. In addition, each region may be
contaminated with both lens cell types. Therefore, procedures to detect the
specific locations of the estrogen receptors, such as IHC, will be required to
verify the presence of the ERα, ERβ, and/or GPR30 protein products in the three
regions of the anterior epithelium, the peripheral cortex, and the organelle‐free
zone. Overall, these results suggest ERα and GPR30 may be expressed diversely
throughout the lens, while ERβ is more specific to the LEC and each receptor
might regulate specific physiological events in the lens.
The bulk of the lens is primarily comprised of non‐nucleated fiber cells
with a monolayer of epithelial cells along the anterior surface.

Therefore,

estrogen action in the lens may be directed through membrane estrogen
receptors. The presence of membrane receptors in lens fiber cells may be
responsible for the homeostatic control of both cell types in the lens and/or
provide a means of communication for the non‐nucleated fiber cells to respond
to estrogen. The mRNA for the membrane estrogen receptor, GPR30, was
detected in both the LEC and fiber cells (Figure 16).

If GPR30 is localized

exclusively to the plasma membrane of fiber versus epithelial cells, expression in
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the fiber cells would be expected to be higher compared to the LEC. However,
GPR30 was shown to be expressed 4.4‐fold lower in the fiber cell‐rich lens cortex
compared to the epithelial cell‐rich lens capsule (Figure 17).

Therefore, the

higher expression of GPR30 mRNA in the epithelial cells versus the fiber cells
may be due to its exclusive expression in the lens epithelium. Expression levels
observed in the fiber cells may be due to the presence of nucleated cells
undergoing the process of differentiation.

Numerous reports have detected

GPR30 in the endoplasmic reticulum versus the plasma membrane (Revankar et
al., 2005; Revankar et al., 2007). Since the superficial fiber cells are in the earlier
stages of differentiation (Bassnett et al., 1995), the endoplasmic reticulum would
be expected to be present in some cells within the cortex. Therefore, if GPR30 is
solely expressed on the endoplasmic reticulum, these superficial fiber cells may
explain the lower expression of GPR30 in the fiber cells versus the lens epithelial
cells adhered to the lens capsule. The detection of GPR30 transcripts is the first
evidence of this receptor in the mouse and human lens and its expression may be
localized to cells of the LEC and/or fiber cells. Differential expression of estrogen
receptors in both cell types in specific regions of the lens may lead to an
understanding of how estrogen acts in the lens to inhibit cataract development.
The mechanism of action for estrogen in the lens may not be gender‐
specific since [125I]‐17β‐estradiol binding sites (Figure 15) and expression of
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transcripts for all three estrogen receptor subtypes, ERα, ERβ, and GPR30 (Figure
16) in the male mouse lens is similar in the female lens (Figure 18). However,
women have an increased risk of cataracts and cataracts spontaneously develop
in the female, but not male, ER∆3 mice upon estrogen activation of the dominant
negative estrogen repressor. Therefore, the observable gender difference in the
incidence of age‐related cataracts in humans and ER∆3 mice may be due to a
difference in circulating estrogen levels or expression levels of estrogen receptor.
Therefore, regardless of the estrogen signaling pathway, the level of
circulating hormone may be critical for estrogen protection in the lens. The
higher incidence of age‐related cataracts in post‐menopausal women may be due
to low levels of circulating endogenous estrogens that are available to act via
genomic and non‐genomic signaling pathways. Menopause occurs in women
around age 52 and is accompanied by decreases in circulating estrogen levels, in
contrast to men who can produce sex hormones well into their 70s (Saladin,
2006).

Estrogen in males is produced by the conversion of testosterone to

estrogen by aromatase (Carreaus et al., 2002). As a result, endogenous estrogens
remain in the male as long as testosterone is being synthesized. Epidemiological
studies have also investigated the effect of age of menarche and menopause on
the risk of age‐related cataract development. These studies suggest that the
longer a women is producing endogenous estrogens, the lower her risk is for
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developing age‐related cataracts (Klein et al., 1994; Cumming and Mitchell, 1997;
Klein et al., 2000) Therefore, the observed increase in gender‐related cataract
incidence in humans may be a result of post‐menopausal women have lower
circulating estradiol levels compared to men of similar ages (Greendale et al.,
1997).
Estrogen receptor expression may vary during different stages of life,
which may also alter protection against the development and progression of age‐
related cataracts. Binding studies were only performed at one age in the mice,
but mRNA RNA levels were examined in different ages. Similar expression of
ERα, ERβ, and GPR30 transcripts in the lenses of female mice at 1 month, 3
months, and greater than 12 months of age (Figures 16 and 19) suggests all three
receptors are present prior to puberty and persist through older ages in adult
mice. However, differential expression of ER at various life stages may explain
our inability of inducing cortical cataracts in the aged ER∆3 female and male
mice. Since RNA may not indicate changes in protein level, protein or binding
studies in prepubertal and older aged adult mice are required to determine if
expression levels vary at different ages.
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Role of Estrogen Receptors in Lens Physiology
The estrogen receptor knock‐out (ERKO) mouse studies were completed
in animals on the C57H background, the same background strain used in WT
binding studies, to examine the roles of ERα and/or ERβ in lens development
and lens physiology. Knockout models are a useful tool that allows researchers
1) to determine what phenotypes are lost or gained in a specific tissue as a result
of removing a functional receptor, 2) to identify the physiological action of other
receptors still present in a specific tissue, and/or 3) to identify new receptors or
receptor‐independent functions in a specific tissue. Spontaneous cataracts were
not detected in male and female ERKO (αERKO, βERKO, and αβERKO) mice up
to 16 months of age, regardless of estrogen receptor subtype loss.

At

approximately 12 months of age, early morphological changes in the anterior,
axial region of the lens were detected by slit‐lamp analysis in both male and
female ERKO mice as well as wild‐type (WT) mice. These changes correlated
with anterior subcapsular vacuoles that were detected by histology at age 16
months. The presence of the subcapsular vacuoles in WT as well as all ERKO
mice suggest such pathologies are related to the C57H or normal aging and not
to the loss of either or both nuclear estrogen receptors. Therefore, an individual’s
specific genetic background may influence their susceptibility to form cataracts
and possibly their response to estrogen therapies.
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Cataract development in male ERKO mice was investigated because 17β‐
estradiol binding sites (Figure 15) and expression of both ERα and ERβ mRNAs
(Figure 16) were detected in the male mouse lens in the same background strain
as the ERKO mice (C57H). Additionally, no significant difference in detectable
binding sites and ER mRNA expression was observed between female and male
WT mice. Like the female mice, spontaneous cataracts were not detected by slit‐
lamp biomicroscopy in the aged male ERKO and WT mice. These results suggest
that loss of nuclear estrogen receptors, ERα and/or ERβ, and estrogen actions
through these receptors are not detrimental to the lens of either gender.
Furthermore, estrogen may be acting through other pathways not associated
with the two known nuclear estrogen receptors to preserve lens transparency, for
example estrogen, receptor‐independent mechanisms, GPR30, or an unknown
estrogen receptor. At the time of these studies, a knockout model for GPR30 was
not available to investigate the role of GPR30 in cataract development or
protection of lens transparency.
The outlined work shows that the loss of ERα or ERβ does not induce
spontaneous cataracts in mice; however, loss or diminished levels of ERα in the
ERΔ3 transgenic female mice increased the severity and shortened the onset of
cataract induction compared to ER∆3 female mice expressing ERα. Both αERKO
females, with higher endogenous estrogen levels, and females heterozygous for
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the ERα disruption have a similar effect on ER∆3‐induced cataracts. These data
suggest that the increase in endogenous estradiol in the absence of ERα (due to
the loss of negative feedback on the hypothalamic‐pituitary‐gonadal axis that
regulates estrogen synthesis) does not, in itself, result in the earlier onset of
ER∆3‐induced cataracts.
Estrogen has been reported to be protective in cataracts models induced
by TGFβ (Hales et al., 1997) and MNU (Bigsby et al., 1999). Studies in the ER∆3
mice agree that estrogen would be protective since spontaneous cataracts
develop due to inhibition of estrogen action in this model (Davis et al., 2002).
However, the lack of lens abnormalities due to loss of ERα and/or ERβ in the
ERKO models still do not provide insight as to how estrogen may act to provide
such protection.

To date, the protective nature of estrogen has only been

observed in cataract models that resulted from an insult or inducing agent. The
ERKO mice were housed in a controlled environment void of known risk factors
associated with cataract development in humans (UV light, smoking, diabetes,
etc.). Since there was no insult to the lens, the lack of lens abnormalities in the
ERKO mice was not unexpected. Essentially, the protective effect of estrogen
may only be evident if the mice were exposed to a factor that induces cataracts.
Therefore, the role of estrogen receptors, ERα and ERβ, in an inducible model of
age‐related cataracts was investigated
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The ER∆3 model was utilized over other models of age‐related cataracts
because ER∆3‐induced cataracts develop spontaneously in adult‐aged female
mice (Davis et al., 2002) and can be induced in immature female and male mice
with estrogen supplementation. Histopathology confirmed these results because
the lens appeared normal prior to the onset of puberty and estrogen synthesis
(results not shown). Since the work presented within was concerned with age‐
related, not embryonic, cataract development, the ER∆3 model is an appropriate
model for the investigation.
Spontaneous cataracts did not result from the loss of either nuclear ER in
the lens.

However, diminished levels or loss of ERα in ER∆3 female mice

increased the severity of cortical cataracts with age. These results suggest that
ERα in the lens may provide partial protection against the progression of
cataracts in the ER∆3 model. Additionally, the increased incidence of gross
cataracts in the ERα+/‐ female mice expressing ER∆3 and ERβ compared to
females without ERβ expression suggests that ERβ also has a role in maintaining
lens transparency.
The presence of cortical vacuoles was observed by slit‐lamp analysis in the
ER∆3 female mice on the C57H/FVB background expressing both WT ERα and
ERβ. In the ER∆3 (C57H/FVB) mice, these morphological changes began later
than the ER∆3 (FVB/n) mice. On average, C57H/FVB female mice developed
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ER∆3‐induced cortical cataracts that were detected at 3 months of age by slit‐
lamp biomicroscopy and 5‐10 months by gross inspection (Figure 24).

In

contrast, ER∆3 female mice on a FVB/n background strain are reported to have
detectable gross cataracts at age 3 months (Davis et al., 2002). Cortical vacuoles
are characteristic of the ER∆3 model and, therefore, the primary focus when
examining

ERKO/ER∆3

mice

for

biomicroscopy and histopathology.

cataract

development

by

slit‐lamp

(However, strain specific characteristics,

such as the subcapsular vacuoles, were observed in WT and ERKO models on
the hybrid background strains; see Results, Subsection B).

Strain‐specific

differences between the FVB/n and C57H backgrounds, such as retinal
degeneration, eye pigmentation, and possible variability in endogenous estrogen
levels, may explain the later onset of gross cataracts between the two mouse
stains of ER∆3 mice.
To investigate the role of each nuclear estrogen receptor (ERα and/or
ERβ) in a model of inducible cataracts, mice with the disruption of ERα and/or
ERβ, but expressing the ER∆3 repressor were generated. No significant
difference in the incidence of gross cataracts was observed between female mice
expressing ER∆3 and ERα, but lacking ERβ (βERKO/ER∆3) and in female mice
expressing ER∆3, ERα, and ERβ (Figure 24; summarized in Table 20). These data
suggest that ERβ is not critical for the protection exerted by estrogen. However,
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due to the limited number of βERKO/ER∆3 female mice generated, a protective
effect may be obscured.

Nonetheless, it is unlikely that the loss of ERβ

expression increases cataract development as observed in female mice with
diminished or reduced levels of ERα (Table 20).

Table 20: Gross Cataract Incidence in Female ERKO/ER∆3 Mice.
Genotypes
ER∆3
αERKO/ER∆3
ERα+/‐/ER∆3
αβERKO/ER∆3
βERKO/ER∆3
ERα+/‐/βERKO/ER∆3
WT

Age of Females
4‐5 months
+ (n=11)
‐ (n=9)
++ (n=13)
++++ (n=5)
‐ (n=5)
+ (n=11)
‐ (n=10)

10 months
+ (n=8)
+++++ (n=5)
+++ (n=9)
ND
‐ (n=3)
+ (n=8)
‐ (n=6)

Incidence of cataract detection by gross inspection is indicated by – (0% incidence); + (9‐25%
incidence); ++ (26‐50% incidence); +++ (51‐75% incidence); ++++ (75‐80% incidence); +++++ (100%
incidence). Not all animals were observed for gross cataract at both time points; some animals
were euthanized prior to 10 months or were only examined at death ND indicates, at this age,
cataract incidence could not be determined since animals were euthanized prior to this age.

In contrast to ERβ, ERα in the lens was found to be protective against
cataract formation as the loss of ERα showed earlier onset of cataracts in mice
lacking ERα (Figure 24).

However, the mechanism by which estrogen acts

through ERα is still unknown (see Figure 36). The earlier onset and higher
incidence of cataracts in αERKO/ER∆3 female mice may be explained by elevated
levels of endogenous estrogen, since serum 17β‐estradiol levels are at least 3‐fold
higher in αERKO females compared to WT females (Couse and Korach, 1999;
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Couse et al., 2003). Thus, the higher serum levels may result in an increase in
17β‐estradiol bioavailability in the lens to saturate the ER∆3 receptor to result in
increased inhibition and cataract incidence.
The loss or partial loss of ERα in the lens, rather than differences in
circulating 17β‐estradiol serum levels, was found to be more critical with regards
to cataract development in the ER∆3 female mice. This hypothesis is supported
by the observed occurrence of pathological changes and gross cataracts in
similarly aged ER∆3 female mice heterozygous or homozygous for the ERα
disruption with or without ERβ. Of these three genotypes, serum estradiol levels
are significantly higher in female mice null for ERα only; whereas, ERα+/‐ and
αβERKO females are have comparable endogenous levels to WT female mice
(Couse and Korach, 1999; Couse et al., 2003). The earlier cataract onset in
αβERKO compared to the other genotypes examined (Figure 24 and Table 21)
suggests that the additional loss of ERβ expression may be a factor in the
accelerated onset of cortical cataracts. The earlier onset and incidence of ER∆3‐
induced cataracts in the αβERKO female mice may be the result of ER∆3
dimerizing with itself (homodimers) or to an unknown receptor to inhibit
estrogen action.
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Table 21: Gross Cataract Incidence in ER∆3 Female Mice with Reduced ERα
Expression.
Female Genotypes
ER∆3
ERα+/‐/ER∆3
ERα+/‐/βERKO/ER∆3
αERKO/ER∆3
αβERKO/ER∆3

Age
4‐5 months
+ (n=11)
++ (n=13)
+ (n=11)
‐ (n=9)
++++ (n=5)

10 months
+ (n=8)
+++ (n=9)
+ (n=8)
+++++ (n=5)
ND

Incidence of cataract detection by gross inspection is indicated by – (0% incidence); + (9‐25%
incidence); ++ (26‐50% incidence); +++ (51‐75% incidence); ++++ (75‐80% incidence); +++++ (100%
incidence). Not all animals were observed for gross cataract incidence at the earlier time point;
some animals were euthanized prior to 10 months or were only examined at euthanasia. ND
indicates at this age cataract incidence could not be determined since animals were euthanized
prior to this age.

The onset of morphological changes in ER∆3 females with diminished
levels of ERα+/‐ and devoid of ERβ is similar to ER∆3 females expressing both WT
ERα and ERβ (Table 21). However, the incidence of gross cataracts is higher in
female ER∆3 mice with diminished levels of ERα+/‐, but still expressing ERβ
(Table 21). These results suggest ER∆3 may preferentially bind ERβ to induce
cortical cataracts in the ER∆3 mice. This preferential dimerization of ER∆3 to
ERβ is plausible since ERβ has a higher propensity to bind ERα and ERα and
ER∆3 are homologous, except for the second zinc finger of the DNA binding
domain encoded by exon 3 which is missing in the ER∆3 repressor.
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Table 22: Potential Dimers in ERKO/ER∆3 Animals.

GENOTYPES

ERα:ERΔ3

ERβ:ERΔ3

ERΔ3:ERΔ3

ERα:ERα

ERβ:ERβ

ERα:ER
β

ERΔ3

x

x

x

x

x

x

βERKO/ ERΔ3

x

x

x

αβERKO/ ERΔ3

x

αERKO/ ERΔ3
ERα±/ERΔ3

x

x

x

x

x

WT

x
x

x

x

x

x

x

In the classical mechanism of action for estrogen, transcriptional activity
of ERα is affected by a number of regulatory cofactors including chromatin‐
remodeling complexes, coactivators, and corepressors.

Since the relative

concentrations of these molecules is cell‐specific, sex steroid hormones can have
vastly different functions in different tissues of the same organism. Therefore,
based on suggested mechanisms of dominant negative receptors (Schodin et al.,
1995), the ER∆3:ERα and ERΔ3:ERβ heterodimers that form may adversely effect
the recruitment or release of regulatory cofactor associated with the classical
mechanism of estrogen action to result in its inhibitory actions.
Since cortical cataracts were observed in αβERKO/ER∆3 female mice
(Table 19), their presence suggests that ER∆3 homodimers are capable of acting
on their own to elicit an effect. Since ER∆3 is homologous to ERα with the
exception of the missing portion of the DNA binding domain, the ER∆3
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homodimers should still be able to recruit cofactors normally involved in the
classical pathway. It is the relative balance of receptors, coactivator, and
corepressor proteins, which is a critical determinant of the ability of this classical
pathway to initiate responses. Since cofactors are not specific to one type of
receptor complex, these cofactors may form complexes with the ER∆3 dimers
and not be available to interact with wild‐type ER or other nuclear receptors
(Schodin et al., 1995). Subsequently, non‐ER receptors would be unable to form
the complexes required for eliciting their normal functions in the lens, such as
mediating proliferation, differentiation, and lens transparency. Therefore, other
signaling pathways besides estrogen responses may also be perturbed to
contribute to cataract formation.
If ER∆3 is inhibiting another estrogen receptor besides ERα and ERβ
GPR30 may be the potential unspecified receptor in which ER∆3 interacts.
However, if it actions require dimerization, this event is very unlikely given the
localization of GPR30 as a membrane receptor and ERΔ3 as a nuclear receptor.
For this dimerization event to occur, the ER∆3 repressor would have to be
expressed in the plasma membrane of the same cell which expresses GPR30 and
possess a dimerization domain which GPR30 recognizes.

Future work to

confirm the mouse lens expresses GPR30 protein and to investigate the cellular
location may also address the potential dimerization of ER∆3 with GPR30.
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A. Wild‐Type Estrogen Receptor Dimers and Actions

ERE

ERE

ERα homodimers

ERE

ERβ homodimers

ERα:ERβ heterodimers

Normal Lens Physiology (Proliferation, Differentiation, etc.)
Protection of Lens Transparency

B. Membrane GPR30 and Actions
GPR30

Ca2+

PI3K
MAPK

NO

Homeostasis,
Growth,
Cataractogenesis

Cell Survival,
Proliferation

Cell Death,
Cell Survival

Growth,
Differentiatio,
Development

C. Estrogen Receptor:ERΔ3 Dimers and Actions

ERE

ERE

ERE

Aberrant Lens Physiology
Vacuole and Cataract Formation

Figure 37: Potential Estrogen Receptor, GPR30, and ERΔ3 Dimers and Actions in the Lens. A.
Classical Mechanism of Estrogen Action. Three potential nuclear estrogen receptor dimers that
may form in the lens include: ERα (blue parallelogram):ERα, ERβ (green trapezoid):ERβ and/or
ERα:ERβ. B. Potential GPR30 regulated cascades based on its actions in other tissues (Filardo et
al., 2002; Prossnitz et al., 2007) include the generation of Ca2+ and nitric oxide (NO), and
activation of the MAPK and PI3K pathways. C: Mechanism of ERΔ3 inhibition of estrogen
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action. The following dimers may form to initiate vacuoles and cataracts development in the
lens: ERα:ERΔ3 (red hexagon), ERβ:ERΔ3, and/or ERΔ3:ERΔ3.

Additionally, the cataract development studies in ERKO and ERKO/ER∆3
mice only investigated tissue‐specific roles of the nuclear estrogen receptors, ERα
and ERβ. Therefore, GPR30 in the lens has not been determined from these
studies.

GPR30 may act positively or negatively in the lens. If GPR30 has

negative effects and ERα and/or ERβ regulates or suppresses its actions, then the
more robust phenotype observed in the ER∆3 female mice with reduced levels of
ERα may be a result of GPR30 action not being controlled. Furthermore, ERα
may be present as a nuclear and/or a membrane receptor and function via
individual mechanisms specific to its cell location. Given the unlikelihood of
ER∆3 being expressed in the plasma membrane, ER∆3 could not inhibit
membrane bound ERα. So the observed cortical cataracts in ER∆3 mice may due
to ERα action in the plasma membrane.
As previously shown by Davis et al., (2002), ER∆3 male mice do not
spontaneously develop cataracts, which is likely due to insufficient circulating
estrogen levels.

In this study, as expected, spontaneous cataracts were not

observed in the males of any genotype expressing ER∆3 with or without ERα
and/or ERβ (Table 23).

Therefore, these findings suggest that endogenous

estrogen levels in the ERKO/ER∆3 male mice may not be sufficient to result in
the activation of adequate ER∆3 repressors to induce cataracts.
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Table 23: Gross Cataract Incidence in ERKO/ER∆3 Male Mice.
Male Genotypes
ER∆3
ERα+/‐/ER∆3
αERKO/ER∆3
βERKO/ER∆3
αβERKO/ER∆3
WT

Age
4‐5 months
‐ (n=10)
‐ (n=4)
‐ (n=7)
‐ (n=7)
‐ (n=5)
‐ (n=10)

10 months
‐ (n=6)
‐ (n=6)
‐ (n=4)
‐ (n=4)
‐ (n=2)
‐ (n=6)

Incidence of cataract detection is indicated by – (0% incidence); + (1‐100% incidence).

Identification of Potential Estrogen‐Regulated Biomarkers in the Lens
Cataract induction studies in the ER∆3 female and male mice validate that
the ER∆3 model of inducible cataracts is an appropriate model to study the rapid,
spontaneous induction of age‐related cataracts.

The development of cortical

cataracts in the ER∆3 mice is dependent upon exogenous or endogenous
estrogen activation and these pathological changes do not begin during
embryonic development since slit‐lamp examinations and histopathology of
prepubescent ER∆3 mice confirmed the lens remained normal prior to puberty.
Also, the ability to induce cataracts in this model allows for the identification of
genes which are regulated by estrogen activation of ER∆3 and involved in
pathways critical in lens development, proliferation, differentiation, and
transparency.

Furthermore, genes identified to play a vital role in the
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development of ERΔ3‐induced cataracts can serve as biomarkers when
investigating estrogen therapies designed to delay the development of cataracts.
Of the four initial questions (page 163), the last question addressed
estrogen’s ability to regulate genes associated with critical pathways involved in
lens development, proliferation, differentiation, and transparency.

Since

observable morphological changes occur as early as 48 hrs post‐treatment in
prepubertal ER∆3 male and female mice (refer to Table 13), potential markers for
pathways involved in cataract development associated with the ER∆3 transgenic
mouse model were identified by examining differential gene expression in
immature ER∆3 female mouse lenses 6 hrs after 17β‐estradiol treatment.
Estradiol‐induced changes in gene expression detected at 6 hrs post‐treatment
suggests these genes, and the pathways in which they belong, may promote
cataract development in the ER∆3 model.
As noted previously, ER∆3‐induced cataracts are classified as cortical
cataracts based on the location of vacuoles. It is in this region that lens epithelial
cells differentiate into fiber cells (Coulombre and Coulombre, 1963). As a result
of the observed pathology in the ER∆3 mice and the biological processes
(differentiation) that occur in this region, pax6, tcfap2a, tgfb2, and sox2 were
chosen for investigation by real‐time RT‐PCR because of their involvement in
differentiation. In addition to their roles in differentiation, many of the candidate
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genes identified are involved in lens development (pax6 gene), proliferation (pdgfa
and tgfb2 genes) , migration of epithelial cells (pdgfa gene), and regulation of
specific crystalline proteins responsible for lens transparency (pax6, six3, and sox2
genes) (Duncan et al., 2004; West‐Mays et al., 2002 Laiho and Keski‐Oja, 1992
Kamachi, 2001; Furuta and Hogan, 1998; Kamachi et al., 1998; Nishiguchi et al.,
1998).
Cortical vacuoles in the transitional zone of the lens are the main
phenotypical change associated with ER∆3‐induced cataracts. The gene pax6 is
expressed in the epithelial cells in this region and its down‐regulation in the fiber
cells during adulthood is critical for the maintenance of homeostasis and lens
development (Koroma et al., 1997; Duncan et al., 2000; Duncan et al., 2004).
Furthermore, sustained expression of pax6 in the lens fiber cells (a region of the
lens which should be void of pax6 expression) has been shown to disrupt lens
fiber differentiation (Duncan et al., 2004). The observed up‐regulation in pax6
gene expression at 6 hrs post‐17β‐estradiol treatment in ER∆3 immature male
and female mice (Figure 33 and Table 14) suggests homeostasis or fiber cell
differentiation in the lens may be perturbed. These data suggest that the
observed cortical vacuoles at 48 hrs in ER∆3 animals may be due to disruption of
the lens fiber differentiation process as a result of up‐regulation of the pax6 gene
expression in the lens. In future studies, the fiber cells (primarily fiber cells) will
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be investigated to determine if pax6 is expressed in these cells. If pax6 is detected
in the fiber cells, these results might suggest that disruption to the lens fiber cell
differentiation process is responsible for the ER∆3 phenotype.

Table 24: Differential mRNA Expression in 17β‐Estradiol‐Treated ER∆3 and
WT Lenses.
Genes
Tgfβ2
Six3

Pax6

Tcfap2a

Sox2

Pdgfa

Prepubescent ER∆3 ♀

2.33*

5.51*

1.94*

3.05*

4.00*

3.35*

Prepubescent ER∆3 ♂

2.67*

2.83*

2.48*

2.59*

4.82*

5.08*

Adult ER∆3 (OVX) ♀

1.85*

1.64

1.35

1.02

2.22*

1.18

Prepubescent WT ♀

1.19

1.25

1.16

1.08

1.31

0.65

Prepubescent WT ♂

1.27

1.21

1.10

1.14

1.01

1.03

Female (♀); Male (♂); Wild‐type (WT). Relative fold changes were determined for pax6, tcfap2a,
tgfβ2, six3, sox2, and pdgfa in ER∆3 and WT lenses using the 2‐ΔΔCt method as described in the
methods section. Vehicle‐treated groups were normalized to 1.00 and fold‐changes in 17β‐
estradiol‐treated groups are shown. Statistical significance was determined using Mann‐Whitney
U test, GraphPad® Prism software, * p<0.05.

The transcription factor, tcfap2a, is a known inhibitor of differentiation
(West‐Mays et al., 2002; Eckert et al., 2005) and under normal conditions, tcfap2a
is locally expressed in lens epithelial cells and expression terminates at the lens
equator where epithelial cells terminally differentiate into fiber cells. Ectopic
expression of tcfap2a in the fiber cells has been reported to result in bilateral
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cataracts by blocking the migration of newly formed fiber cells (West‐Mays et al.,
2002). Therefore, the observed cortical vacuoles in the immature ER∆3 mice may
be a result of the increased expression of tcfap2a. The ER∆3‐induced increase in
tcfap2a gene expression may result in the increased inhibition of terminal
differentiation of epithelial cells into fiber cells. The inability of those fiber cells
to migrate centrally may cause the vacuoles observed in the cortical region of the
lens.
Additionally, expression levels of tcfap2a between adult, ovariectomized
(OVX) ER∆3 mice treated with 17β‐estradiol compared to vehicle was
approaching significance (Figure 38; Table 17). The dose administered to the
OVX ER∆3 mice was half the dose given to the immature ER∆3 mice; therefore, a
significant difference in these groups may have been observed if a higher dose of
17β‐estradiol was administered to these animals.

However, the inability to

induce cataracts in the OVX ER∆3 mice may explain the lack of differential
expression of tcfap2a in the lens of the 6‐week‐old mice.
Another candidate gene that was significantly regulated in the microarray
was tgfb2. In addition to the observed regulation, estrogen has been shown to
inhibit TGFβ2‐induced subcapsular cataracts in rats (Hales et al., 1997); therefore,
its regulation in the ER∆3 model was relevant. In addition to its known ability to
induce subcapsular cataracts, tgfb2 regulates growth and differentiation in
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numerous tissues (Laiho and Keski‐Oja, 1992); therefore, an increase in gene
expression may increase proliferation and/or result in an increased rate of
differentiation in the lens. As shown in Figure 33 and Table 14, tgfb2 mRNA was
significantly up‐regulated in lens tissues from ER∆3 immature male and female
mice treated with 17β‐estradiol compared to control‐treated mice. These animals
are at a similar age to those in which cortical vacuoles are rapidly induced within
48 hrs post‐treatment (refer to Results Subsection C). The lack of significant
regulation and the inability to induce cortical cataracts in the 6‐week‐old, OVX
females (Figure 35) suggest the higher levels of tgfb2 mRNA in the prepubertal
ER∆3 mice (Figure 33) may be related to cataract development. Additional
experiments to detect TGFβ2 protein will be examined in future studies to
determine if the upregulation of its gene correlates with increased levels of
protein.
Analysis of six3 mRNA in individual lenses from ERΔ3 immature female
and male mice treated with 17β‐estradiol compared to vehicle show an up‐
regulation in its gene expression (Table 14). Numerous researchers suggest six3
can function as a transcriptional repressor in many tissues (Kobayashi et al.,
1998; Zhu et al., 2002; Lopez‐Rios et al., 2003). Therefore, the higher expression
of six3 mRNA may lead to the activation of downstream genes critical for lens
transparency, such as sox2.
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The expression of sox2 is critical to embryonic lens cell differentiation and
is regulated by pax6, tcfap2a, tgfb2, and six3 (Furuta & Hogan, 1998; Kamachi et
al., 1998; Nishiguchi et al., 1998), although its regulation is unknown in the lens
at later ages. The levels of sox2 transcript were significantly increased in lenses
from immature ER∆3 female and male mice and OVX ER∆3 female mice by 17β‐
estradiol versus vehicle (Table 24). In addition to the up‐regulated expression of
sox2 mRNA, levels for all four of these potential regulators (pax6, tcfap2a, tgfb2,
and six3) were also increased in the lenses from immature ER∆3 female mice
treated with 17β‐estradiol compared to vehicle to suggest the coordinated
regulation of all five genes.
In addition to the process of differentiation, controlled cell proliferation in
the lens is critical for lens transparency. In addition to tgfb2, expression of pdgfa
transcripts was up‐regulated in the lens of immature ER∆3 mice treated with
17β‐estradiol (Table 24). Both genes are growth factors that play a role in cell
proliferation; more specifically, TGFβ can stimulate proliferation through the
production of PDGF (Huang and Lee, 2003). Together, the results suggest that
observed pattern in regulation of pdgfa may be a result of the up‐regulation of
tgfb2 in the mouse lens to control proliferation.
The candidate genes (pax6, tcfap2a, tgfb2, six3, sox2 and pdgfa) were not
found to be differentially expressed in the lenses of immature WT mice treated
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with 17β‐estradiol compared to vehicle, unlike in the immature ER∆3 mice (Table
24). The data suggest that estrogen activation of the ER∆3 repressor, to inhibit
estrogen action, results in modification of these genes since estrogen does not
regulate these genes in WT mice.
Another plausible explanation to the increase in expression of these six
genes is that estrogen functions to regulate these six genes by turning off gene
transcription. Thus, inhibition of estrogen action by the ER∆3 repressor would
result in the inability of estrogen to silence the expression of these six genes. For
example, if estrogen normally acts in the lens to inhibit the expression of tgfb2,
inhibition of estrogen action can result in abnormal regulation of tgfb2; hence,
this may explain the observed upregulation of tgfb2 expression in immature
ER∆3 mice. Therefore, based on the data presented within, a proposed pathway
by which ER∆3 alters expression of the tested genes is depicted in Figure 38.
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TGFβ2
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Pax6
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Tcfap2a
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?
Proliferation
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Ocular Transparency

ER∆3‐induced Cortical Cataracts
Figure 38: Proposed Mechanism of Action for ER∆3 in the Mouse Lens. After 17β‐estradiol (E2)
crosses the cell membrane, it activates the ER∆3 repressor which, in turn, suggests it has
transcription actions (Tcfap2a, Pax6 and Six3). These transcription factors signal downstream to
Sox2 and other unknown targets impinging on differentiation and the maintenance of lens
transparency to ultimately results in the induction of cortical cataracts. In addition, activation of
ER∆3 stimulates TGFβ2 may induce lens epithelial cell proliferation mediated through the
production of PDGFα.

Together, the presented work suggests that estrogen is capable of acting
directly in the lens via estrogen receptors.

Such estrogen receptors may be ERα,

ERβ, and/or GPR30, as transcripts for these receptors were detected by RT‐PCR
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in mouse lens (see Results, Subsection A). The human and mouse 17β‐estradiol
binding studies also suggest the presence of a membrane estrogen receptor,
which, in turn, may have a role in estrogen action in the lens. Additionally, 17β‐
estradiol is capable of stimulating the expression of several genes in the lenses of
the ER∆3 mice, which supports the theory that estrogen may possess actions in
the lens (see Results, Subsection D). Since estrogen regulation was investigated
only at one time point (6 hrs), it still remains unknown if estrogen is directly
regulating pax6, tcfap2a, tgfb2, six3, sox2, and pdgfa. Also, these data do not negate
the potential of estrogen acting in neighboring tissues that influence
transparency in the lens, especially in the retina.
Previous studies have demonstrated that ER∆3 is expressed in the retina
(Davis et al., unpublished). The influence of the retina on lens differentiation and
homeostasis was established many decades ago (Coulombre and Coulombre,
1963; Coulombre and Coulombre, 1965; Coulombre and Coulombre, 1979).
Specifically, fibroblast growth factor (FGF), a specific retinal factor, is reported to
influence lens epithelial proliferation, migration, and differentiation (McAvoy et
al., 1991). Anti‐estrogens can inhibit estrogen‐induced expression of the FGF
family in well‐differentiated endometrial cancer cells (Fujimoto et al., 1997).
Therefore, ER∆3 suppression of estrogen action in the retina may inhibit FGF
expression resulting in abnormal differentiation of lens epithelial cells into fiber
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cells. Differentiation of lens epithelial cells into fiber cells occurs in the cortical
region of the lens; therefore, it is plausible that misregulation of FGF, or other
influential factors, in the retina by ER∆3 could result in or contribute to the
cataracts observed in the cortical region of these mice.
Together, this work provides the necessary foundation for elucidating the
mechanistic role of estrogen in the lens. First, detection of 17β‐estradiol binding
sites in the nuclear, cytosolic, and membrane fractions of both the mouse and
human lens indicates that estrogen binds directly to receptors present in the lens
and, therefore, has the potential to regulate downstream targets critical for the
maintenance of lens transparency. Additionally, transcripts for ERα and ERβ
were detected in the mouse lens, and the novel, GPR30 was detected in the
mouse and human lens.

With the detectable 17β‐estradiol binding in the

membrane fraction and the expression of GPR30 mRNA, the data suggest that
the lens expresses the novel membrane estrogen receptor. However, the binding
in the membrane fraction and expression of ERα in the fiber cells may suggest
ERα is also localized in the plasma membrane of the epithelial and/or fiber cells
of the lens. Collectively, these results suggest that the crystallin lens may express
all three estrogen receptor subtypes and their differential expression in the lens
epithelial cells and fiber cells may be responsible for distinctive actions.
Furthermore, critical genes known for lens development, proliferation, and
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differentiation were differentially modified in mice upon activation of the ERΔ3
repressor. These results suggest that therapies, specifically topical estrogens,
may be designed to protect and/or delay the development of age‐related
cataracts.
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